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Background: Cystic fibrosis (CF) is a chronic, life-limiting disease caused by mutations in the CF
transmembrane conductance regulator (CFTR) gene leading to abnormal airway surface ion transport,
chronic lung infections, inflammation and eventual respiratory failure. With the exception of the
small-molecule potentiator, ivacaftor (Kalydeco®, Vertex Pharmaceuticals, Boston, MA, USA), which is
suitable for a small proportion of patients, there are no licensed therapies targeting the basic defect.
The UK Cystic Fibrosis Gene Therapy Consortium has taken a cationic lipid-mediated CFTR gene therapy
formulation through preclinical and clinical development.
Objective: To determine clinical efficacy of the formulation delivered to the airways over a period of
1 year in patients with CF.
Design: This was a randomised, double-blind, placebo-controlled Phase IIb trial of the CFTR gene–liposome
complex pGM169/GL67A. Randomisation was performed via InForm™ version 4.6 (Phase Forward
Incorporated, Oracle, CA, USA) and was 1 : 1, except for patients in the mechanistic subgroups (2 : 1).
Allocation was blinded by masking nebuliser chambers.
Settings: Data were collected in the clinical and scientific sites and entered onto a trial-specific InForm,
version 4.6 database.
Participants: Patients with CF aged ≥ 12 years with forced expiratory volume in the first second (FEV1)
between 50% and 90% predicted and any combination of CFTR mutations. The per-protocol group
(≥ 9 doses) consisted of 54 patients receiving placebo (62 randomised) and 62 patients receiving gene
therapy (78 randomised).
Interventions: Subjects received 5ml of nebulised pGM169/G67A (active) or 0.9% saline (placebo) at
28 (±5)-day intervals over 1 year.
Main outcome measures: The primary end point was the relative change in percentage predicted FEV1
over the 12-month period. A number of secondary clinical outcomes were assessed alongside safety
measures: other spirometric values; lung clearance index (LCI) assessed by multibreath washout; structural
disease on computed tomography (CT) scan; the Cystic Fibrosis Questionnaire – Revised (CFQ-R), a
validated quality-of-life questionnaire; exercise capacity and monitoring; systemic and sputum inflammatory
markers; and adverse events (AEs). A mechanistic study was performed in a subgroup in whom transgene
deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) was measured alongside nasal and
lower airway potential difference.
ABSTRACT
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Results: There was a significant (p= 0.046) treatment effect (TE) of 3.7% [95% confidence interval (CI)
0.1% to 7.3%] in the primary end point at 12 months and in secondary end points, including forced vital
capacity (FVC) (p= 0.031) and CT gas trapping (p= 0.048). Other outcomes, although not reaching
statistical significance, favoured active treatment. Effects were noted by 1 month and were irrespective
of sex, age or CFTR mutation class. Subjects with a more severe baseline FEV1 had a FEV1 TE of 6.4%
(95% CI 0.8% to 12.1%) and greater changes in many other secondary outcomes. However, the more
mildly affected group also demonstrated benefits, particularly in small airway disease markers such as LCI.
The active group showed a significantly (p= 0.032) greater bronchial chloride secretory response. No
difference in treatment-attributable AEs was seen between the placebo and active groups.
Conclusions: Monthly application of the pGM169/GL67A gene therapy formulation was associated with
an improvement in lung function, other clinically relevant parameters and bronchial CFTR function,
compared with placebo.
Limitations: Although encouraging, the improvement in FEV1 was modest and was not accompanied by
detectable improvement in patients’ quality of life.
Future work: Future work will focus on attempts to increase efficacy by increasing dose or frequency,
the coadministration of a CFTR potentiator, or the use of modified viral vectors capable of
repeated administration.
Trial registration: ClinicalTrials.gov NCT01621867.
Funding: This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a Medical
Research Council and National Institute for Health Research partnership.
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Plain English summary
Cystic fibrosis (CF) is an inherited disease that significantly shortens life because of severe lung disease.Only one treatment aimed at the underlying cause is currently available and this is suitable for only
the 4% of patients who have specific types of gene mutations; standard care for all other patients targets
the symptoms of the disease rather than the cause.
Gene therapy aims to insert a normal copy of the gene back into the lungs’ cells and restore function.
In the UK CF Gene Therapy Consortium we have (1) identified the best vector with which to gain cell
entry; (2) designed a piece of genetic material capable of safely expressing the missing protein for a
prolonged duration; (3) found out how we can deliver this to the lungs using a clinical nebuliser;
(4) tested safety in two animal models; and (5) confirmed a safe dose in a single-administration trial.
In this trial, CF patients (aged ≥ 12 years) randomly received gene therapy or placebo every month for
1 year. The primary outcome was a change in lung health, measured by a standard breathing test [forced
expiratory volume in the first second (FEV1)]. In addition, we included a number of secondary and
safety outcomes.
One hundred and sixteen patients received at least nine doses and were analysed for efficacy. After
12 months, a statistically significant, but modest, difference was observed between the two groups for
FEV1; this was supported by trends in other outcomes. Effects were independent of gene mutation, age
and sex. There were no significant safety concerns.
We suggest the results reported here provide proof of concept that repeated administration of CF
transmembrane conductance regulator (CFTR) gene therapy can alter clinically relevant outcomes,
providing another step along the path of translational CF gene therapy.
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Scientific summary
Background
Cystic fibrosis (CF) is a chronic, life-limiting disease caused by mutations in the CF transmembrane
conductance regulator (CFTR) gene encoding a chloride ion channel active on the apical surfaces of
epithelia. Although it is a multisystem disease, the major morbidity and mortality is as a result of lung
disease. In the conducting airways, lack of normal CFTR protein function leads to airway surface
dehydration and impairment of the body’s primary innate defence system, mucociliary clearance. Bacterial
infections ensue from early life and the aggressive inflammatory response that results ultimately leads to
irreversible airway scarring in the form of bronchiectasis and respiratory failure. Approximately 95% of CF
patients die of respiratory failure unless a transplant is performed. The median age of death in the UK
currently is 29 years.
With the exception of one new drug, the small-molecule potentiator ivacaftor (Kalydeco®, Vertex
Pharmaceuticals, Boston, MA, USA), there are no licensed therapies targeting the basic defect. This drug
is currently suitable for only a minority of patients (4–5%) with particular, relatively rare, CFTR gene
mutations. All the other clinically available treatments target downstream consequences of the disease
rather than the cause, and at best delay, rather than prevent, the decline in lung function.
Gene therapy, whereby a normal copy of the CFTR gene is introduced into cells of the conducting airways,
has been considered for some time to be an attractive option, as, unlike the small-molecule approach, it
would be mutation independent. Viral vectors have proved problematic because of immune responses
occurring on repeat application, but non-viral approaches do not suffer from the same problem. Proof
of principle has been confirmed for non-viral gene therapy, although trials have largely been single
application and outcomes have been molecular rather than clinical.
The UK Cystic Fibrosis Gene Therapy Consortium (UK CFGTC) comprises scientists, clinicians and allied
health professionals from three sites in the UK: University of Edinburgh, Imperial College London and
University of Oxford. The consortium has been working together for more than a decade with the aim of
developing clinically applicable gene therapy for patients with CF. In our wave I programme, we have
chosen the most optimal non-viral vector; designed a plasmid capable of long-duration expression, with
limited proinflammatory potential; identified the optimal nebuliser delivery system; and tested the product
in two preclinical animal models and a single-application safety and dose-ranging trial.
Objective
The primary objective of this trial was to determine the clinical efficacy of the formulation delivered to the
airways over a period of 1 year in patients with CF.
Design
This was a randomised, double-blind, placebo-controlled Phase IIb trial of the CFTR gene–liposome
complex, pGM169/GL67A. Randomisation was performed via InForm™ version 4.6 (Phase Forward
Incorporated, Oracle, CA, USA) and was 1 : 1, except for patients in the mechanistic subgroups (2 : 1).
Allocation was blinded by masking nebuliser chambers.
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Setting
Data were collected as the clinical and scientific sites and entered onto a trial-specific InForm,
version 4.6 database.
Participants
Eligible CF subjects were at least 12 years old and had mild to moderate lung disease, with forced
expiratory volume in the first second (FEV1) between 50% and 90% predicted. Subjects could have any
combination of CFTR mutations. Exclusion criteria included infection with organisms related to an increased
rate of disease progression or posing a cross-infection risk (meticillin-resistant Staphylococcus aureus,
Mycobacterium abscessus and the Burkholderia cepacia complex).
Intervention
Following a successful screening visit, subjects received 5ml of pGM169/lipid 67A (GL67A) (active) or
0.9% saline (placebo) at 28 (±5)-day intervals over 1 year. Based on previous trial data identifying
cytosine–phosphate–guanidine (CpG) motifs within the bacterially derived deoxyribonucleic acid (DNA) as
the most likely cause of mild flu-like responses, and with an aim to increase the duration of expression, our
chosen formulation comprises a plasmid, pGM169, encoding the CFTR gene driven by a CpG-free human
cytomegalovirus enhancer/elongation factor 1a (hCEFI) enhancer/promoter. The cationic lipid is made up
of three components to optimise DNA binding, stability and gene transfer: (1) cholest-5-en-3-ol (3β)-,
3-[(3-aminopropyl)[4-[(3-aminopropyl)amino]butyl]carbamate] (GL67); (2) 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE); and (3) 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-n-[methoxy
(polyethylene glycol 5000)] (ammonium salt) (DMPE-PEG5000) formulated at a 1 : 2 : 0.05 molar ratio.
Components were mixed following stringent standardised operating procedures by unblinded trial
pharmacists on the day of dosing. The formulation was nebulised via a breath-actuated nebuliser, the
AeroEclipse® II (Trudell Medical International Europe Ltd, Nottingham, UK), which had been masked and
locked to prevent unblinding of patients or trial team. A subgroup of patients also received doses to the
nasal epithelium via a standard nasal spray device. Randomisation was 1 : 1 except for the mechanistic
subgroups, which were randomised 2 : 1 in favour of active treatment to enrich for this group.
Main outcome measures
The primary end point was the relative change in percentage predicted (based on Stanojevic reference
ranges) FEV1 over the 12-month period. Secondary clinical outcomes included other physiological tests
[spirometric values, lung clearance index (LCI) assessed by multibreath washout using sulphur hexafluoride
as a tracer gas, exercise testing and activity monitoring], structural changes on a computed tomography
(CT) scan and a disease-specific, validated quality-of-life questionnaire. We also assessed inflammatory
markers, infection burden and a large number of additional safety measures and collected data on adverse
events (AEs). A mechanistic study was performed in two subgroups: one group of patients underwent
bronchoscopies pre and post dosing, during which CFTR function was assessed with lower airway potential
difference (PD) and samples were obtained for transgene DNA and messenger ribonucleic acid (mRNA)
quantification as well as histology; the second group underwent similar measures in the nose after
additional nasal dosing.
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Results
We recruited 136 patients into the intention-to-treat cohort; the active and placebo groups were well
matched at baseline with regard to age, sex, lung function severity and CFTR mutation class. The
per-protocol cohort was predefined as those patients receiving at least 9 monthly doses of trial
formulation; it consisted of 54 patients receiving placebo and 62 receiving gene therapy. The uneven split
relates to the 2 : 1 randomisation in the mechanistic subgroup. There was a significant (p= 0.046)
treatment effect (TE) of 3.7% [95% confidence interval (CI) 0.1% to 7.3%] in the primary end point of
relative change in percentage FEV1 at 12 months. There were also significant TEs in secondary end points,
including forced vital capacity (FVC) (p= 0.031) and gas trapping on CT scans (p= 0.048); supportive,
non-statistically significant changes were seen in the majority of other outcomes. Effects were noted by
1 month and were irrespective of sex, age or CFTR mutation class. Subjects with a more severe baseline
FEV1 had a FEV1 TE of 6.4% (95% CI 0.8% to 12.1%) and larger responses in most other outcomes.
However, the milder group also demonstrated trends towards a TE in the small airway measure, LCI,
confirming that this group of patients may still benefit. The active group showed a significantly (p= 0.032)
greater bronchial chloride secretory response; overall, there were no significant changes in nasal PD but
some actively treated patients demonstrated improved chloride secretion. Plasmid DNA was detectable in
the majority of samples from both upper and lower airways, although mRNA was not detectable; this
assay is known to lack sensitivity. The formulation was safe with no evidence of immune responses and no
differences in treatment-attributable AEs seen between the placebo and active groups.
Conclusions
The UK CFGTC has conducted the first trial of non-viral CFTR gene therapy designed specifically to detect
clinical benefit. The trial formulation was designed to (1) permit repeated application over a period of time
sufficient to determine change in clinically relevant outcomes; (2) minimise inflammatory responses by
removing all CpG motifs; and (3) lead to extended duration of expression with a non-viral, humanised
promoter. Monthly application of the pGM169/GL67A gene therapy formulation was associated with a
significant improvement in the primary outcome, FEV1. There were also significant improvements in FVC
and gas trapping on CT scans, with supportive signals in other outcomes. Signals were larger in patients
entering the trial with lower lung function, although they were apparent across the spectrum of disease
severity. Evidence for CFTR expression was seen in the lower airway with changes in bronchial PD. The
formulation did not lead to the generation of host immune responses and was confirmed as safe.
The approach is of relevance to CF patients, independent of their underlying CFTR gene mutation.
Limitations
Although encouraging, the difference in FEV1 between groups was modest and was not accompanied by
detectable improvement in the quality of life of patients. The molecular assays appear to lack efficacy,
and, although supportive changes were observed in bronchial PD, the mechanistic subgroups
were underpowered.
Future work
The almost doubled benefit in patients in the more severe half of the group, based on FEV1 < 70%, is
probably, in our opinion, related to increased proximal airway drug deposition. This provides encouraging
support for improved outcomes if higher doses could be delivered. We will seek to explore this in a future
trial, by increasing each dose, decreasing the dosing interval or, possibly, by maximising transgene-derived
CFTR function with the coadministration of a potentiating drug. The consortium is also developing a
pseudotyped lentivirus that leads in preclinical testing to high-level gene expression.
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Trial registration
This trial is registered as ClinicalTrials.gov NCT01621867.
Funding
This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a Medical Research
Council and National Institute for Health Research partnership.
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Chapter 1 Introduction and background
Cystic fibrosis
Pathophysiology
Cystic fibrosis (CF), a common, genetically inherited disease, is caused by mutations in the CF
transmembrane conductance regulator (CFTR) gene. Inherited in an autosomal recessive fashion, it has a
prevalence of approximately 1 : 2500 and a carrier rate of around 1 : 25 in the Caucasian population. It is
estimated that there are approximately 70,000–100,000 people with CF worldwide and over 10,000 on
the current UK registry. It is a multisystem disease, primarily affecting the lungs, but also with significant
pancreatic, liver and gastrointestinal involvement and infertility in the majority of males. Lung involvement
occurs from an early age with intermittent then chronic bacterial infection, inflammation and eventual
bronchiectasis, fibrosis and death from respiratory failure.1 People affected with CF are particularly
susceptible to certain bacteria, including Staphylococcus aureus Rosenbach 1884, Pseudomonas
aeruginosa (Schroeter 1872) Migula 1900 and Burkholderia cepacia (Palleroni and Holmes 1981) Yabuuchi
et al. 1993, although more recently the use of molecular detection techniques has revealed much more
diverse bacterial populations present in the lower airway than hitherto suspected.2
The gene responsible for CF was identified in 1985 and found to be localised to the long arm of
chromosome 7, position 7q21–24,3 with the sequence being fully identified in 1989.4 Over 2000 mutations
in the CFTR gene have been described, although not all are disease-causing; some mutations still produce a
functional protein and are probably more accurately termed benign polymorphisms. In its normal, wild-type,
form, the CFTR gene encodes a 1480-amino-acid protein5 that sits on the cell surface and acts as a cyclic
adenosine monophosphate (cAMP)-regulated ion channel. CFTR is a direct conductor of chloride and
(probably) bicarbonate ions and interacts closely with the major sodium-absorbing channel, epithelial sodium
channel (ENaC), inhibiting its activity. Defects in CFTR lead to reduced chloride secretion and hyperabsorption
of sodium and, thus, water, the combined effect of which is dehydration of the cell surface.6 Mucociliary
clearance is impaired and the infective/inflammatory sequelae of this ensues. It is not known if the decreased
volume of airway surface liquid alone causes the predisposition to infection, if the immune system is also
affected causing a defect in pathogen killing,7 or whether or not other environmental factors within the CF
airway prevent the innate immune system functioning as efficiently as in individuals without CF.
Clinical presentation, diagnosis and disease manifestation
The majority of today’s older children and adults, the population included in this trial, will have been
diagnosed once they had developed symptoms suggestive of the disease. In many countries, the UK
included, this picture has changed dramatically with the introduction of newborn screening; currently,
infants are diagnosed around 3–4 weeks of age based on dried-blood-spot screening.8 The screens differ
somewhat globally, but the UK test measures immunoreactive trypsinogen (IRT) and pancreatic enzyme
levels, which are increased in CF because of pancreatic duct obstruction. Samples with high levels of IRT
are sent for mutation testing. This allows identification and initiation of treatment presymptomatically and
before the downstream sequelae have arisen.
The gold standard diagnosis is based on measuring chloride ion levels in sweat samples. Lack of chloride ion
reabsorption by CFTR in the sweat gland leads to high levels being lost in the sweat, typically > 100mmol/l in
comparison with values of < 30mmol/l in healthy individuals.9 Diagnosis can also be established on CFTR
mutation testing, although, because of the large number of mutations, a negative test cannot rule out the
diagnosis unless the entire CFTR gene has been sequenced; this is rarely employed as a first-line diagnostic
tool and is reserved for difficult diagnoses. However, whereas previously it may have been sufficient to secure
a diagnosis on the basis of a sweat test, with the recent development of mutation-specific small-molecule
treatments,10 it is becoming increasingly necessary for a patient’s mutation(s) to be defined.
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Disease presentation may be respiratory or nutritional and is often both.1 Respiratory problems present as
cough, wheeze, lower respiratory tract infections, sputum production and upper airway disease including
nasal polyps and sinusitis. Lung health deteriorates over time, largely driven by infection and the host
inflammatory response. Disease is thought to begin in the small airways, although this may just reflect a
greater impact of obstruction at this site. Airway obstruction related to mucus accumulation and airway
wall inflammation is measurable on physiological testing, the most commonly employed being forced
expiratory manoeuvres with spirometry. Over time, and despite optimal treatment at specialist centres, lung
function declines. A major contributor to this decline is episodes of pulmonary exacerbation, periods of
increased symptoms and acute drop in lung function that is often not fully regained after treatment.11
The most common manifestation of the pancreatic exocrine disease, present in > 95% of patients, is poor
weight gain with steatorrhoea. Later, patients may develop pancreatic endocrine dysfunction with impaired
glucose metabolism and CF-related diabetes mellitus; this has respiratory consequences that are poorly
understood, but is clearly associated with an increased rate of progression of lung disease.
Conventional management of patients with cystic fibrosis
Cystic fibrosis is a multisystem disease and treatment can be optimally conducted only with the help of a
full multidisciplinary team (CF physician, specialist nurse, physiotherapist, dietitian, clinical psychologist,
pharmacist) and input from ancillary specialists with expert knowledge of CF (ear, nose and throat
surgeon, obstetrician, endocrinologist). CF patients should be seen at least every 3 months by the core CF
team. A large number of treatment guidelines have been published.12–14
The main aims of respiratory care are clearance of mucus, prevention and early eradication of infection and
suppression of infection once chronic. Sputum clearance is achieved with regular physiotherapy alongside
adjunctive inhaled mucoactive agents: hypertonic saline has been shown to aid clearance,15 most likely be
rehydrating the airway surface and stimulating cough. Recombinant human deoxyribonuclease (DNase)
(dornase alfa; Pulmozyme®, Roche Products Ltd) breaks down the high levels of deoxyribonucleic acid
(DNA) in the CF airway resulting from degradation of neutrophils and decreases mucus viscosity.16 Regular
microbiological surveillance is essential for the early detection of infecting bacteria; sputum samples or
cough swabs are collected at every patient contact. P. aeruginosa is an extremely common pathogen,
often being acquired first in childhood and becoming chronic in adulthood in around 60–70% of patients.
Its presence is associated with a more rapid decline in lung function and, therefore, aggressive eradication
is employed when it is first encountered.17 Once it becomes chronic, long-term nebulised antibiotics such
as colistimethate sodium (Colomycin®, Forest Laboratories UK Ltd) or the aminoglycoside, tobramycin for
inhaled solution (Tobi®, Novartis Pharmaceuticals UK Ltd), are administered to maintain suppression of
bacterial numbers and thereby attempt to limit the host inflammatory response.18 There are a small
number of other organisms that pose particular problems, either because of high transmissibility [e.g.
meticillin-resistant Staphylococcus aureus (MRSA) and B. cepacia], or because they are related to a more
rapid rate of clinical decline [e.g. Mycobacterium abscessus (Moore and Frerichs 1953) Kusunoki and Ezaki
1992]. These organisms are difficult to treat and, furthermore, such patients often miss out on inclusion in
clinical trials of new drugs, either because of infection control issues or concerns over baseline stability.
Periods of pulmonary exacerbation are treated with increased attention to airway clearance and antibiotics,
often given intravenously and requiring hospital admission.
Therefore, CF management not only poses a huge burden on the patients and their families, but also
carries with it substantial health-care system costs.19 Ultimately, once respiratory failure has ensued, lung
transplantation is the only option. There is a shortage of organs in most developed countries and many
patients die while on the waiting list. Even after receiving a transplant, complications frequently occur,
most importantly the development of bronchiolitis obliterans, although some patients may do well for
many years.20 Currently in the UK, median age at death is around 29 years of age.21 Thus, despite
expensive and burdensome treatments, life expectancy is significantly reduced for CF patients. Progress is
being made in several areas of drug development, for example with newer antibiotics, but many feel that a
significant improvement in health is likely to be achievable only with novel strategies to tackle the basic
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defect in the CFTR gene rather than these downstream consequences. The next sections describe the
progress that has been made in small-molecule and gene therapy fields to this end.
Novel small-molecule cystic fibrosis transmembrane conductance
regulator modulators
An understanding of the various mechanisms by which different mutations lead to CFTR dysfunction has
led to the grouping of mutations into classes.22
Class I mutations lead to a premature ‘stop’ in the messenger ribonucleic acid (mRNA) and a short,
non-functioning protein. Mutations of class II encode a structurally abnormal, misfolded protein that does
not traffic to its site of action on the apical cell surface but is removed by the endoplasmic reticulum and
degraded. Class III–VI mutations reach the cell surface but fail to function appropriately: class III mutations
have decreased activation of the channel and remain closed; and class IV mutations cause decreased
conductance of ions across the channel. Class V mutations encode proteins with splice-site mutations and
result in reduced amounts of CFTR at the cell surface, so some function occurs but at a reduced level.
Class VI mutations lead to a shortened half-life because of protein instability and may also impair CFTR’s
regulation of neighbouring channels. Many mutations lead to defects in more than one of these classes; for
example, F508del (previously ΔF508), the most common mutation worldwide, is clearly a class II misfolding
defect, but also opens infrequently and has a short half-life, so also possesses class III and VI features.
Treatments for class I mutations
Class I, or nonsense, mutations account for approximately 5–10% of the worldwide CF population,
although the incidence is increased to around 60% among Israeli Jewish CF subjects.23,24 Based on the initial
observation that premature truncation codons could be over-read in the presence of gentamicin (Garamycin®,
Schering-Plough)24–27 one synthetic agent, ataluren (previously known as PTC124; Translarna™, PTC
Therapeutics), has progressed to clinical trials.28 This drug was administered orally to CF patients aged
≥ 6 years with at least one class I mutation in a parallel-design randomised controlled trial. Despite
encouraging Phase II data, neither the primary end point (change in forced expiratory volume in the first
second; FEV1) nor multiple secondary end points were met. A post hoc subgroup analysis demonstrated a
treatment effect (TE) in the subgroup who were not receiving nebulised aminoglycoside antibiotics, which
may have been interfering with the mechanism of action. A further trial is planned, but to date these
patients do not have any other mutation-specific drug approaches in the pipeline.
Treatments for class III mutations
Ivacaftor (Kalydeco®, Vertex Pharmaceuticals, Boston, MA, USA) is the first mutation-specific drug to be
approved in the USA, Europe and Australasia. It is a CFTR potentiator, which increases the channel’s open
probability. Clinical trial results prove, for the first time, that improving CFTR function can lead to
significant benefits.
Class III mutations lead to a protein that remains closed for almost 100% of the time, a so-called ‘gating’
defect. The most common class III mutation is G551D (new nomenclature Gly551Asp). Other class III
mutations are rare and together probably account for only a further 1% of patients.
Ivacaftor was identified via high-throughput screening technology,29–31 and progressed rapidly through
preclinical testing into CF clinical trials, based on significant financial support from the CF Foundation in
the USA. Twice-daily oral administration in patients with a G551D mutation led to a 10% absolute
improvement in FEV1, a reduction in pulmonary exacerbations and improved quality-of-life scores;
additionally, it seemed to have benefits outside the lungs, with improvement in weight and body mass
index (BMI) thought to be related to gut bicarbonate secretion. It was initially licensed (and is now
available in the UK) for patients with the G551D mutation, but a subsequent trial demonstrated similar
benefit for the small group of patients with other class III mutations,10 for which the drug has now also
been licensed and is awaiting funding approval. Furthermore, a trial in patients with the class IV mutation
R117H (NCT01614457), which demonstrated smaller benefits, has led, to date, to the US Food and Drug
Administration approval and is being considered by the European Medicines Agency.
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Treatments for class II mutations
Class II defects are present in the majority of patients with CF worldwide. F508del is carried by
approximately 70–80% of the CF population, with 50% of the total CF population being homozygous.32
As described above, the vast majority of class II CFTR is degraded by intracellular processes and fails to
reach the cell surface. The absolute amount that escapes this degradation differs between individuals and,
may account, in part, for the phenotypic variation observed. The concept of CFTR ‘correctors’ has been
around for many years, although the term has only recently been coined. In the 1980s, an observation was
made that low temperatures and the compound glycerol, stabilised misfolded CFTR protein and facilitated
trafficking; the term ‘molecular chaperone’ was coined for a drug with these capabilities.32,33 High-throughput
screening was conducted by several commercial and academically funded groups and one of these, Vertex
Pharmaceuticals, identified a promising small molecule, named VX-809 (lumacaftor, Vertex Pharmaceuticals).
In vitro chloride transport could be achieved at 14% of wild-type CF levels.34 The results from the first Phase II
trial in 89 patients were somewhat disappointing. As the drug is given systemically, sweat chloride is a
convenient biomarker and had shown utility in trials of potentiator agents. In this trial, there was a statistically
significant reduction in sweat chloride, confirming proof of concept, but the magnitude was small at around
7mmol/l. In addition, no change was seen in nasal potential difference (PD), a localised bioelectrical read-out
of CFTR ion transport, nor clinical parameters within the 4-week treatment period.35 As well as a trafficking
defect, F508del CFTR protein is abnormally gated. It was, therefore, hypothesised that VX-809 could improve
the localisation of CFTR protein to the cell surface, but once there it would need additional help to function;
this led to the notion of combination trials with potentiators.
Ivacaftor, which had been shown to have dramatic improvement in the movement of ions across the cell
membrane in class III mutations,29–31 was considered unlikely to benefit patients homozygous for F508del,
and this was borne out in a Phase II study of 140 patients.35 However, in vitro, combining VX-809 with
ivacaftor doubled the chloride transport compared with that of VX-809 alone. A large Phase III global
clinical trial programme has recently been reported to demonstrate a statistically significant but relatively
modest 2–4% absolute improvement in percentage predicted FEV1 and to reduce the frequency of
pulmonary exacerbations.36 It did not show clinical benefit in patients with only one copy of F508del.
Vertex is also developing an alternative corrector, VX-661. It possesses a possible advantage over
lumacaftor in that its metabolic pathway does not interact with that of VX-770 and achieving therapeutic
levels may be easier. Phase II clinical trials of VX-661 alone, and in combination with ivacaftor, in CF
patients homozygous for F508del have been encouraging and a Phase III programme is planned.
Gene therapy
In contrast to the mutation-specific approach described above, gene therapy, described as ‘the
introduction or alteration of genetic material within a cell or organism with the intentions of curing or
treating a disease’,37 has potential for CF patients with mutations in any class. The first studies of human
administration of healthy copies of the CFTR gene in CF patients were developed very soon after the gene
was cloned in 1989.38
Two components are required in a gene therapy product: (1) a normal copy of the CFTR gene (along with
required regulatory constructs); and (2) a gene transfer agent, either a viral or non-viral vector. The choice
and suitability of such a vector depends on a number of factors, such as the size of the gene to be carried,
the requirement for, and tolerability of, repeated administration and the target cells for treatment.
Choice of vector and clinical trials
Clinical trials of CFTR gene transfer to CF subjects have been undertaken using a variety of viral vector
systems, including adenovirus and adeno-associated virus (AAV). Encouragingly, adenovirus-based gene
transfer led to the correction of the cAMP-stimulated CFTR chloride channel defect in the nose of treated
CF subjects.39,40 However, the efficiency of adenovirus-based gene transfer to human tissues appears to be
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low,41,42 and is associated with lung inflammation43,44 and the development of neutralising immune
responses that, to date, has precluded repeated administration.45 AAV-based CFTR gene transfer appears
less proinflammatory,46–48 although repeated administration is also inhibited by immunological reactivity.49
Non-viral vectors have also been used in clinical trials of CFTR gene transfer to CF subjects. Ten clinical
trials have been performed worldwide to date,50–58 six of which have been in the UK [Gene Therapy
Advisory Committee (GTAC) numbers: 002, 007, 008, 009, 015 and 140] and conducted by current
groups within the UK CF Gene Therapy Consortium (UK CFGTC). The first of these non-viral-formulation
clinical trials assessed the safety and efficacy of a single nasal delivery of plasmid DNA (pDNA) containing
the CFTR complementary DNA (cDNA) under the transcriptional control of the simian virus 40 (SV40)
promoter complexed with 3beta-[N-(N′,N′-dimethylaminoethane)carbamoyl]cholesterol (DC-Chol)–dioleoyl-
sn-glycero-3-phosphoethanolamine (DOPE) liposomes (GTAC number: 002).50 Evidence for pDNA transfer,
vector-derived CFTR mRNA expression and partial correction of the CFTR chloride ion channel defect was
obtained in a subset of subjects. Similar modest, but positive evidence of CFTR gene transfer and function
were obtained after nasal delivery of a pDNA containing the CFTR cDNA under the transcriptional
control of the respiratory syncytial virus 3′ long terminal repeat (RSV 3’LTR) promoter complexed with
DC-Chol–DOPE liposomes (GTAC number: 007).51 Alternative formulations in which pDNAs containing
the CFTR cDNA under the transcriptional control of the human cytomegalovirus (CMV) immediate early
enhancer/promoter were complexed with 1,2-dioleoyl-3-trimethylammoniumpropane liposomes (GTAC
number: 008),52 p-ethyl-dimyristoylphosphaditylcholine–cholesterol liposomes,53 or a polycationic peptide
consisting of a N-terminal cysteine followed by 30 lysine residues54 were broadly shown to be similarly
effective. Importantly, in an additional clinical trial utilising the RSV 3′LTR promoter plasmid complexed
with DC-Chol–DOPE liposomes, repeated nasal delivery of a non-viral formulation was shown to be
equivalently effective after each of three successive administrations (GTAC number: 015).55 Crucially,
no important safety considerations were raised after nasal application of any of these formulations.
Collectively, these clinical data provided proof of principle for CF non-viral gene therapy, but highlighted
the need for formulations with enhanced efficacy. Extensive chemical optimisation of the promising DC-
Chol formulation by Genzyme Inc. (Cambridge, MA, USA) generated the cationic lipid cholest-5-en-3-ol
(3β)-,3-[(3-aminopropyl)[4-[(3-aminopropyl)amino]butyl]carbamate] (GL67) with improved gene transfer
potency,59 well-characterised safety parameters60 and desirable stability during aerosolisation.61 Clinical
trials with GL67-based non-viral formulations have been encouraging. A single nasal administration of
a pDNA containing the CFTR cDNA under the transcriptional control of the CMV promoter (plasmid
pCF1-CFTR) complexed with GL67–DOPE was shown to be safe, to direct vector-derived mRNA expression
and to produce an overall ≈ 20% correction of the CFTR chloride ion channel defect.56 For efficient jet
nebuliser-directed aerosol delivery, 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-n-[methoxy
(polyethylene glycol 5000)] (ammonium salt) (DMPE-PEG5000) was added to the GL67–DOPE to generate
a formulation termed GL67A that consisted of a mixture of GL67–DOPE–DMPE-PEG5000 at a 1 : 2 : 0.05
molar ratio61 (for further details see GL67A cationic lipid). The GL67A formulation lacking pDNA was
shown to be safe and well tolerated after a single lung administration in healthy volunteers.62 Delivery of
pCF1-CFTR complexed with GL67A to the lungs57 or nose and lungs (GTAC number: 009)58 of CF subjects
led to an overall ≈ 25% correction of the CFTR chloride ion channel defect. However, CFTR expression in
these subjects, and those in all other clinical trials described above, diminished quickly, such that it was
essentially undetectable within 1 week of administration. Furthermore, pCF1-CFTR/GL67A lung
administration was associated with a mild flu-like syndrome that resolved within 36 hours.57,58
Further in vivo preclinical studies have identified cytosine–phosphate–guanidine (CpG) dinucleotides in the
pCF1-CFTR pDNA as the likely cause of the mild flu-like symptoms following dosing and may also impact
on the duration of pDNA-mediated transgene expression. The CpG motifs delivered by the pCF1-CFTR/
GL67A formulation appear to be sensed by the innate immune system via the toll-like receptor 9 (TLR9)
pathway.63 Stimulation of the TLR9 pathway led to a host inflammatory reaction typified by the elevation
of inflammatory cytokines within the lung milieu and recruitment of lung neutrophils.64
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Thus, proof of principle for non-viral CFTR gene therapy had been demonstrated, but improvements were
needed specifically with regard to duration of expression and pro-inflammatory responses.
UK Cystic Fibrosis Gene Therapy Consortium
At this stage, in 2001, and in response to an initiative launched by the UK CF Trust, the three UK sites active
in CF gene therapy (University of Edinburgh, Imperial College London/Royal Brompton Hospital and University
of Oxford) came together to form the UK CF Gene Therapy Consortium (www.cfgenetherapy.org.uk/).
The aim of the consortium is to develop clinically relevant gene therapy for patients with CF. The wave 1
programme was based on the recognition that repeated application would necessitate a non-viral vector and
aimed to identify the best, currently available non-viral formulation coupled with a long-lasting plasmid with
little or no proinflammatory potential and to take this into a clinical trial designed and powered, for the first
time, to detect clinical benefit. The repeated-dose trial is the focus of this report. Work packages in the wave
1 programme leading up to this point have included a study of outcome measures on patients undergoing a
pulmonary exacerbation;65 a large, longitudinal study of outcome measures in stable patients (from which
power calculations were made for this trial); and a single-application safety and dose-ranging pilot study
(see Choice of dose and adjunctive treatments: single-dose pilot study). The consortium is also working on a
wave 2 programme developing and assessing a pseudotyped lentiviral vector, which seems to be repeatedly
administrable. Although gene transfer efficiency seems greater with this approach than with our non-viral
equivalents, the requirement for preclinical development and toxicity testing placed this further in the future
and led to the initial focus on wave 1.
Section pGM1/GL67A for clinical trial use describes our chosen clinical trial formulation in detail and the
rationale for its development.
pGM1/GL67A for clinical trial use
Composition
We found GL67A (further details in GL67A cationic lipid) to be superior to others in both small and large
animal models, having undertaken an extensive preclinical assessment of available non-viral formulations.
GL67A has previously been administered to both healthy volunteers and CF subjects, including in a
single-dose nebuliser study66 and our recently completed safety study Evaluation of safety and gene
expression with a single dose of pGM169/GL67A administered to the nose and lung of individuals with
cystic fibrosis (sponsor’s protocol number: cro851; EudraCT reference: 2007-004050-85).62 For both the
single-dose safety study and the trial described in this report, we made substantial changes to the CFTR
plasmid, which was specifically designed with the following features:
l The promoters most commonly used are of viral origin; we had previously incorporated a CMV promoter
which, although capable of high-level gene expression, is usually of short duration. The current
formulation contains a human elongation factor 1 alpha (EEF1A1) gene promoter. Our preclinical work
demonstrated more sustained levels of expression (up to 2 months) with this new promoter; this could
translate into a less frequent dosing regimen. The gene expression profile observed in the recent
single-dose study supported this hypothesis, with relatively few changes observed at early time points
and several subjects demonstrating functional changes in nasal PD several months after dosing.
l Unmethylated CpG dinucleotides are present in high numbers in pDNA used in gene therapy trials.
These bacterially derived components are recognised by humans as foreign and likely responsible for
the flu-like responses, reported in our previous trial in the group receiving DNA/lipid but not lipid alone.
Although these responses were mild and self-limiting, requiring only treatments with antipyretics, we
considered them undesirable in a repeated-dose trial. In an attempt to reduce such an inflammatory
response, the new plasmid has been rendered completely CpG free.
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Plasmid
pGM169 is a covalently closed, circular, double-stranded pDNA molecule of 6549 base pairs purified from
bacteria. It is based on a novel CpG-free plasmid backbone described in the international patent
application PCT/GB2007/00110433. A diagrammatic representation of pGM169 is presented in Figure 1.
pGM169 contains a CpG-free version of the CFTR coding sequence termed soCFTR2 under the
transcriptional control of a novel CpG-free human CMV enhancer/elongation factor 1 alpha (hCEFI)
enhancer/promoter. Other plasmid elements include a CpG-free version of the bovine growth hormone
polyadenylation sequence, a CpG-free version of the R6K bacterial plasmid origin of replication and a
CpG-free version of the kanamycin resistance gene under the transcriptional control of the CpG-free
synthetic bacterial promoter sequence termed EM7.
Good manufacturing practice (GMP) manufacture of pGM169 was conducted by VGXi Inc. (The Woodlands,
TX, USA). Bacteria containing the plasmid were fermented to a high density and harvested. The bacteria were
then lysed to release their contents, including the plasmid, into solution. The lysate was subjected to three
significant purification steps: (1) solid/liquid separation, (2) ion-exchange chromatography and (3) hydrophobic
interaction chromatography. Subsequently, the purified plasmid was concentrated and desalted by
ultrafiltration/diafiltration into a sterile 8mM sodium chloride (NaCl) solution and finally subjected to aseptic
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FIGURE 1 Plasmid pGM169. The basic features of pGM169 (proceeding clockwise from 0 base pairs) are the
CpG-free human cytomegalovirus enhancer/elongation factor 1 alpha enhancer/promoter; a CpG-free synthetic
intron sequence to enhance mRNA splicing; a CpG-free version of the CFTR coding sequence termed soCFTR2;
a CpG-free version of the bovine growth hormone polyadenylation sequence; a CpG-free version of the R6K
bacterial plasmid origin of replication; a CpG-free version of the kanamycin resistance gene; and a CpG-free
synthetic bacterial promoter sequence termed EM7. bp, base pair; BGH, bovine growth hormone.
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filtration to provide the bulk drug substance. This bulk was aseptically filled into single-unit vials and stored
at ≤ –70 °C. To prepare the final drug substance, single or multiple pooled lots of bulk drug substance were,
if necessary, diluted to 5.3 ± 0.3mg/ml with sterile 8mM NaCl and then filled into 10-ml clear glass vials at a
fill level of 5.2 ± 0.2ml. Vials were stored at –80 °C. The material is stable for at least 3 years.
GL67A cationic lipid
The cationic lipid mixture GL67A is an excipient, consisting of a mixture of three components (the structure
of which is shown in Figures 2–4; GL67, DOPE, and DMPE-PEG5000) formulated at a 1 : 2 : 0.05 molar ratio.
The final formulation containing GL67, DOPE and DMPE-PEG5000 at a 1 : 2 : 0.05 molar ratio and a
GL67-to-DNA ratio of 0.75 : 1 was termed GL67A.
Good manufacturing practice-grade GL67 was manufactured by Sanofi-Genzyme (Haverhill, UK).
GMP-grade DOPE and DMPE-PEG5000 were purchased from Avanti Polar Lipids (Alabaster, AL, USA).
GL67A was formulated from GMP-grade GL67, DOPE and DMPE-PEG5000 by OctoPlus N.V. (Leiden,
Netherlands). Briefly, the individual constituents were first dissolved in 2-methylpropan-2-ol (9 : 1
weight-to-weight ratio of 2-methylpropan-2-ol to water) and then mixed in appropriate quantities to
obtain a GL67–DOPE–DMPE-PEG5000 molar ratio of 1 : 2 : 0.05. After sterile filtration the lipid mixture was
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FIGURE 2 Structure of GL67. GL67 is included in the GL67A cationic lipid mixture for its DNA-binding properties
(i.e. binding of pGM169).
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FIGURE 3 Structure of DOPE. DOPE is included in the GL67A cationic lipid mixture for its endocytosis-
inducing properties.
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FIGURE 4 Structure of DMPE-PEG5000. DMPE-PEG5000 is included in the GL67A cationic lipid mixture for its
charge-shielding properties that facilitate final preparation of the pGM169/GL67A drug product and allow
efficient nebulisation.
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dispensed into individual 10-ml glass lyophilisation vials such that each vial contained 38.8mg of GL67,
93.7mg of DOPE and 17.8 g of DMPE-PEG5000. The vials were freeze-dried under nitrogen gas for
approximately 94 hours at temperatures ranging from –50 °C to +10 °C. The vials were capped with
aluminium crimp caps, coded and stored at –80 °C. The material is stable for at least 3 years.
Preclinical toxicology of the selected formulation: murine
To comply with the Medicines and Healthcare products Regulatory Agency (MHRA) regulations, a
multidose toxicology study in rodents (mice) was performed under good laboratory practice and the study
was outsourced to a clinical research organisation (CRO).
Protocol development and selection of clinical research organisations
The protocol was developed with the help of a toxicology consultant (Professor Anthony Dayan, Professor
of Toxicology at Barts Hospital, London, UK). In addition to standard toxicology, assessment of DNA and
mRNA biodistribution into organs other than the lung was assessed using molecular assays. The study was
tendered to six national and international CROs, and selection was based on expertise in conducting
inhalation toxicology studies and molecular analysis, costs and flexibility. The inhalation study and
toxicology assessment were placed with Charles River (Edinburgh, UK) and the molecular analysis at
BioReliance (Glasgow, UK). The studies were performed in several stages, detailed in Inhalation study and
toxicology assessment at Charles River and Molecular analysis at BioReliance.
Inhalation study and toxicology assessment at Charles River
This was performed in three phases: (1) analytical development; (2) a feasibility study; and (3) the main
toxicology study.
Analytical development
This phase was used to develop methodologies, validation and specifications for the analysis of pDNA and
liposome in inhalation toxicology studies. An important aspect was to show that the AeroEclipse® II (Trudell
Medical International Europe Ltd, Nottingham, UK) nebuliser to be used in the trial was able to generate
droplet sizes suitable for mouse inhalation studies.
Feasibility study
This showed that mice tolerated the prolonged (6 hour=maximum feasible dose) exposure in the
nebulisation chamber and that gene transfer and gene expression could be achieved using the inhalation
chambers used at Charles River.
Main toxicology study
This consisted of four dosing cohorts (low, medium, high and air control), corresponding to approximately
5-, 20- and 60-fold the anticipated human dose (mg/kg). Mice were exposed on 12 occasions over a
6-month period to mimic the human trial protocol (consistent with relevant guidelines). Controls were
exposed to air for 6 hours. The study involved approximately 700 mice (including animals dosed for
assessment of gene expression and biodistribution; see Molecular analysis at BioReliance). Standard
non-invasive assessments were made at regular intervals and post-mortem toxicology undertaken 2 weeks
or 3 months after the last dose. Additionally, molecular analyses to assess gene expression and
biodistribution were performed. The treatment was well tolerated by all mice. In the high-dose group,
small increases in lung weight and circulating neutrophils were seen 2 days after the last dose (dose 12);
this was not observed in the cohort sacrificed 14 days after the last dose. Two weeks after administration
of the last dose scattered alveolar macrophages were seen on histology in the low- and medium-dose
groups. Multifocal alveolar foamy macrophage accumulation and occasional inflammatory changes were
recorded in the high-dose group. Fat-laden macrophages were observed by Oil Red O (ORO; VWR
International Ltd, Lutterworth, UK) staining. There was no evidence of structural remodelling. All other
organs were unremarkable. Three months after administration, findings were no different from baseline in
the low-dose group, but were still observed in the medium- and high-dose animals.
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Molecular analysis at BioReliance
The study was again performed in three phases: (1) assay transfer; (2) validation of extraction methods;
and (3) the main biodistribution study.
Assay transfer
Molecular assays [quantitative polymerase chain reaction (qPCR) and quantitative reverse transcription PCR
reaction (qRT-PCR) for the detection of pGM169 were developed by the UK CFGTC and the know-how
and experimental details were transferred to BioReliance where the protocols were validated to ensure that
sensitivity and reproducibility of the assays were compliant with regulatory requirements.
Validation of extraction
The validation of extraction study demonstrated that the clinical trial plasmid could be successfully retrieved
from all tissue selected for the biodistribution and gene expression studies (lung, gonad, gut, spleen,
kidney, liver, lymph nodes and blood), as well as determining the detection limits of the assays.
Main biodistribution study
The main biodistribution study was designed to assess the level and persistence of DNA and
pGM169-specific mRNA in the above organs. Male and female mice (n= 10 per treated group) were
sacrificed after one, six and 12 doses and organs analysed using qPCR. A dose–response relationship was
observed between duration of inhalation and the quantity of pDNA present in the lungs 1 day after
delivery of 1, 6 and 12 doses (p< 0.0001; Spearman's rank correlation coefficient). pDNA remained
detectable in the lungs of animals for up to 21 weeks after the final (high) dose. Levels of pDNA in
non-target organs were several orders of magnitude lower than the lungs at day 1 and generally did not
persist for > 2 months. pGM169-specific mRNA was not detectable in any organs other than the lung.
When CFTR mRNA was measured in the lungs, low levels were detected after a single dose in the
low- and medium-dose groups, with increased signal in the high-dose group (p< 0.001; equivalent to
≥ 100% endogenous levels). Robust levels of CFTR mRNA remained in the lung for at least 21 weeks after
the final exposure.
In conclusion, all animals tolerated the treatment well. The transient and dose-related systemic
inflammatory responses and drop in lung function observed in the single-dose pilot study (see Choice of
dose and adjunctive treatments: single-dose pilot study) were not replicated in non-CF mice. Mice only
developed mild systemic inflammation at the highest dose (≈50-fold of the human dose) possibly
highlighting species differences or an increased response to the lipid–DNA complexes in the inflamed
human CF lung. The mouse multidose toxicology study supports progression into a multidose CF gene
therapy trial. Key data are summarised in Alton et al.67
Preclinical toxicology of the selected formulation: ovine
Following MHRA discussions, the UK CFGTC also used its in-house sheep core facility to undertake a study
of nine monthly administrations of 10ml of the therapeutic product administered via the inhalation route.
Repeated gene delivery was very well tolerated by the animals, with no obvious clinical signs throughout
the study. The majority of changes observed were mild and were observed both in anaesthetic controls
(CONs) and gene therapy-treated (GT) animals. Some mild changes in animal body weight and
haematological parameters were observed at day 1 in both groups, and are likely to be a consequence of
the anaesthetic procedure; for example, food was withheld from animals the night before an anaesthetic
procedure to avoid bloating as a result of rumen gas accumulation. Specifically, the absence of a gene
therapy-related increase in the acute-phase protein haptoglobin contrasts with previous studies that
demonstrated a significant rise following a 20-ml dose of the same pGM169/GL67A complex. Although an
upwards trend in the serum creatinine levels was observed in the GT group, the increase was small, all
values were within the normal reference range and final values after the 4-week recovery period were
lower than baseline levels.
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A gene therapy-specific effect was seen in bronchoalveolar lavage (BAL), which was assessed after doses 1,
5 and 9. This was manifested by increases in total BAL cell number, neutrophils, macrophages and
lymphocytes. These changes are consistent with the previously observed changes in the sheep lung at
day 1 after a 20-ml dose. However, encouragingly, rather than being exacerbated by repeated delivery,
the response was less pronounced after dose 9 and the observed changes had always fully resolved by
day 15 after delivery. The increase in BAL macrophage and lymphocyte numbers was only observed after
dose 1. There were no significant changes in any aspect of lung function attributable to the gene
therapy administration.
In the lungs, common to all three groups (GT, CON and untreated animals), was minimal/mild
lymphoplasmacytic, and sometimes eosinophilic, inflammation around bronchioles and some blood vessels.
This was present in most samples, and is consistent with background immunosurveillance and/or indicative
of previous parasite exposure. Alveolar histiocytosis was also common to all three groups, and is not
unusual in the ovine lung, especially if sheep are not specific pathogen free or in climate- or pathogen-
controlled housing. There were no notable changes that suggest accumulation of lipid related to gene
therapy treatment. No adverse effect of the test article was observed on lung morphometry, indicating no
changes in alveolar septal thickness or alveolar size after nine doses. In the additional organs assessed,
there was nothing to point to an adverse effect of treatment. Lesions present were consistent with
background inflammation or immunosurveillance, were incidental and present in all three groups.
Choice of nebuliser for clinical trial programme
In total, five commercially available, Conformité Européenne marked jet nebuliser devices were compared
(four PARI Medical Ltd breath-enhanced design nebulisers and one inherently breath-actuated nebuliser:
the AeroEclipse® II, Trudell Medical International Europe Ltd, Nottingham, UK).
The different investigations focused on:
1. Median mass aerodynamic diameter (MMAD) aerosol droplet size and fine particle fraction (FPF; that
proportion of the aerosol droplets ≤ 5 µm, which are those thought likely to be deposited within the
airways) with two commercially available nebuliser compressor devices, or with continuous gas supplies
operating at either 29 psi or 50 psi.
2. Aerosol delivery rate, and inhalation efficiency (the proportion of the produced aerosol that can be
retained within the lung rather than immediately exhaled) in breath actuated and non-breath actuated
modes at an operating gas pressure of 50 psi.
3. pDNA stability during the aerosolisation process. Jet nebulisation results in a modest degree of
non-specific pDNA damage.68 The damage is associated with loss of supercoiled pDNA forms, an
increase in linear forms and the appearance of degraded DNA after agarose gel electrophoresis.
All test nebuliser device and operating gas supply combinations resulted in the generation of respirable
pCIKLux/GL67A aerosol droplets. A reduction in aerosol MMAD and an increase in aerosol FPF were
generally observed with increasing operating pressures. Operating the test nebuliser devices under breath
actuation conditions reduced the rate of aerosol delivery, but increased the inhalation efficiency. Both Pari
LC+ (PARI Medical Ltd, Surrey, UK) and AeroEclipse® II devices impart a modest degree of pDNA damage
during aerosolisation. Of the five nebuliser devices evaluated, only the AeroEclipse® II device is capable of
operating in a breath-actuated mode. Given the considerable enhancement in inhalation efficiency of
pCIKLux/GL67A aerosol observed and the lack of inferiority in the other parameters measured, the
AeroEclipse II was selected as the preferred nebuliser device for clinical studies of pGM169/GL67A. The
measured MMAD of pGM169/GL67A aerosols using the AeroEclipse® II was 3.4 ± 0.1 µm, with a FPF of
71.4% ± 1.5%.69 To confirm that nebulisation does not alter the ability of pGM169/GL67A to generate
11
DOI: 10.3310/eme03050 EFFICACY AND MECHANISM EVALUATION 2016 VOL. 3 NO. 5
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Alton et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
functional chloride channels, HEK-293T cells [American Type Culture Collection (ATCC), Teddington, UK]
were transfected with pGM169/GL67A. The cells were collected prior to nebulisation and at the end of
nebulisation (residual volumes in the nebuliser) and an iodide efflux assay, commonly used to assess CFTR
function, was performed as previously described.70 Levels of cAMP-mediated iodide efflux were similar
when using pGM169/GL67A before and after nebulisation (data not shown).
Choice of dose and adjunctive treatments: single-dose
pilot study
Dose ranging was undertaken in the single-dose trial (manuscript in preparation). In brief, we observed
that, despite depletion of pro-inflammatory CpG motifs, 20-ml nebulised doses led to systemic
inflammatory responses and an acute reduction in pulmonary function; although these were largely well
tolerated, we considered them unacceptable for repeated application. The side effects were clearly dose
related. The group receiving 5-ml doses had no, or very low-level, fever, minimal rises in systemic
inflammatory markers and small, self-limiting reductions in lung function after dosing; 10ml was
somewhere in between and, although probably acceptable, we had concerns that blinding, of either
patients or staff, could be compromised. A 5-ml dose was therefore chosen for the current trial. In
addition, standard doses of the antipyretic agent paracetamol post dosing appeared to further reduce both
symptoms and inflammatory markers and was administered within 2 hours of dosing and again 6 hours
later, with a specific aim to ensure patient blinding.
Summary
Cystic fibrosis is a life-limiting disease; currently, there is no treatment targeted at the basic defect in
the majority of patients. The UK CFGTC considers that gene therapy has the potential for broad,
mutation-independent applicability and has set out to design a clinical trial of the optimal non-viral
formulation powered to detect clinical benefit.
In Chapter 2, the specific design of the trial, along with background and rationale for the choice of
outcome measures, is discussed.
INTRODUCTION AND BACKGROUND
NIHR Journals Library www.journalslibrary.nihr.ac.uk
12
Chapter 2 Methods: clinical trial design and
outcome measures
This trial was a placebo-controlled, parallel trial of 12 monthly doses of the gene therapy product orplacebo. Given the chronic nature of the disease, this time period was judged to be an adequate one
over which to observe potential improvements in clinical outcomes, while not overburdening patients. It is
a time period chosen in similarly designed trials of other agents.
Trial formulation
l Active: GL67A nebulised and applied via nasal spray.
l Placebo: 0.9% saline.
Trial objectives
1. To assess the clinical benefit of the gene therapy formulation when given on a monthly basis over a
period of 1 year.
2. To assess the safety and tolerability of the formulation over the same period.
3. To assess gene expression of the formulation over the same period.
Additional research questions
1. Will markers of molecular efficacy (mRNA and PD) measured in the lung correlate with changes in
clinical end points?
2. Will markers of molecular efficacy measured in the nose correlate with these markers measured in the
lungs in the same patients?
3. Will molecular efficacy increase with repeated administration when measured serially in the same patient?
4. Will it be possible to identify the phenotype of responders or non-responders to allow stratification of
patients for future gene therapy trials?
5. Will it be possible to identify stratifiable biomarkers from the secondary outcomes, based on
disease severity?
6. Will one (or more) of the secondary outcome measures provide different or better information than
FEV1, allowing it to be proposed as a novel registrable biomarker for future trials?
7. Will the extensive preclinical molecular efficacy data produced in support of this study correlate with
similar data in humans?
8. Will the extensive two species toxicology package produced in support of this study correlate with the
findings in humans?
13
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Trial sponsorship, oversight and approvals
The protocol was developed by the UK CFGTC Strategy Group members and trial statistician (GM) and
sponsored by Imperial College London, London, UK.
The protocol was submitted to the GTAC on 7 October 2011 and received approval on 8 March 2012
(GTAC number 184). Clinical trials authorisation was received from the MHRA on 2 February 2012
(EudraCT number 2011-004761-33) and approvals from research and development at all clinical sites was
obtained prior to commencing. The trial is registered on clinicaltrials.gov (NCT01621867) and ISRCTN
(Current Controlled Trials ISRCTN71164341).
Trial outcome
For a detailed description see Detailed description of outcome measures and assays.
Relative change from baseline in percentage predicted FEV1.
Major secondary outcomes
These include:
l change in other spirometric values [forced vital capacity (FVC), mid-expiratory flow 25–75% (MEF25–75%)]
l lung clearance index (LCI)
l structural parameters on computed tomography (CT) scans of the chest
l a validated quality-of-life score (as measured by the Cystic Fibrosis Questionnaire – Revised; CFQ-R).71
Other secondary outcomes
Other measures of lung physiology including:
l exercise capacity [maximal oxygen uptake (VO2max)] and activity monitoring
l gas transfer
l Inflammatory markers:
¢ blood – white blood cell count and differential count, C-reactive protein (CRP), serum calprotectin
¢ sputum – soluble inflammatory markers, cellular inflammation, 24-hour weight, solid content, DNA
content, microbiology.
Adverse events (AEs) and other safety measures including:
l blood biochemistry
l haematology
l liver and renal function
l urinary markers
l histology
l fat-laden airway cells.
Mechanistic outcomes
l Transgene-specific DNA and mRNA on bronchial and nasal brushings.
l Nasal and lower airway PD measurements (CFTR protein function).
METHODS: CLINICAL TRIAL DESIGN AND OUTCOME MEASURES
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Statistical considerations in design and analysis
Proposed sample and effect sizes
The sample size derivation was based on outcomes of previous clinical trials in CF and available data on
what is widely considered the minimum clinically meaningful difference. Over the last two decades, a
relatively small number of new drugs have been licensed for the treatment of patients with CF and adopted
internationally as standards of care. Those of particular note include the mucolytic agent, recombinant
human DNase [rhDNase; dornase alpha (Pulmozyme®, Roche)]; tobramycin for the inhaled solution; and the
macrolide, azithromycin.
(a) Recombinant DNase acts by breaking down neutrophil-derived DNA, which contributes significantly to
mucus viscosity. In the most widely cited double-blind, placebo-controlled trial, the drug led to a relative
improvement in FEV1 of 5.8%; this was accompanied by a significant reduction in the frequency of
infective exacerbations.72 This agent is now a licensed product in routine clinical use worldwide.
(b) Tobramycin for inhalation solution (TOBI) was designed as an antipseudomonal antibiotic to be
administered on alternate months, in contrast to other agents that are administered continuously. At
the end of a 6-month trial period, the relative improvement in FEV1 was around 7%.73 This agent is
now considered the gold standard by the regulatory agencies both in Europe and in the USA, to the
extent that all other inhaled antibiotics are required to undergo head-to-head testing with it.
(c) Azithromycin is an orally bioavailable macrolide that was first considered as a useful therapy in CF
after significant success in Japanese panbronchiolitis sufferers. Its mechanism of action is unknown,
but is thought likely to relate to its known anti-inflammatory actions. Several trials have been
conducted in CF, the largest of which reported a 6.2% TE on FEV1 and a significant reduction in the
frequency of exacerbations.74 Azithromycin is now in widespread clinical use for CF.
Our decision to power for a relative change of 6% in FEV1 was made, in part based on these data, and in
part on pragmatic considerations of patient recruitment feasibility and cost of materials. We suggest that the
current consensus supports this change as being a clinically meaningful improvement. Based on run-in study
data [longitudinal assessment of clinical measurements in patients with cystic fibrosis in preparation for a
clinical trial of CFTR gene therapy (unpublished data, Gene Therapy Consortium)], and using the mean of
two measurements at baseline and the mean of two measurements at 12 months, we estimate the standard
deviation (SD) of the percentage change in percentage predicted FEV1 over 12 months to be 10.0%. The
use of duplicate measurements reduces variability substantially, with resultant increases in power. The
corresponding SD using only single measurements is 12.2%. We also demonstrated, using data from the
run-in study, that analysis of percentage predicted FEV1 is more sensitive than analysis of absolute FEV1; the
corresponding SD for percentage change from baseline based on duplicate measurements was 11.6% for
absolute FEV1. With the SD of 10.0%, a total sample of 120 evaluable patients would provide 90% power
at the 5% significance level (2-sided) to detect a difference of 6% between the randomised groups in the
mean change from baseline. With a plan to recruit 130 patients, we would allow a safety margin for
subjects leaving the study prior to completion. This number also allows us to be powered at ≥ 80% to
detect changes in the secondary outcomes LCI and CT scan parameters, which were smaller than we had
previously observed in a study of intravenous antibiotics.65 The above power calculation was conservative in
that covariate adjustment can be anticipated to increase the statistical power.
Statistical analysis
We reviewed the approach taken to the analysis of FEV1 in over 40 published randomised trials of
interventions in CF. There is no consistent approach, with roughly half of the trials using absolute changes
from baseline (for either absolute FEV1, measured in litres, or percentage predicted FEV1) and the other half
using relative changes (i.e. percentage change from baseline in terms of either absolute FEV1 or percentage
predicted FEV1). Analysis of absolute changes is typically based on an analysis of covariance (ANCOVA)
with baseline FEV1 as a covariate, and in some instances relative changes were also analysed with an
ANCOVA to adjust for baseline FEV1.75 The clinical investigators were of the opinion that in the context of
this trial and, in particular, given the age range of the recruits, the clinically relevant measure of TE is the
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relative (percentage) change from baseline in the percentage predicted FEV1 and not the absolute change.
The primary analysis was designed to compare the two randomised groups in terms of the mean
percentage change in percentage predicted FEV1 from baseline to end of treatment.
An ANCOVA model was designed to include baseline percentage predicted FEV1, together with the other
variables used in the randomisation algorithm, as covariates. ‘Baseline’ will be defined as the mean of the
FEV1 values from the two pretreatment assessments. ‘End of treatment’ will be taken as the mean of the
values obtained at 14 days and 28 days following the final treatment. The TE will be presented as an
adjusted difference in mean percentage change along with its corresponding 95% confidence interval (CI).
No interim efficacy analyses were planned. As a sensitivity analysis the above analysis would be repeated,
but with the logarithm of the end of treatment percentage predicted FEV1 taken as the response variable,
and the logarithm of the baseline percentage predicted FEV1 included as a covariate in place of its raw
value. An exploratory analysis compared the two randomised groups in terms of the evolution of FEV1 over
the 12 months of treatment. The study was not adequately powered to explore subgroup effects for the
primary outcome measure, although we did plan to look at the stability of the TE over subgroups defined
by the covariates included in the ANCOVA model. The formal analyses were performed by including
interaction terms in the model. A similar approach could be used with certain secondary outcome
measures that are closer to the direct mechanism of action of the study intervention, as there is likely to be
more statistical power with such variables to explore subgroup effects, which could support a ‘stratified
medicine’ approach to the use of gene therapy.
The intention-to-treat (ITT) group was defined as patients randomised and having any subsequent
follow-up data. The per-protocol (PP) population was defined as patients receiving ≥ 9 doses. Demographic
and safety data are presented for both populations. All efficacy data are presented for the PP population.
Subject identification, recruitment and randomisation
Inclusion criteria
1. Cystic fibrosis confirmed by sweat testing or genetic analysis.
2. Males and females aged ≥ 12 years.
3. FEV1 between 50% and 90% predicted inclusive (Global Lung Function Initiative reference ranges;
www.ers-education.org/guidelines/global-lungfunction-initiative.aspx).
4. Clinical stability at screening defined by:
i. not on any additional antibiotics (excluding routine, long-term treatments) for the previous 2 weeks
ii. no increase in symptoms such as change in sputum production/colour, increased wheeze or
breathlessness over the previous 2 weeks
iii. no change in regular respiratory treatments over the previous 4 weeks
iv. if any of these apply, entry into the study can be deferred.
5. Prepared to take effective contraceptive precautions for the duration of their participation in the study
and for 3 months thereafter (as stated in GTAC guidelines)
6. If taking regular rhDNase and is willing, and considered able by independent medical carers, to
withhold treatment for 24 hours before and 24 hours after the gene therapy dose
7. Written informed consent obtained.
8. Permission to inform general practitioner of participation in study.
Exclusion criteria
1. Infection with Burkholderia cepacia complex organisms, MRSA or M. abscessus.
2. Significant nasal pathology including polyps, clinically significant rhinosinusitis, or recurrent severe
epistaxis (nose bleeds; nasal cohort only).
3. Acute upper respiratory tract infection within the last 2 weeks (entry can be deferred).
METHODS: CLINICAL TRIAL DESIGN AND OUTCOME MEASURES
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4. Previous spontaneous pneumothorax without pleurodesis (bronchoscopic subgroup only).
5. Recurrent severe haemoptysis (bronchoscopic subgroup only).
6. Current smoker.
7. Significant comorbidity including:
i. moderate/severe CF liver disease (varices or significant, sustained elevation of transaminases: alanine
transaminase/aspartate transaminase levels of > 100 IU/l)
ii. significant renal impairment (serum creatinine levels of > 150 µmol/l)
iii. significant coagulopathy (bronchoscopic group only)
8. Receiving second-line immunosuppressant drugs, such as methotrexate, ciclosporin and intravenous
immunoglobulin preparations.
9. Pregnant or breastfeeding.
Patient recruitment
We had originally anticipated that the majority of trial participants would be recruited from an earlier
study (the Gene Therapy Run-in) assessing outcome measures at periods of stability (unpublised data,
Gene Therapy Consortuim). However, delays because of funding issues and the resultant drop-off in
patient interest meant that recruitment had to be spread more widely. Initial patients were recruited by
study staff from the adult and paediatric clinics at the Royal Brompton Hospital and from across Scottish
CF centres. Once it was apparent that the pace of recruitment was slower than required, we activated
participant identification centres. Local CF centres were activated in November 2012 and nationwide CF
centres followed in January 2013; in total, 16 outside centres referred patients. These patients attended
one of the three sites for trial-related visits, but continued their clinical care at their referring hospital. All
patients had read a detailed, age-specific information sheet and underwent a thorough briefing before
signing consent. Parents provided consent for participation of paediatric subjects, who were also asked for
their assent to take part. Patient information sheets are available in Appendix 1.
Randomisation
Randomisation was performed by trial staff following a successful screening visit using the electronic
InForm™, version 4.6 (Phase Forward Incorporated, Oracle, CA, USA) system. Patients consenting to
participate in one or more of the mechanistic subgroups were randomised 2 : 1 to enrich for subjects
receiving active treatment; all others were randomised on a 1 : 1 basis. The data required for randomisation
and stratification [centre (London or Edinburgh), age (< 18/≥ 18 years), FEV1 (< 70/≥ 70%) and inclusion in
the mechanistic subgroups] were entered by a member of the trial team, which led to the generation of a
unique patient number corresponding to a blinded randomised arm of the trial. In the event of computer
system failure, a prearranged manual randomisation method was available from the InForm team. The unique
patient number was entered onto the subject’s prescription sheet and submitted to the trial pharmacists who
had access to the unblinding code and prepared the active or placebo product as appropriate.
Preparation of dose and blinding
Assembly of pGM169/GL67A complexes
The pGM169 drug substance and GL67A cationic lipid mixture are imported into the UK by The Clinical
Biotechnology Centre of the University of Bristol, Bristol, UK, by a qualified person acting on behalf of the
UK National Blood Service, a division of the NHS Blood and Transplant Special Health Authority. The dose
preparation is described in full in Appendix 2. Briefly, immediately prior to use, pGM169 and GL67A are
thawed to room temperature and GL67A is hydrated in water for injection. pGM169/GL67A complexes are
prepared by rapidly mixing 5ml of pGM169 and 5ml of GL67A using a disposable syringe-based static
mixer device [Plas Pak Industries, Norwich, CT, USA (Figure 5)]. The final dosage form of pGM169/GL67A
contains nominally 2.6 mg/ml of pGM169, 3.7 mg/ml of GL67, 8.9mg/ml of DOPE and 1.7 mg/ml of
DMPE-PEG5000. The shelf life of the final formulation was 6 hours.
17
DOI: 10.3310/eme03050 EFFICACY AND MECHANISM EVALUATION 2016 VOL. 3 NO. 5
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Alton et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
Blinding
pGM169/GL67A or placebo (0.9% saline) were then filled into AeroEclipse II breath-actuated nebulisers by
unblinded trial pharmacists. To avoid any inadvertent unblinding by clinical staff, nebulisers were taped
and a tamper-proof seal was attached (Figure 6 and see Appendix 3 for details). Clinical trial staff,
participants and trial analysts were blind to allocation until database lock. The 10-ml volumes were placed
in opaque nasal spray devices (GlaxoSmithKline parts number AR5989 30ml bottle/AR9488 30ml
actuator) and the device was primed.
(a)
(b)
FIGURE 5 Mixing of the trial formulation. The pGM169 and GL67A were mixed in a dual-barrel mixing device by
loading the components into the syringe (a) and using a fixed-rate plunge mechanism (b) to deliver this into the
receiving container.
(a) (b)
FIGURE 6 Masking of the nebuliser pots to ensure blinding. AeroEclipse II nebuliser pots are transparent (a) as the
gene therapy formulation has a milky appearance that contrasts clearly with that of the 0.9% saline (clear,
colourless liquid), it was necessary to mask the pots, which was achieved with tape and (b) a tamper-proof seal was
applied to the lid, which also prevented any unintentional spillages.
METHODS: CLINICAL TRIAL DESIGN AND OUTCOME MEASURES
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Administration of doses to trial participants
Patients were pretreated with 200–400 µg of salbutamol via a metered-dose inhaler and spacer device
approximately 20 minutes prior to receiving the trial treatment to prevent bronchospasm in response to the
hypotonic nature of the trial preparation. Nebulisation took place in sealed negative-pressure cubicles, with
external venting to limit spread within the hospital setting; patients were observed and communicated with
through a glass window by the trial team. The 5-ml aliquot was nebulised during cycles of tidal breathing
while patients were wearing a nose clip (Figure 7) for 3 minutes, following which the nebuliser air supply
(8 l/minute) was turned off for a 2-minute rest period. Nebulisation continued for 40 minutes, which was
predetermined as a period after which delivery was complete. Patients in the nasal subgroup administered
one actuation of the nasal spray device to each nostril during the 2-minute ‘off-nebuliser’ period, which
resulted in an approximate 1-ml dose to each nostril (see Figure 7). After dosing, patients either remained in
the cubicle for 40 minutes, or were able to leave wearing a mask to limit spread of exhaled trial product in
the unit. They were observed for 1–2 hours, but no spirometry or temperature measurements were made,
to limit the potential for unblinding related to transient dose-related fever or drop in lung function. Patients
were administered paracetamol (dose adjusted for body weight if < 40 kg) within 2 hours of dosing and
asked to take another dose 6 hours later, once at home. This was again to prevent unblinding of the
active group.
(a) (b)
FIGURE 7 Dose administration. Nebulisation of the trial product in a sealed, negative-pressure cubicle while subject
(a) wears a nose clip and; (b) receives delivery of nasal dose. A member of the study team illustrates the technique.
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Study visits and interventions
Early patient safety cohort adaptive design
An adaptive early recruitment phase was designed to permit the early identification of any cumulative side
effects: 20 subjects (10 active treatment and 10 placebo) would receive three doses at 4-weekly intervals
before any further subjects were dosed. In addition to the visits described below undertaken by the entire
cohort, they were also seen on day 2 post each dose. Clinical examination findings, lung function, gas
transfer and systemic inflammatory markers would then be reviewed in an unblinded fashion by the Data
Monitoring and Ethics Committee (DMEC).
l Should data prove satisfactory, these subjects would continue with subsequent visits and the remainder
of the cohort will begin dosing.
l Should the data be of sufficient concern to the DMEC that progression was unacceptable, a second
cohort of 20 patients would receive three doses of the formulation at a 2.5-ml dose, followed by
DMEC review in a similar fashion.
¢ If these data were acceptable, the trial would continue with all subjects receiving a 2.5-ml dose of
either gene therapy or placebo. In this instance, the initial cohort would be discontinued and an
additional 20 ‘naive’ subjects recruited.
¢ Should the DMEC have considered these data unacceptable, the trial would have been halted.
The adaptive design was not in fact required as there were no concerning safety signals. Safety data from
this cohort are presented in Chapter 5.
Schedule of trial visits
Scheduled study visits and interventions are shown in Table 1.
METHODS: CLINICAL TRIAL DESIGN AND OUTCOME MEASURES
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Detailed description of outcome measures and assays
Clinical examination
Clinical examination included recording pulse rate, blood pressure (BP), respiratory rate, temperature, pulse
oximetry, height, weight and lung auscultation. Patients were assessed by a team comprising medical,
nursing and respiratory physiology personnel.
Spirometry
Forced expiratory manoeuvres from which the FEV1 and the total volume exhaled (FVC) are conventional
measures of airway patency and lung health, and are widely used both clinically and in trial settings for CF.
The MEF (flow at varying percentages of vital capacity) are thought to more closely reflect small, distal
airway disease, but are recognised as being more inherently variable. In CF, FEV1 is closely linked to survival
and is the most widely used primary outcome in clinical trials of respiratory interventions. It is recognised
by regulatory agencies as a surrogate outcome and for this reason, alongside our longitudinal data
demonstrating good power, it was chosen as the primary outcome for this trial. Spirometry was
performed on the EasyOne spirometer (New Diagnostic Design Technologies, Zurich, Switzerland) with
disposable mouthpiece and filter according to the American Thoracic Society (ATS)/European Respiratory
Society (ERS) criteria.76 A minimum of three measurements and the best FEV1, FVC and MEF25–75% were
recorded in absolute values. These values were converted to percentage predicted values based on the
Stanojevic references.77
Lung clearance index
The LCI is a measure derived from a multiple breath washout (MBW), which provides a global
measurement of ventilation inhomogeneity. It can be performed either with inhalation of an inert tracer
gas, such as sulphur hexafluoride (SF6), or by using 100% oxygen to wash out resident nitrogen. In the
case of an exogenous tracer, the gas is inspired until equilibrium is reached between the inhaled and
exhaled air at which point the gas source is removed. The number of lung volume turnovers required until
the expired tracer gas concentration falls to an arbitrary 1/40th of its starting value is used to calculate the
LCI. Individuals with lung disease and greater ventilation inhomogeneity require longer to clear the tracer
gas and, therefore, will have a higher (more abnormal) LCI.
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Many different systems have been used to measure MBW in clinical trials in CF and these have been
summarised in a recent ATS/ERS consensus document.78 Although the mass spectrometer is considered the
gold standard gas analyser, it is very expensive, custom built for MBW and, therefore, not suitable for
widespread use.78 The method adopted in this trial used the tracer gas, SF6, detected by the Innocor™
photoacoustic gas analyser (Innovision, Glamsbjerg, Denmark). Methodology was as described in a recent
trial of the small molecule, ivacaftor.79 In brief, the procedure is performed with a mouthpiece during tidal
breathing while patients wear a nose clip (Figure 8). Triplicate measures are undertaken, with each test
taking approximately 15 minutes. Data are subsequently analysed off-line according to strict standard
operating procedures (SOPs) for quality control using software developed within the consortium. Every
seventh trace was analysed in duplicate by a corresponding team member from the other site.
Cycle ergometry
This test of exercise capacity was performed on a stationary exercise bike with breath-by-breath analysis on
the Innocor photoacoustic gas analyser and was used to calculate VO2max. Subjects were asked to pedal at
a set speed of 70 rpm and maintain this speed throughout the test while wearing a nose clip and
breathing via a mouthpiece attached to a gas analyser. The resistance increased automatically each minute
for as long as pedalling could be sustained. The starting workload and increase in workload was
dependent on the patient’s height, and calculated using the Godfrey protocol.
l Patients < 120 cm use 10W starting resistance and 10-W increments.
l Patients 120–150 cm use 15W starting resistance and 15-W increments.
l Patients > 150 cm use 20W starting resistance and 25-W increments.
The subject’s heart rate, oxygen saturations and Borg scale were measured at rest and at each minute
during exercise. The test was stopped by the operator if the patient’s oxygen saturation fell below 80%,
if they were unable to maintain the required pedalling rate or if there was any concern about the patient’s
condition. Once the test was complete, patients had a 2-minute cool-down period and were monitored
until their oxygen saturation returned to baseline. The Innocor system was validated against standard
calibrated VO2 equipment using paired exercise tests in 12 CF patients. For VO2max, the mean difference
(reference equipment – Innocor) was –0.026 l/minute and the 95% CI was –0.27 to 0.22 l/minute.
(a)
FIGURE 8 Lung clearance index. (a) A child performs a LCI on the Innocor gas analyser; (b) wash-in of the tracer
gas, SF6 (in green) is undertaken until equilibrium; and (c) the gas supply is disconnected and concentration falls
with each subsequent breath as washout occurs (bottom). The black trace denotes flow. (continued )
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Body-worn activity monitoring
Patients were asked to wear the SenseWear® body monitoring system™ (BodyMedia, Pittsburgh, PA, USA)
for at least 7 whole days at time points throughout the trial. The device uses accelerometry, heat flux, skin
temperature and galvanic skin response sensors to gather physiological data on movement and daily
physical activity patterns. These armbands have been validated in normal subjects and a number of patient
groups.80 Data from activity monitors were downloaded and analysed using proprietary software. Final
data were analysed when there were at least 4 days of data, at least 1 day was on a weekend and there
were at least 10 hours of data for each day.
This analysis yields data for the proportion of time that wearers spend at various levels of energy
expenditure. For the purposes of summarising these data in the present trial, a comparison was made
(between active and placebo groups) of the percentage of time spent in vigorous exercise (defined as
> 3 metabolic equivalents; METs) compared with the percentage of time spent at ≤ 3 METs of activity,
as well as the mean number of steps taken per day.
Gas transfer
The transfer factor of the lung for carbon monoxide (TLCO) was measured using a single-breath technique
(London site: Jaeger Masterscreen, CareFusion, Germany; Edinburgh site: CPL, nSpire Health, England).
Subjects, who were seated and wearing a nose clip, were asked to exhale to residual volume, then take a
maximal inspiration (required to be > 90% vital capacity) of the test gas (medical air with 0.28% carbon
monoxide and 9% helium) prior to a breath hold of 10 seconds’ duration and a smooth exhalation. This
procedure was repeated at least twice on each test day (minimal interval between tests was 4 minutes).
Duplicate estimates of TLCO were required to be within 10% or 1.0 mmol/minute/kPa (whichever was
greater) to meet requirements for inclusion. At least two technically acceptable tests from up to 10
attempts were obtained and the mean values were used for analysis. The following values were recorded
for each test: single-breath TLCO, alveolar volume (VA), transfer coefficient (KCO; derived from TLCO/VA)
and inspiratory vital capacity. TLCO and KCO were corrected for most recent haemoglobin (usually
obtained on the same day) and expressed as corrected TLCO (TLCOc) and corrected KCO (KCOc) using
standard formulae.
Quality-of-life questionnaire
The validated CFQ-R for either adults or children was completed by subjects at time points throughout the
trial, always at the start of a visit before any other study investigations. The questionnaire is available in
Appendix 4.
Lung computed tomography scanning
High-resolution CT scans were obtained on 64-channel multidetector scanners (SOMATOM Sensation 16
or 64; Siemens Medical Solutions, Erlangen, Germany). On two occasions (pre-dosing and at 28± 5 days
after dose 12) patients underwent a full scan comprising contiguous thin sections (1.25mm) through the
entire volume of the lungs obtained during inspiration and also interspaced (1-mm sections at 10-mm
increments) at end-expiration. A high-spatial-resolution algorithm was used for image reconstruction. All
CT scans were scored independently by the same two radiologists specialising in thoracic imaging; scans
had been anonymised and scores were assigned with the radiologists blinded to both subject identification
and whether pre- or post-dosing. All scoring was performed directly from workstations with access to
image manipulation including window settings (default: width 1500 Hounsfield units, centre 500
Hounsfield units). The presence and severity of specific CT scan features were recorded for each lobe as
previously described.81 The features studied were extent of bronchiectasis, severity of bronchiectasis,
bronchial wall thickness, small and large airway mucus plugs (all scored per lobe on a range of 0–4 and
the results meaned) and gas trapping (scored on a percentage basis) (features illustrated on examples
in Figure 9). In addition, as a safety outcome, all subjects underwent a limited-cut inspiratory CT scan
pre-dosing at the dose 4 visit; these scans were not formally scored, but were reviewed in real time by the
clinical radiology team for any acute changes and the reports were provided to the DMEC.
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(a)
Thickened, 
bronchiectatic airways
(b)
FIGURE 9 Computed tomography parameters. (a) Examples of bronchiectasis; (b) gas trapping (areas of mosaic
attenuation highlighted in yellow where gas has failed to empty from areas of lung on expiration); and (c) an area
of dense small mucus plugs in the left-lower lobe highlighted in yellow. (continued )
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(c)
FIGURE 9 Computed tomography parameters. (a) Examples of bronchiectasis; (b) gas trapping (areas of mosaic
attenuation highlighted in yellow where gas has failed to empty from areas of lung on expiration); and (c) an area
of dense small mucus plugs in the left-lower lobe highlighted in yellow.
Venepuncture for blood sampling
This was performed by an experienced practitioner after the application of topical anaesthetic cream,
if desired by the patient, via a peripheral vein. The use of central indwelling intravenous catheters was
discouraged but not prohibited.
Urine sampling
Urine was collected into a sterile container and tested immediately by dipstick.
Sputum sampling
Sputum was collected after spontaneous expectoration whenever possible. In patients unable to
expectorate, induction was considered at screening and follow-up visits only; all other visits included
administration of study drug and it was considered undesirable to expose the patients to a procedure
known to induce a degree of bronchospasm prior to dosing. The induction protocol followed clinical
guidelines and included pretreatment with an inhaled bronchodilator (200 µg of salbutamol or equivalent,
15 minutes before test). Hypertonic saline (7%) was administered via a deVilbiss 2000 (DeVilbiss
Healthcare Ltd, Tipton, UK) or equivalent ultrasonic nebuliser. Attempts to induce sputum were made
during and after nebulisation and FEV1 was monitored carefully throughout. Prior to dose 1, sputum was
expectorated in 72 out of 116 (62%) of patients [active group, 37/62 (60%); placebo group, 35/54
(65%)]. After the last dose, sputum was expectorated in 57 out 116 (49%) of patients [active group:
27/62 (44%); placebo group: 30/54 (56%)].
At certain visits, patients were asked to collect all sputum expectorated over the previous 24 hours into
50-ml Falcon tubes (VWR International Ltd, Leicestershire, UK) and to bring these with them to the study visit.
Nasal potential difference
The characteristic CF ion transport defects, involving the charged ions chloride and sodium, result in an
altered PD across the respiratory epithelium, measurable in millivolts. Techniques to measure this for both
clinical diagnostic purposes and in the context of trials have been developed.82,83 When compared with
healthy cells expressing CFTR, in CF the absent chloride secretion and sodium hyperabsorption result in an
apical cell surface that is electrically more negative under basal or resting (non-stimulated) conditions.
Amiloride, as a sodium channel blocker, results in a greater reduction (depolarisation) in nasal PD for CF
than non-CF subjects and subsequent ionic and pharmacological challenges to stimulate chloride secretion
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(via chemical gradients and cAMP stimulation) are largely ineffective in CF but lead to pronounced
hyperpolarisation in the presence of functional CFTR (Figure 10).
There have been over 20 previous clinical trials of CF gene therapy, which have involved dosing to the
nose, lung or both.84 In trials involving nasal dosing, nasal PD has been used as a main outcome for
efficacy.39,42,50–52,55,58,84–86 However, these tests are inherently variable and gene therapy-related results have
been similarly so; correlation of any change in nasal PD with molecular evidence of CFTR has also often
been lacking.50,52,58 Where changes in PD have been reported following gene therapy, these have almost
uniquely been restricted to the chloride secretion phase rather than correcting sodium hyperabsorption
phases. This likely reflects the higher proportion of cells required to be corrected before changes in sodium
hyperabsorption can be corrected (> 90% vs. < 10% for restoration of chloride transport).87–89 Use is not
limited to gene therapy evaluation, and recent studies have included trials of the small-molecule drugs
ataluren and ivacaftor. Interestingly, while the latter small-molecule potentiator demonstrated significant
and large-magnitude clinical changes, changes in nasal PD were much more modest.
For reasons of variability, patients electing to participate in the nasal dosing substudy underwent up to
three nasal PDs on different days prior to dosing and two at follow-up appointments. A minority of
subjects also underwent on-treatment recordings at other time points, but these are not included in the
analysis owing to the small number.
0
0
–20
–40
–60
–80
(a)
R RA
c
d
ZCA ZCAI
60 120 180 240 300 360 420 480
Time (seconds)
M
ill
iv
o
lt
s
540 600 660 720 780 840 900 960
(b)
0
0
–20
–40
–60
–80
R RA
a
b
ZCA ZCAI
60 120 180 240 300 360 420 480
Time (seconds)
M
ill
iv
o
lt
s
540 600 660 720 780 840 900 960
FIGURE 10 Representative nasal PD traces from (a) a CF patient; and (b) a healthy volunteer. The CF basal (Ringer’s, R)
measures are higher (more negative) than non-CF largely related to sodium hyperabsorption. For the same reason,
there is a larger drop (depolarisation) to the sodium channel blocker, amiloride (RA). There is little chloride secretion
in response to either a zero chloride solution (ZC, passive gradient) or the cAMP stimulator, isoproterenol (ZCAI), in
contrast to the hyperpolarisation observed in the healthy volunteer.
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At the time of the first measurement in any subject, a single-use, disposable, dual-lumen catheter
(Marquat, France) was fixed in place at the site of maximal unstimulated PD in one nostril; for all
subsequent measurements, the same nostril and the same distance into the nasal cavity was used.
Solutions comprised chemicals listed in the Cystic Fibrosis Foundation Therapeutic Development Network
(CFF TDN)’s SOP90 and were perfused at room temperature at a rate of 4ml/minute in the following
sequence: Ringer’s solution, Ringer’s plus amiloride (0.1 mM), Ringer’s plus amiloride plus zero chloride
and Ringer’s plus amiloride plus zero chloride containing isoproterenol (0.01mM) (Figure 11). Post-dosing
measurements were obtained after 14± 2 days and 28± 5 days.
Traces were obtained using a high-impedance, low-resistance voltmeter (LR-4; Logan Research UK Ltd,
Rochester, UK) onto a laptop computer and were scored by four investigators experienced in the technique
(EWFWA, JCD, SNS and MDW). The four components (baseline, amiloride, zero chloride and isoproterenol
responses) were scored individually using standard criteria.
Nasal brushings
Nasal brushings were performed in subjects in the nasal subgroup both pre-dosing and at 28± 5 days
post final dose from under the middle or inferior turbinate of both nostrils using interdental brushes
(Dent-o-care, London, UK). Cells were suspended in 800 µl of phosphate-buffered saline (PBS) and
processed for transgene DNA/mRNA analysis (see Nasal and bronchial brushings).
Bronchoscopy and associated procedures
Bronchoscopy was undertaken in a subgroup of patients for both efficacy (gene transfer assessed by
mRNA on brushings and PD) and safety assays (remodelling or lipid deposition in endobronchial biopsies).
Potential difference
Cystic fibrosis transmembrane conductance regulator-mediated ion transport is clearly of more relevance in
the lower airway than the nose, but is more complex and invasive to measure. No standardised technique
has been developed and only a few research groups perform this procedure. General anaesthesia is
required to overcome the challenges of interference from patient movement or coughing, and to avoid
local anaesthetic agents that affect ion channel function. The single operating channel within most
fibreoptic bronchoscopes limits the size of the PD catheters used. Although some systems allow for a
double-lumen PD catheter to pass through this port, our group has designed a single-lumen technique.91
PD trace visible on 
laptop computer
Perfusion
pumps
Millivoltmeter and
electrodes
FIGURE 11 Nasal PD. The subject has a double-lumen catheter inserted in one nostril. Solutions are pumped
through one lumen while the other is connected to an electrode via conducting cream. There is a reference
electrode placed subcutaneously on the forearm.
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The technique permits basal and stimulated measurements, although pooling of solutions which then
dilute subsequent perfusate needs to be carefully avoided; for this reason, perfusion rate is slower than
for nasal measurements and an amiloride phase is omitted. We have previously shown clear separation
between CF and non-CF basal PD in the proximal airways, although in both groups PD falls with
distal progression and a disease-specific difference is not seen in the most peripheral sites measured.
As expected, chloride secretory responses are significantly different between CF and non-CF (Figure 12).
This technique was used in our previous trial of GL67-mediated CFTR (with a previous version of the CFTR
plasmid incorporating a CMV promoter) and showed significant improvement in chloride secretion on
day 2 post dosing.58
In the current trial, all bronchoscopies and associated procedures were performed by a single operator
(JCD), with the same senior anaesthetist (BK). Solutions (Ringer’s and a zero-chloride solution) were
manufactured by the pharmacy at Eastbourne Hospital, UK and constituted the chemicals in the CFF TDN
SOP,90 with the exception that amiloride was omitted from the latter. They were warmed prior to use to
reduce the formation of microbubbles, but were used at room temperature and perfused at 100 ml/hour
(Figure 13). Basal (non-stimulated) PD was measured on each wall of the distal trachea with sterile Ringer’s
solution. Where possible, a stable period (< 1mV change over 30 seconds) was recorded. Subsequently, at
three sites more distally (approximately fifth-generation airways; all in one lung), following a second period
with Ringer’s solution, the solution was switched to a zero-chloride equivalent containing isoproterenol
(10 µM) for 5 minutes. The catheter was removed and reprimed between measurements. Hardware and
software were as previously described.91 Measurements were completed before the samples described
below were obtained.
For analysis, recordings (1–3) from the same patient at the same time point were pre-grouped and scored
blinded both for acceptability and response. Recordings were only accepted for scoring if (a) the time of
any inflexion owing to the zero chloride/isoproterenol solution was approximately 50–80 seconds after
onset of perfusion, this duration having previously been shown to represent clearing of the dead space
within the catheter (≈50 seconds) and allowing ≈30 seconds for the initiation of any isoproterenol
response; and (b) the response fell into one of three categories namely no response, continuous upwards
(hyperpolarisation) or continuous downwards (depolarisation) deflection. Recordings were excluded if
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FIGURE 12 Chloride secretory responses on lower airway PD. Summary data demonstrating the increase in
millivolts in lower airway PD in non-CF patients following perfusion with a zero-chloride solution containing
isoprenaline (indicating chloride secretion). The effect is absent in patients with CF. The pre–post design of
measurements in this trial is in an attempt to detect a signal over and above pre-dosing traces in the actively
treated group.91
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(a) the response at the 50- to 80-second time point was unstable (rising or falling); or (b) the deflection
was characterised by both a depolarisation and a hyperpolarisation. Traces were scored by four
investigators with experience in the technique (EWFWA, JCD, KH and SNS).
Bronchial brushing
Ten bronchial brushing samples were obtained from throughout the airways of the same lung using
disposable cytology brushes (BC-202D-5010; Olympus UK, Southend-on-Sea, UK); to prevent cell loss that
occurs while resheathing the brush, the entire bronchoscope was removed each time and the brush cut
while still exposed at the distal end of the scope. Brushed cells were placed into two aliquots of PBS
(five brushings in each) and processed for DNA/mRNA analysis (see Nasal and bronchial brushings).
Endobronchial biopsy
Two endobronchial biopsies were obtained from approximately fifth-generation subcarinae with disposable
forceps (BC-202D-5010, Olympus UK, Southend-on-Sea, UK; Figure 14) and processed as described in
Endobronchial biopsies. Bronchoalveolar lavage was not undertaken, but, where possible, samples of
secretions were sent for microbiological culture.
Post procedure, patients were observed for 4–6 hours prior to discharge.
Single lumen perfusion and recording
catheter on surface epithelium of ≈ fourth
generation airway
Laptop
Millivoltmeter and electrodes
Infusion pumps
FIGURE 13 Bronchial PD measurement. Under video control, the PD catheter is advanced via the bronchoscope
onto the lower airway epithelial surface and can be observed on the screen towards the top of the picture.
Solutions are perfused via pumps to the right and recordings made via a millivoltmeter connected to a
laptop computer.
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Sample handling, preparation and assays
Blood
Routine clinical
Blood samples for electrolytes, renal function, CRP, full blood count and coagulation screen were
processed and reported by the clinical laboratories in accordance with usual routine hospital practice.
Inflammatory markers
Serum was frozen and stored for subsequent cytokine analysis. Serum interleukin 6 was measured on the
Beckman Access 2 immunoassay analyser (Beckman Coulter, High Wycombe, Buckinghamshire, UK).
An in-house calprotectin enzyme-linked immunosorbent assay (ELISA) was used (intra-assay coefficient
of variation= 5.6%; unpublished observations). Calprotectin antibodies were kind gifts of Erling Sundrehagen,
Oslo, Norway. Incubations were carried out in a damp box to prevent potential evaporation during the ELISA
protocol. Microtitre plates (Immulux HB, Dynex Technologies, Chantilly, VA, USA) were coated overnight at
4 °C with 100 µl of anticalprotectin (mouse antihuman) (Axis-Shield Diagnostics Ltd, Dundee, UK; Diatec mAb
Clone Cp5 B1252, Product number 9790) monoclonal antibody at 2.5 µg/ml in coating buffer (KPL/Insight
Biotechnology). Plates were blocked with 1% bovine serum albumin (BSA; Sigma-Aldrich Company Ltd,
Gillingham, UK) for 1 hour at 37 °C and washed four times with 0.05% Tween-20 (Sigma-Aldrich Company
Ltd, Gillingham, UK). Duplicate samples of 100 µl were added to the plate in 1 : 60,000 dilutions for sputum
in PBS and 1 : 500 for serum [50% fetal calf serum (Sigma-Aldrich Company Ltd, Gillingham, UK) in PBS].
Positive controls of calprotectin (Immundiagnostik, Oxford Biosystems, Oxford, UK) were included. Human
recombinant calprotectin (Cambridge Biosystems, Cambridge, UK) was used to produce 1.56–100 ng/ml
standard curves. The samples: anti-calprotectin [chicken antihuman (Axis-Shield Diagnostics, Ltd, Dundee,
UK; lot number: 4095804)] polyclonal antibody at 1 : 5000 dilution; 100 µl of alkaline phosphatase-conjugated
donkey anti-chicken immunoglobulin G (Jackson Product Code 703-055-155, Jackson ImmunoResearch,
Suffolk, UK) at 1 : 5000 dilution were added to wells in three cycles of incubation at room temperature for
1 hour on a platform vibrator (450 rpm) followed by washings. Finally, 100 µl of BluePhos® Microwell
Phosphatase Substrate System (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD, USA) was added to
each well. Plates were incubated in the dark at 600 rpm until the blue colour developed, and reached an
absorption of 620 nm on a BioTek plate reader (BioTek UK, Swindon, UK). Sample concentrations were
calculated using the five-parameter logistic (5PL) non-linear regression curve-fitting model.92
Open biopsy forceps 
approaching a subcarina
Glandular
tissue
Smooth 
muscle
Epithelium
(a) (b)
FIGURE 14 Endobronchial biopsy. (a) The biopsy forceps were advanced under direct vision to a subcarina of an
approximate third- to fifth-generation airway where two biopsies were obtained; and (b) representative
morphology on a haematoxylin and eosin (H&E)-stained section of an endobronchial biopsy demonstrating
pseudostratified columnar epithelium and a submucosa containing smooth muscle, glandular tissue and an
inflammatory cell infiltrate.
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Antibodies against double-stranded DNA (dsDNA) (immunoglobulin G) were processed by the clinical
laboratories using a commercial dsDNA assay was performed on the Immunocap 250 analyser
(ThermoScientific, ThermoFisher Diagnostics, Milton Keynes, UK) in accordance with routine hospital
practice. Out of 232 samples, 218 (94%) were available for analysis. Peripheral blood mononuclear cells
(PBMCs) were extracted and human interferon-γ ELISA for the analysis of CFTR-specific T cells was
performed as previously described.93 Out of 232 samples, 170 (73%) were suitable for analysis.
In the remaining 27% of samples, cell viability was too low to perform the assay. Cell viability was likely
affected by storage of PBMCs in liquid nitrogen and shipment of samples from the UK to the USA, where
the assays were performed.
Sputum
Samples collected into Falcon tubes for 24 hours prior to a visit were weighed. Freshly expectorated
sputum obtained during the trial visit was stored on ice for a maximum of 2 hours and processed as
previously described.65 If patients did not produce sufficient sputum to perform all sputum assays, the
following priority for assays was assigned: (1) clinical microbiology (generated from cough swabs if patients
were completely non-productive); (2) soluble sputum that generated samples for quantification of
interleukin 8 (IL-8), calprotectin and extracellular DNA as well as sputum cells; and (3) sputum solid
content. Samples to prepare soluble sputum were available from 130 out of 232 samples (56%).
Microbiology
Samples were processed according to CF-specific protocols in the microbiology laboratories at the clinical
centres. Semiquantitative reports of cultured bacteria and fungi (and non-tuberculous mycobacteria
pre-dose 1 and at follow-up) were provided. Completely non-productive patients underwent cough swabs
for microbiological surveillance following clinical protocols.
Soluble inflammatory mediators
Sputum calprotectin was measured as described above for serum. Sputum IL-8 assays were performed
using a commercial kit (Human IL-8 Ultra Sensitive Kit, kit number KAC1301; Biosource/Invitrogen, CA,
USA), following the manufacturer’s instructions. Plates were read using a Biotek plate reader, and standard
curves produced using the 5PL non-linear regression curve-fitting model. Extracellular DNA was quantified
in the soluble sputum fraction using the Quant-iT™ PicoGreen® dsDNA Assay Kit (Invitrogen, Paisley, UK)
according to the manufacturer’s recommendations. Sputum solid content was determined as previously
described.65 Out of the expected 232 samples, 169 (63%) were not available because patients did not
expectorate sufficient sputum.
Cell counts
Cells were isolated from solubilised sputum as described (Tracking65) and approximately 105 sputum cells
were cytospun (5 minutes at 500 rpm) onto cytoslides (Thermo Shandon Ltd, Cheshire, UK) (six slides per
subject). Slides were air dried and fixed for 10 minutes in 4% formalin (Sigma-Aldrich, St Louis, M0, USA)
and subsequently stored at –20 °C until further use. For total and differential cell counts, cells were
fixed for 10 minutes in cold methanol (Fisher Scientific, Loughborough, UK), dried and stained with
May–Grünwald–Giemsa (MGG quick stain; Bio-Optica, Milan, Italy) using routine histological procedures
and neutrophils, lymphocytes, macrophages and eosinophils quantified. Cells were counted on random
fields until 300 neutrophils were counted. Total and differential cell counting could be performed on
129 out of 232 (56%) and 111 out of 232 (48%) samples, respectively.
Quantification of intracellular lipid droplets could be performed on 121 out of 232 (52%) of samples
and was performed on slides stained with ORO using a protocol adapted from Lian et al.94 Briefly,
defrosted slides were washed in distilled water, dried and placed for 3 minutes in 100% propylene glycol
(Sigma-Aldrich, St Louis, M0, USA). Slides were then transferred into pre-warmed (60 °C) ORO solution
(0.5% weight to volume in propylene glycol) and stained for 10 minutes in a 60 °C oven. Subsequently
slides were placed into 85% (v/v) propylene glycol for 3 minutes at room temperature and rinsed three
times in distilled water, counterstained with Harris’s haematoxylin (VWR International Ltd, Lutterworth, UK)
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and mounted in Aquatex mounting medium (VWR International Ltd, Lutterworth, UK). Quantification of
lipid staining was performed blinded on each slide. On each slide 300 neutrophils, 100 macrophages and
100 squamous cells were evaluated for the presence of cytoplasmic lipid droplets. The data are presented
as a percentage of lipid-containing cells.
Urine
Samples were dipsticked routinely for glucose, protein and blood. At the start of the trial and on visits
including CT scans, post-menarche female patients underwent urinary pregnancy testing.
Nasal and bronchial brushings
Deoxyribonucleic acid and ribonucleic acid (RNA) were simultaneously isolated from nasal and bronchial
brushing samples using the AllPrep DNA/RNA Mini Kit (QIAGEN, Manchester, UK). Levels of pGM169-specific
and endogenous CFTR DNA and mRNA were quantified using TaqMan® (Life Technologies, Paisley, UK)
qRT-PCR instruments and supplies, following reverse transcription, when appropriate, as described by
Rose et al.95 Absolute DNA and in vitro transcribed RNA calibration standards allowed precise copy number
quantification. pGM169 DNA levels were determined using a qPCR primer set specific for the soCFTR2 cDNA:
l 50 nM forward primer: 5′-GGAACAGCTCCAAGTGCAAGA-3′
l 900 nM reverse primer: 5′-CCTGGTGTCCTGCACTTCCT-3′
l 100 nM probe: 5′-FAM-CAAGCCCCAGATTGCTGCCCTG-TAMRA-3′.
Levels were normalised to total genomic DNA, as determined using a qPCR primer set specific for the
endogenous CFTR gene:
l 300 nM forward primer: 5′-CTTCCCCCATCTTGGTTGTTC-3′
l 300 nM reverse primer: 5′-TGACAGTTGACAATGAAGATAAAGATGA-3′
l 100 nM probe: 5′-VIC-TGTCCCCATTCCAGCCATTTGTATCCT-TAMRA-3′.
pGM169-derived mRNA was determined using qRT-PCR. Reverse transcription reactions (20 µl) contained
≤ 5 µl total RNA, 1.25 units of MultiScribe™ Reverse Transcriptase (Life Technologies) and 0.4 units RNAse
inhibitor (Life Technologies) and 400 nM of the appropriate primer:
l soCFTR2 mRNA: 5′-CCAGCTGAAGAACAGCTTGCT-3′
l human CFTR (hCFTR) mRNA: 5′-CCAGGCGCTGTCTGTATCCT-3′.
pGM169-derived cDNA levels were determined using a qPCR primer set specific for the correctly spliced
exon 1–2 soCFTR2 mRNA:
l 300 nM forward primer: 5’-TCTCCCTCCTGTGAGTTTGGTT-3′
l 300 nM reverse primer: 5’-GCTCACCACAGAGGCCTTCT-3′
l 100 nM probe: 5’-FAM-CTAGCCACCATGCAGAGAAGCCCTCTG-TAMRA-3′.
Levels were normalised to endogenous hCFTR mRNA as determined using a qPCR primer set specific for
the correctly spliced exon 1–2 endogenous CFTR mRNA:
l 300 nM forward primer: 5’-GGAAAAGGCCAGCGTTGTC-3′
l 300 nM reverse primer: 5’-CCAGGCGCTGTCTGTATCCT-3′
l 100 nM probe: 5’-VIC-CCAAACTTTTTTTCAGCTGGACCAGACCAA-TAMRA-3′.
The qPCR reactions (10 µl) contained 0.6–6 ng of total DNA or 2 µl of cDNA and 1 × TaqMan® Universal
MasterMix (Life Technologies Manchester, UK). Thermocycling was performed in 384-well plates, on a
7900HT cycler (Applied Biosystems, Thermofisher, Foster City, CA, USA), with SDS 2.2 software, and the
following cycling conditions: 50 °C for 2 minutes; 95 °C for 10 minutes; then 40 cycles of 95 °C for
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15 seconds and 60 °C for 1 minute. Data were calculated as the percentage of pGM169 specific to
endogenous CFTR copy number. When samples were positive for pGM169-specific signal, but either
quantification fell below the linear range of the standards (limit of quantification; LOQ) or quantification
of endogenous CFTR signal was negative, they were scored as positive but not quantifiable (PBNQ).
Remaining samples that were negative for endogenous CFTR signal were scored as not determined.
Samples negative for the pGM169-specific signal but positive for endogenous CFTR signal were scored as
zero. When data are presented as post–pretreatment difference, a conservative approach was adopted for
samples scored with the nominal value of PBNQ by substituting a value of either zero or the LOQ as
appropriate to maximise the post–pre difference for placebo samples and minimise the post–pre difference
for active samples. For bronchial brushings, two nominally identical samples were typically available
(each pools of five independent bronchial brushings) and the maximum score was reported.
Endobronchial biopsies
Two biopsies were collected from each patient. One was frozen in 2-methylbutane-cooled liquid nitrogen
at –196 °C and the other was immediately fixed in 10% formal saline. The formalin-fixed samples were
processed using a Tissue Tek Sakura VIP processor (Sakura Finetek UK Ltd, Thatcham, UK) and embedded
in paraffin wax blocks. Three micron sections were then cut from these blocks for haematoxylin and eosin
(H&E) staining. For frozen samples, 6- to 8-µm sections were cut for H&E and ORO staining. For H&E
staining, slides were thawed at room temperature for 30 minutes, and then placed in Harris’s haematoxylin
for 1 minute. Subsequently, they were differentiated in acid alcohol for 5 seconds and left to blue in tap
water for 5 minutes. They were then counterstained with eosin for 30 seconds and cover-slipped using an
aqueous mountant.
For ORO staining, frozen sections were thawed and air dried at room temperature for 30 minutes.
Slides were rinsed in 60% 2-propanol then placed in filtered ORO working solution for 15 minutes.
Subsequently, the slides were taken out of the ORO solution and excess dye was washed off with 60%
2-propanol, before rinsing in three changes of distilled water. The sections were counterstained using
Harris’s haematoxylin for 30 seconds in order to visualise the nuclei. The sections were left to blue in
running tap water for 5 minutes and mounted with a coverslip using Aquatex (an aqueous mountant).
H&E slides were scored independently by two blinded pathologists using a semiquantitative scoring system
for goblet cell hyperplasia, basement membrane thickening, presence of chronic inflammatory cells
(lymphocytes and plasma cells), neutrophils, eosinophils and seromucinous gland hyperplasia. ORO slides
were scored for the presence of lipid-laden macrophages using a semiquantitative scoring system.
Data collection and analysis
Trial database, monitoring and audit
The Imperial College Trials Unit (ICTU) built an InForm database specifically for the trial and the staff
working on the trial entered the data from source. The InForm database was monitored by both ICTU on a
regular basis and the Imperial College Research Office undertook on-site source data verification. Two
patients had 100% source data verification and the remainder had 10%. Any queries were flagged on the
database as well as in the case report forms and dealt with by the study team.
Data analysis
A detailed statistical analysis plan (SAP) was drafted by the trial statistician (GDM) and was further refined
with input from the Trial Management Group (see Appendix 5). The SAP was approved by the Trial
Steering Committee (TSC) and finalised ahead of the database being locked and the trial unblinded.
Data management was undertaken using Microsoft Excel® (version 14.4.6 for Mac OSX; Microsoft
Corporation, Redmond, WA, USA). Descriptive statistics and standard analyses were performed using Prism
(Version 5.0c for Mac OSX, Graph Pad Software Inc., San Diego, CA, USA) and or IBM SPSS (version 22.0,
IBM Corporation, Armonk, NY, USA). There was no exploration of the impact of missing values in the
primary analysis as data were available for 114 out of the 116 PP patients.
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Patient and public involvement
Since 2000, when the UK CFGTC started working together, we have had a close relationship with patients
and their families, the ethos of the consortium being to take the patients with us along the gene therapy
pathway. As well as having a formal patient representative on the TSC and input from the National
Institute for Health Research (NIHR) Respiratory Biomedical Research Unit patient group, the UK CFGTC has
attended numerous patient and family meetings to discuss the trial programme as well as future research
projects. Patient input enabled us to refine the trial design in a number of ways, including the length of
time for which a nebuliser may be tolerated and which side effects in an eventual clinical product would
be tolerated.
Owing to the length of the study, one of the biggest challenges we had during the trial was patient
recruitment. Being so involved with the patient groups enabled us to take advantage of social media and
local networks across the UK ensuring that when we opened the patient identification centres patients
were already aware of the study and wanted to participate. Importantly, having patients involved at every
stage of the research process enabled us to design a product that would be tolerated by the patients if it
becomes a licensable product.
In 2013 the patient and public involvement for this project was written up as an INVOLVE case study.96
Role of the funder
This project was supported by the Efficacy and Mechanism Evaluation (EME) programme, a Medical
Research Council and NIHR partnership. The EME programme covered the costs specifically relating to the
clinical trial, including staff, patient visits, assays and data analysis and management. In addition funding
was received from Medicor Foundation and Cystic Fibrosis Trust to cover the production costs of pGM169/
GL67A. The NIHR Clinical Research Network, initially through the Medicines for Children Network and
later the North West London Local Clinical Research Network, provided funding for a paediatric nurse.
Further funding was provided by Just Gene Therapy.
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Chapter 3 Results of clinical efficacy outcomes
Results are reported according to Consolidated Standards of Reporting Trials (CONSORT) guidelines.
Overall timelines
The first patient was screened on 6 June 2012 and the first dose was administered on 13 June 2012.
The last patient was screened on 24 June 2013, the last dose was administered on 1 May 2014 and the
last follow-up visit was performed on 30 May 2014.
Screening and recruitment
Following prescreening of clinic databases, 191 patients were considered likely to be suitable and agreed
to a screening visit. Forty of these were not enrolled, as they failed to fulfil inclusion criteria (see Figure 15).
Of the 151 who passed screening, 11 patients subsequently withdrew, either because of a change of
mind or because of the development of an exclusion criterion. One hundred and forty patients were
randomised: 62 (44%) to placebo and 78 (56%) to active treatment. Two patients in each group withdrew
post randomisation and were not able to reattend for any further visits; therefore, this left 136 in the ITT
cohort, predefined as being randomised and having any follow-up data available. The PP population was
predefined as those patients receiving ≥ 9 doses and comprised 116 patients (placebo, n= 54; active
treatment, n= 62). The reasons for 20 patients discontinuing are shown in Figure 15. Of note, the first
small-molecule CFTR modulator, ivacaftor, was licensed and approved in UK countries during the trial for
patients with the G551D mutation. Three of our subjects elected to leave the trial to enable them to
receive this treatment; others were prepared to wait until the end of the trial and continued.
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Not enrolled
(N = 40)
• FEV1 < 50%, n = 13
• FEV1 > 90%, n = 19
• Clinically unstable, n = 4
• Significant liver disease, n = 3
• Lack of evidence of CF 
   diagnosis, n = 1
Withdrew
( N = 11)
• Withdrew consent, n = 9
• Developed exclusion criteria, n = 2
Subjects were invited
for screening
(n = 191)
Assigned to receive placebo
(N = 62)
• Main cohort, n = 51
• Bronchoscopy subgroup 
   only, n = 4
• Nasal subgroup only, n = 4
• Both subgroups, n = 3
Dosed with placebo
(n = 60)
Withdrew
(N = 2)
• Clinically unstable, n = 1
• Withdrew consent, n = 1
Withdrew
(N = 6)
• Commenced ivacaftor, n = 1
• Developed exclusion 
   criteria, n = 1
• Withdrew consent, n = 4
Received nine or more doses
(n = 54)
Assigned to receive 
pGM169/GL67A
(N = 78)
• Main cohort, n = 52
• Bronchoscopy subgroup 
   only, n = 9
• Nasal subgroup only, n = 10
• Both subgroups, n = 7
Dosed with pGM169/GL67A
(n = 76)
ITT
PP
Withdrew
(N = 2)
• Withdrew consent, n = 2
Withdrew
(N = 14)
• Commenced ivacaftor, n = 2
• Developed exclusion 
   criteria, n = 3
• Missed more than three
   doses, n = 1
• Withdrew consent, n = 8
Received nine or more doses
(n = 62)
Passed screening
(n = 151)
Randomised
(n = 140)
FIGURE 15 The CONSORT diagram showing screening, randomisation and patients dosed. The ITT and PP groups
are identified.
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Subject demographics
Subjects randomised to active-treatment and placebo groups were well matched at baseline for age (and
proportion of paediatric patients aged < 18 years), sex, centre and CFTR gene mutation class (F508del/F508del
vs. other) (Table 2). The two groups were also similar with regard to clinical characteristics including lung
function (FEV1%) and BMI, used here as a general measure of nutritional status.
TABLE 2 Baseline demographic data of subjects randomised to the active-treatment and placebo groups. Data are
presented for both ITT and PP populations. Groups were well matched
Characteristic
ITT placebo
(n= 60)
ITT active
treatment
(n= 76)
ITT total
(n= 136)
PP placebo
(n= 54)
PP active
treatment
(n= 62)
PP total
(n= 116)
Age (years)
Mean 25.9 25.0 25.4 26.0 23.6 24.7
Range 12–64 12–57 12–64 12–64 12–57 12–64
Age distribution, n (%)
< 18 years 19 (32) 25 (33) 44 (32) 17 (31) 23 (37) 40 (34)
≥ 18 years 41 (68) 51 (67) 92 (68) 37 (69) 39 (63) 76 (66)
Sex, n (%)
Female 29 (48) 37 (49) 66 (49) 25 (46) 31 (50) 56 (48)
Male 31 (52) 39 (51) 70 (51) 29 (54) 31 (50) 60 (52)
Centre distribution, n (%)
Edinburgh 28 (47) 27 (36) 55 (40) 24 (44) 22 (36) 46 (40)
London 32 (53) 49 (64) 81 (60) 30 (56) 40 (64) 70 (60)
Height (cm)
Mean 164.5 164.3 164.4 165.0 163.6 164.3
Range 146.6–191.3 133.8–186.2 133.8–191.3 147.4–191.3 133.8–186.2 133.8–191.3
Weight (kg)
Mean 60.9 61.1 61.0 61.6 61.0 61.3
Range 37.0–120.7 33.6–105.4 33.6–120.7 37–120.7 33.6–105.4 33.6–120.7
Percentage predicted FEV1
Mean 67.9 69.2 68.6 69.0 69.9 69.5
Range 48.4–89.9 50.3–89.6 48.4–89.9 49.6–89.9 50.7–89.6 49.6–89.9
BMI
Mean 22.3 22.3 22.3 22.4 22.4 22.4
Range 16.2–41.0 16.7–40.7 16.2–41.0 16.2–41.0 16.7–40.7 16.2–41.0
Mutation class
F508del/F508del 29 37 66 26 31 57
F508del/class 1–6 23 28 51 22 23 45
Not F508del/class 1 2 5 7 1 3 4
Heterozygous/
homozygous class 3–6
3 2 5 2 2 4
F508del/unknown class 3 4 7 3 3 6
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Primary outcome: relative change in FEV1 percentage
Out of 116 PP subjects, 114 (placebo, n= 54; active treatment, n= 60) had paired pre–post-treatment
measurements of percentage predicted FEV1. Two patients, despite fulfilling the PP definition of receiving
≥ 9 doses, were excluded from this analysis as they did not have spirometry performed at follow-up visits;
in one case, this test was contraindicated owing to a recent surgically induced pneumothorax. The other
patient had recently withdrawn from the trial because of time commitments and was unable to return
for follow-up measurements. There was a significant (p= 0.046; Figure 16) TE in the primary outcome,
percentage predicted FEV1, with the active-treatment group having an ANCOVA-adjusted 3.7% (95% CI
0.1% to 7.3%) greater change in FEV1 than the placebo group at 12 months’ follow-up. The effect was
seen from month 1 onwards, with a sustained divergence of the two groups (see Figure 16).
Changes in FEV1 over the course of the trial were variable between subjects. Figure 17 illustrates individual
relative improvements from pretreatment to follow-up in a waterfall plot in which improvement is
indicated by a positive value. Post hoc analysis showed that 21 subjects [placebo, n= 6 (11%); active
treatment, n= 15 (25%)] demonstrated a change in percentage predicted FEV1 of ≥ 5%.
The TE in the ITT population with spirometry measurements both pre-dosing and within the protocol-defined
window after their final dose (placebo, n= 56; active treatment, n= 65) was 3.6% (95% CI 0.2% to 7.0%;
p= 0.039). The SAP prespecified an additional sensitivity analysis based on the area under the curve for
the percentage predicted FEV1. With this analysis, using the PP population, the estimated TE (in units of
percentage predicted FEV1, rather than the relative change) was 1.32% (95% CI –0.48% to 3.12%;
p= 0.15), consistent with the relative TE observed in the primary analysis.
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FIGURE 16 Primary end point (relative change in percentage predicted FEV1). Time course of the response of the
primary outcome to either placebo (green) or active treatment (black). ‘Pre’ and ‘post’ indicate the mean of two
measurements at the respective time points. Error bars indicate SEM. There was a significant (p= 0.046) TE, with
the active-treatment group having an ANCOVA-adjusted improvement of 3.7% (95% CI 0.1% to 7.3%) than
placebo at 12 months’ follow-up. The effect was seen from month 1 onwards, with a sustained divergence of the
two groups. SEM, standard error of the mean.
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FIGURE 17 The distribution of FEV1 changes in individual patients, shown separately for the two groups. (a) Active
treatment; and (b) placebo. Positive values indicate an improvement.
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Major secondary outcomes
Physiology
There was also a significant TE in FVC (p= 0.031; Figure 18; see also Figures 25 and 26). No difference was
observed in the LCI at the follow-up period, although the serial time point graph (Figure 19) demonstrates
that the active-treatment group appear to have a better-preserved LCI in the earlier stages of the trial.
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FIGURE 18 Forced vital capacity. Time course of the response of FVC to either placebo or active treatment.
‘Pre’ and ‘post’ indicate the mean of two measurements at the respective time points. Error bars indicate SEM.
There was a significant (p= 0.031) TE, with the active group having an ANCOVA-adjusted improvement of 3.0%
(95% CI 0.3% to 5.8%) compared with placebo at 12 months’ follow-up. SEM, standard error of mean.
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FIGURE 19 Change in LCI. There was no significant TE in LCI, both groups increasing (worsening) slightly over the
year of the trial.
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Computed tomography scans
Paired pre and post follow-up high-resolution CT scans were available for 115 patients; the one PP patient
missing is the same patient also missing from the analysis of the primary end point as she had been lost to
follow-up. The other patient missing from the primary outcome is represented here, as CT scanning did
not pose the same risks following her pneumothorax as a forced expiratory manoeuvre would have done.
Bronchiectasis is defined as dilatation and thickening of the airways. It is considered irreversible. An
intervention applied for this period of time would not therefore be expected to have any impact on the
extent of bronchiectasis and this was the case in this cohort (Figure 20). Although it was not statistically
significant, it was interesting to note a trend for less worsening in the severity of bronchiectasis in the
active-treatment group than in the placebo.
Gas trapping is a feature visible on expiratory films when areas of lung fail to empty properly because of
airway obstruction. There were increases in the percentage of gas trapping in the placebo group that were
not demonstrated in the active-treatment group and which led to a significant TE (p= 0.048; Figure 21).
Scores of mucus plugging (large or small; Figure 22) and airway wall thickness (Figure 23) did not differ
significantly between the two groups, although, for every parameter, the change was smaller in and,
therefore, favoured the active-treatment group.
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FIGURE 20 Change in CT scores for bronchiectasis (a) extent; and (b) severity.
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FIGURE 21 Gas trapping on CT scan. Over the course of the study, gas trapping indicative of small airways disease,
increased in the placebo group (worsened) but did not in the active-treatment group leading to a statistically
significant TE (p= 0.048).
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Quality-of-life scores
Baseline quality-of-life scores for the domains of major interest in a trial of respiratory treatment
(respiratory and physical) were high for the group as a whole (median 87.5%). There were no statistically
significant TEs at the end of the trial, although, again, the TE appeared to favour the active-treatment
group (Figure 24).
Other secondary outcomes
Figures 25 and 26 show that for all the assays, even those which did not reach significance, the
standardised TE favoured the active-treatment group.
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FIGURE 22 Mucus plugging on CT scan. (a) Large mucus plugging; and (b) small mucus plugging (sometimes
termed ‘tree in bud’).
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FIGURE 23 Airway wall thickness on CT scan.
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FIGURE 24 Quality-of-life (QoL) scores. Change in the (a) respiratory and (b) physical domains on the validated CF
quality-of-life questionnaire CFQ-R.
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Influence of baseline parameters on primary outcome
We had predefined that the influence of baseline parameters on TE of the primary outcome would be
explored in an attempt to define a ‘responder’ group. We reasoned that differences between responders
and non-responders could be based on any of the following:
l Severity of underlying lung disease: patients with milder disease could respond more because the
inhaled medication reached further into the airways, or less because they were already so well.
We examined this using FEV1, LCI and CT parameters.
l Age.
l Sex.
l CFTR mutation class: although we expect gene transfer to be mutation independent, this seemed
necessary to confirm.
l The presence or absence of P. aeruginosa: gene transfer could be affected by the presence of this
organism either because of the greater levels of inflammation likely associated with this chronic
infection or because of an interaction with the wide array of exoproducts it produces. We did not
consider that we had sufficient power to break this down further on the basis of other infections.
l Concomitant medications. Those considered to be particularly important to examine were:
¢ the anti-inflammatory agents, azithromycin and corticosteroids, either of which could affect the
host response to the medication
¢ DNase, which could degrade the DNA in the trial product (of note, patients receiving this drug
were asked to withhold it for 24 hours before and after each dose)
¢ hypertonic saline, which by influencing mucus clearance could potentially reduce contact time.
l Side effects caused by the trial medication: we considered the hypotheses that those patients who
developed either lower respiratory or systemic side effects acutely after dosing could have either a
higher (side effects resulting from successful delivery) or smaller (host response limited success of
transfection) chance of being a responder. To examine this, we classified patients on the basis of
having (1) lower respiratory or (2) flu-like reactions within 48 hours of at least four doses. There were
no subjects in the latter group and, therefore, only the lower airway symptoms were examined in
this analysis.
For each of the continuous variables, the whole PP group was divided based on median values for that
measure. The other variables were divided into two dichotomous groups.
Figure 27 illustrates that TE was independent of age, sex, mutation class, concomitant treatments and
response to dosing. However, stratification by baseline disease severity on the basis of percentage
predicted FEV1 suggested a difference in TE between the lower half (49.6–69.2% predicted FEV1) who
had a TE of 6.4% (95% CI 0.8% to 12.1%) and the upper half (69.6–89.9% predicted) of TE 0.2%
(95% CI –4.6% to 4.9%) (interaction analysis p= 0.065).
This is further illustrated in Figure 28, which shows the evolution of FEV1 over time during the trial in
(a) the half of patients with more severe disease and (b) the half with milder disease. The greater TE was
not because of the use of ‘relative change’ magnifying an effect, as this was also apparent when absolute
change in FEV1 percentage was examined (data not shown).
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FIGURE 28 Primary outcome stratified by baseline FEV1. Time course of the primary outcome response stratified by
baseline FEV1 at trial entry. (a) Severe group, baseline FEV1 49.6–69.2% predicted; and (b) milder group, baseline
FEV1 69.6–89.9% predicted. Error bars indicate SEM. SEM, standard error of the mean.
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Influence of baseline FEV1 on other outcomes
Having observed that baseline FEV1 appeared to have an important influence in the magnitude of the TE
based on the primary outcome, we next examined other outcome measures for this effect. Subjects were
divided into upper and lower halves based on the median value for the entire group, as previously, and TEs
were compared. Figure 29 shows that many of the assays mirrored the effect which had been seen for the
primary outcome, namely the more severe group of patients showing an approximate doubling of the TE
compared with the values in the whole, unstratified group. This resulted in an absolute improvement
(vs. stabilisation) in many of the assays. Of note, in those with less severe FEV1 at trial entry, biomarkers
associated with smaller airways, in particular LCI, still showed a TE favouring the active-treatment group.
We confirmed that these benefits seen in the more severe subgroup were not related to an increased
number of antibiotic courses during the trial. Both active-treatment and placebo groups received a median
of three courses of oral or intravenous antibiotics. In the half with more severe disease, stratified by FEV1,
both placebo and active-treatment groups received three courses, while among those with less severe
disease, the placebo group received three courses and the active-treatment group received two.
Thus, the observed TEs were independent of concurrent antibiotic courses.
Summary of efficacy outcomes
The trial achieved its primary outcome confirming a statistically significant TE favouring the active-treatment
group on relative change in FEV1. This was underscored by statistically significant TEs in the secondary
outcomes, FVC and gas trapping on CT. Furthermore, for all other secondary outcomes, although not
statistically significant, the standardised TE analysis favoured active treatment. In general, these
improvements were seen across the group and were independent of sex, age and mutation class. In
contrast, the magnitude of TE was influenced by the severity of baseline lung disease assessed by FEV1:
patients in the more severe half at baseline experienced larger improvements not only in FEV1 but also in
several other outcomes. Changes in the small airway measure, LCI, were still seen in patients with less
severe baseline FEV1, suggesting that these patients can still benefit.
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Chapter 4 Results of mechanistic substudy
Transgene-specific DNA and mRNA
Nasal
In the nasal arm of the substudy, the assay could quantify a dosing-dependent increase in vector-specific
DNA in 15 out of 15 active-dose subjects post treatment, although in four of these modest levels of DNA
were detected prior to dosing. In the placebo patients, DNA could also be detected in samples from three
out of four subjects post dosing (none prior to dosing); no vector-specific mRNA was quantifiable in
either group.
Lower airway
In the bronchial arm of the substudy, the assay quantified vector-specific DNA in 10 out of 10 active-treatment
patients and zero out of seven placebo subjects post dosing (Figure 30); no vector-specific mRNA was
quantifiable in either group.
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FIGURE 30 Assessment of DNA from bronchial brushings in the placebo (n= 7) and active-treatment (n= 10)
subgroups. Each circle represents an individual patient.
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Potential difference measurements
Nasal
The nasal arm comprised 24 patients in the ITT group, 20 of whom were in the PP. One patient had a
mean total chloride secretory response ≥ 5mV pre-dosing and was, therefore, excluded as prespecified in
the protocol. Day 28 post-treatment recordings for two active-treatment patients had to be delayed
beyond a window of > 7 days of the prespecified interval and were therefore excluded; both patients had
usable values at the day 14 post treatment time point. Overall, 75 out of 106 (70.8%) of zero chloride,
and 70 out of 106 (66.0%) of isoproterenol recordings were interpretable.
There were no significant changes in baseline values or amiloride responses in either the placebo or
active-treatment groups. No significant changes in either the zero chloride or isoproterenol responses were
seen. For the zero chloride component 10 out of 14 active-treatment patients and three out of six placebo
patients showed net secretion (i.e. a more negative value post treatment than pretreatment); 4 out of 14
active-treatment patients showed mean pre–post-treatment responses (ranging from –3.4mV to –7.0mV),
which were more negative than the largest placebo response. For the isoproterenol component, 11 out of
12 active-treatment patients and three out of six placebo patients showed net secretion (Figure 31).
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FIGURE 31 The response of the nasal epithelium to perfusion with (a) a zero chloride solution; and (b) a zero
chloride solution containing isoproterenol (10 µM). Each symbol indicates the change in this response from trial
start to finish for the relevant treatment in an individual patient. The plotted value is the most negative value
obtained from all interpretable recordings (range 1–3) at each time point for that patient. A more negative value
is in the non-CF direction. The placebo group had a median pre–post trial change of + 0.1mV (range +1.1 to
–2.3mV) and the active-treatment group –0.6mV (range +3.5 to –7.0mV) (p= 0.509). The response of the nasal
epithelium to perfusion with a zero chloride solution containing isoproterenol (10 µM). The placebo group showed
a median pre–post trial change of +0.3mV (range +2.9 to –2.6mV) and the active-treatment group –1.0mV
(range +0.1 to –3.8mV) (p= 0.424).
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Bronchial
In the bronchial subgroup, one active-treatment patient withdrew after six doses, but consented to
post-dosing bronchoscopy within the prespecified timing (28± 5 days) after the last dose; values for this
patient are included in the analysis. Post-dosing bronchoscopy was performed on two placebo patients 58
and 62 days after their last doses, and on two active-treatment patients 49 and 111 days after their last
dose. The data for the two placebo patients are included in the final analysis, on the basis that the natural
history of bronchial electrophysiology is unlikely to be influenced by a dose of saline approximately 60 days
previously. Values for the two active-treatment patients were omitted from the final analysis given the
monthly dosing schedule in the trial based on previously generated gene expression data, although their
samples were included in the safety analysis. Overall, 66 out of 102 (64.7%) recordings fulfilled the
acceptability criteria.
There were no significant changes in basal values in either the placebo or active-treatment groups. Figure 32
shows bronchial chloride responses using the mean of all available interpretable tracings for each patient; a
negative value indicates a non-CF direction. The placebo group (n= 7) had a median pre–post trial change
of +3.1mV (range +9.3 to –1.2mV) and the active-treatment group (n= 10) –1.3mV (range +4.0 to
–5.8mV) (p= 0.032). Five out of 10 active-treatment patients had values more negative than the largest
placebo response. Figure 32b shows the same analysis with only the most negative value recorded for
each patient at any time point. The placebo group showed a median pre–post trial change of +2.6mV
(range +9.3 to –1.2mV) and the active group –2.8mV (range + 4.0 to –16.8mV) (p= 0.087). Six out of
10 active-treatment patients had values more negative than the largest placebo response.
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FIGURE 32 Change from pretreatment in the response of the bronchial epithelium to perfusion with a zero
chloride solution containing isoproterenol (10 µM). (a) The response of the bronchial epithelium to perfusion with
a zero chloride solution containing isoproterenol (10 µM). Each symbol indicates the change in this response from
trial start to finish for the relevant treatment in an individual patient. The plotted value is the mean of all
interpretable recordings (range 1–3) at each time point for that patient. A more negative value is in the non-CF
direction. The placebo group had a median pre–post trial change of +3.1mV (range +9.3 to –1.2mV) and the
active group –1.0mV (range +4.0 to –5.8mV) (p= 0.032). (b) The response of the bronchial epithelium to perfusion
with a zero chloride solution containing isoproterenol (10 µM). Each symbol indicates the change in this response
from trial start to finish for the relevant treatment in an individual patient. The plotted value is the most negative
value obtained from all interpretable recordings (range 1–3) at each time point for that patient. A more negative
value is in the non-CF direction. The placebo group showed a median pre–post trial change of +2.6mV (range +9.3
to –1.2mV) and the active group –2.8mV (range + 4.0 to –15.6mV) (p= 0.087).
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Chapter 5 Safety and adverse events
The trial was monitored at intervals by the independent DMEC, who scrutinised the unblinded groupdata and provided written confirmation to the TSC that the trial could continue with no modifications.
Overall, the drug was well tolerated and AEs were of the nature expected in CF trials. In this section we
describe the findings from the early safety cohort, AEs including a detailed description of serious AEs
(SAEs) and present results of safety assays throughout the study.
Early safety cohort
The early safety cohort was designed to include 20 patients receiving three doses under intensified
monitoring conditions ahead of enrolment of the complete cohort. Two patients who had been
successfully screened became unwell before their planned first dose and could not be included without
delaying timelines, so were excluded from this subgroup. The data presented to the DMEC came from
18 patients (eight of whom received placebo), 17 of whom had received three doses and one two doses.
In addition to the procedures outlined in the general protocol, they had been seen for symptom review,
lung function and blood tests (inflammatory markers, liver and renal function) at day 2 following each
dose. The data from this cohort were reviewed by the Data Monitoring Safety Board at a meeting in
September 2012.
Relevant data have been extracted from the closed report, to which the investigators have been unblinded
only since database lock; any amendments to the original text have been made only for typographic or
language errors, otherwise text and tables were as presented.
Throughout this section, the placebo group is referred to as group A and the active-treatment group as
group B.
Adverse events
The AEs are presented as an aggregate number of events and also are listed by site and treatment group.
The total numbers of AEs are presented in Tables 3 and 4.
Table 3 presents the total number of AEs that were observed initially in the trial, we observed that that
there was only one severe AE.
Table 4 presents the number of AEs that were observed 2 days after dosing the subjects. No SAEs were
observed 2 days after dosing the subjects. Table 5 presents changes in spirometric indices.
We observe that, overall, there were no SAEs occurring during the trial.
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TABLE 3 Early safety cohort: number of AEs
Total London Edinburgh
Overall Group A Group B Overall Group A Group B Overall Group A Group B
Number of AEs 130 38 92 103 33 70 27 5 22
Frequency
Single episode 108 32 76 87 27 60 21 5
Intermittent 17 6 11 11 6 5 6 0
Severity
Mild 104 23 72 82 24 55 22 5 17
Moderate 12 4 8 7 4 3 5 0 5
Severe 1 1 0 1 1 0 0 0 0
Life-threatening 0 0 0 0 0 0 0 0 0
Number of expected
AEs
84 22 62 66 18 48 18 4 14
Expected for study
drug
41 16 25 32 12 20 9 4 5
Action taken
None 121 35 86 94 30 64 27 5 22
Dose adjusted 0 0 0 0 0 0 0 0 0
Dose interrupted 1 1 0 1 1 0 0 0 0
Discontinued 0 0 0 0 0 0 0 0 0
Medication used
Yes 24 10 14 18 10 8 6 0 6
No 98 28 70 77 23 54 21 5 16
Outcome
Resolved 105 30 75 83 26 57 22 4 18
Unresolved 9 5 4 5 5 0 4 0 0
Fatal 0 0 0 0 0 0 0 0 0
Relation to study?
Unrelated 19 8 11 11 7 4 8 1 7
Unlike 25 8 17 23 8 15 2 0 2
Possible 39 11 28 25 7 18 14 4 10
Probable 35 6 29 32 6 26 3 0 3
Almost certain 9 5 4 9 5 4 0 0 0
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TABLE 4 Adverse events: 2 days after dosing – number of AEs
Total London Edinburgh
Overall Group A Group B Overall Group A Group B Overall Group A Group B
Number of AEs 10 4 6 10 4 6 0 0 0
Frequency
Single episode 10 4 6 10 4 6 0 0 0
Intermittent 0 0 0 0 0 0 0 0 0
Severity
Mild 9 4 5 9 4 5 0 0 0
Moderate 1 0 1 1 0 1 0 0 0
Severe 0 0 0 0 0 0 0 0 0
Life-threatening 0 0 0 0 0 0 0 0 0
Number of expected
AEs
6 3 3 6 3 3 0 0 0
Expected for study
drug
4 2 2 4 2 2 0 0 0
Action taken
None 10 4 6 10 4 6 0 0 0
Dose adjusted 0 0 0 0 0 0 0 0 0
Dose interrupted 0 0 0 0 0 0 0 0 0
Discontinued 0 0 0 0 0 0 0 0 0
Medication used
Yes 0 0 0 0 0 0 0 0 0
No 10 4 6 10 4 6 0 0 0
Outcome
Resolved 5 1 4 5 1 4 0 0 0
Unresolved 0 0 0 0 0 0 0 0 0
Fatal 0 0 0 0 0 0 0 0 0
Relation to study?
Unrelated 5 1 4 5 1 4 0 0 0
Unlike 0 0 0 0 0 0 0 0 0
Possible 1 1 0 1 1 0 0 0 0
Probable 2 0 2 2 0 2 0 0 0
Almost certain 2 2 0 2 2 0 0 0 0
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Clinical examination
Table 6 presents the change in clinical examination parameters from screening day to dosing day.
The changes in the clinical examination are presented as a number of cases that change from a positive
result to a negative result; change from a negative result to a positive result; and do not change.
TABLE 6 Clinical examination findings: n (%)
Change in clinical
findings
Dosing period 1 Dosing period 2 Dosing period 3
All Group A Group B All Group A Group B All Group A Group B
Ears
Normal to abnormal 0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
No change 18
(100.0)
8
(100.0)
10
(100.0)
18
(100.0)
8
(100.0)
10
(100.0)
17
(100.0)
8
(100.0)
9
(100.0)
Abnormal to normal 0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
Eyes
Normal to abnormal 1
(5.6)
0
(0.0)
1
(10.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
No change 17
(94.4)
8
(100.0)
9
(90.0)
18
(100.0)
8
(100.0)
10
(100.0)
17
(100.0)
8
(100.0)
9
(100.0)
Abnormal to normal 0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
Nose
Normal to abnormal 0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
3
(17.7)
1
(12.5)
2
(22.2)
No change 18
(100.0)
8
(100.0)
10
(100.0)
18
(100.0)
8
(100.0)
10
(100.0)
14
(82.4)
7
(87.5)
7
(77.8)
Abnormal to normal 0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
Throat
Normal to abnormal 0
(0.0)
0
(0.0)
0
(0.0)
1
(5.6)
1
(12.5)
0
(0.0)
2
(11.8)
1
(12.5)
1
(11.1)
No change 17
(94.4)
8
(100.0)
9
(90.0)
16
(88.9)
7
(87.5)
9
(90.0)
14
(82.4)
7
(87.5)
7
(77.8)
Abnormal to normal 1
(5.6)
0
(0.0)
1
(10.0)
1
(5.6)
0
(0.0)
1
(10.0)
1
(5.9)
0
(0.0)
1
(11.1)
Skin
Normal to abnormal 0
(0.0)
0
(0.0)
0
(0.0)
2
(11.1)
0
(0.0)
2
(20.0)
2
(11.8)
1
(12.5)
1
(11.1)
No change 18
(100.0)
8
(100.0)
10
(100.0)
14
(77.8)
8
(100.0)
6
(60.0)
13
(76.5)
7
(87.5)
6
(66.7)
Abnormal to normal 0
(0.0)
0
(0.0)
0
(0.0)
2
(11.1)
0
(0.0)
2
(20.0)
2
(11.8)
0
(0.0)
2
(22.2)
continued
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TABLE 6 Clinical examination findings: n (%) (continued )
Change in clinical
findings
Dosing period 1 Dosing period 2 Dosing period 3
All Group A Group B All Group A Group B All Group A Group B
Heart
Normal to abnormal 0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
No change 17
(94.4)
7
(87.5)
10
(100.0)
17
(94.4)
7
(87.5)
10
(100.0)
16
(94.1)
7
(87.5)
9
(100.0)
Abnormal to normal 1
(5.6)
1
(12.5)
0
(0.0)
1
(5.6)
1
(12.5)
0
(0.0)
1
(5.9)
1
(12.5)
0
(0.0)
Breath sound left lung
Normal to abnormal 0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
No change 18
(100.0)
8
(100.0)
10
(100.0)
18
(100.0)
8
(100.0)
10
(100.0)
17
(100.0)
8
(100.0)
9
(100.0)
Abnormal to normal 0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
Breath sound right lung
Normal to abnormal 0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
No change 18
(100.0)
8
(100.0)
10
(100.0)
18
(100.0)
8
(100.0)
10
(100.0)
17
(100.0)
8
(100.0)
9
(100.0)
Abnormal to normal 0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
Crackles left lung
Absent to present 0
(0.0)
0
(0.0)
0
(0.0)
1
(5.6)
0
(0.0)
1
(10.0)
1
(5.9)
1
(12.5)
0
(0.0)
No change 18
(100.0)
8
(100.0)
10
(100.0)
16
(88.9)
8
(100.0)
8
(80.0)
15
(88.2)
7
(87.5)
8
(88.9)
Present to absent 0
(0.0)
0
(0.0)
0
(0.0)
1
(5.6)
0
(0.0)
1
(10.0)
1
(5.9)
0
(0.0)
1
(11.1)
Crackles right lung
Absent to present 2
(11.1)
1
(12.5)
1
(10.0)
3
(16.7)
2
(25.0)
1
(10.0)
1
(5.9)
0
(0.0)
1
(11.1)
No change 15
(83.3)
6
(75.0)
9
(90.0)
15
(83.3)
6
(75.0)
9
(90.0)
15
(88.2)
8
(100.0)
7
(77.8)
Present to absent 1
(5.6)
1
(12.5)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
1
(5.9)
0
(0.0)
1
(11.1)
Wheeze left lung
Absent to present 0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
Not change 18
(100.0)
8
(100.0)
10
(100.0)
18
(100.0)
8
(100.0)
10
(100.0)
17
(100.0)
8
(100.0)
9
(100.0)
Present to absent 0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
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TABLE 6 Clinical examination findings: n (%) (continued )
Change in clinical
findings
Dosing period 1 Dosing period 2 Dosing period 3
All Group A Group B All Group A Group B All Group A Group B
Wheeze right lung
Absent to present 0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
No change 18
(100.0)
8
(100.0)
10
(100.0)
18
(100.0)
8
(100.0)
10
(100.0)
17
(100.0)
8
(100.0)
9
(100.0)
Present to absent 0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
Other respiratory problems
Absent to present 0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
2
(11.8)
1
(12.5)
1
(11.1)
No change 18
(100.0)
8
(100.0)
10
(100.0)
18
(100.0)
8
(100.0)
10
(100.0)
15
(88.2)
7
(87.5)
8
(88.9)
Present to absent 0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
Abdomen
Normal to abnormal 1
(5.6)
1
(12.5)
0
(0.0)
1
(5.6)
1
(12.5)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
No change 16
(88.9)
7
(87.5)
9
(90.0)
16
(88.9)
7
(87.5)
9
(90.0)
16
(94.1)
8
(100.0)
8
(88.9)
Abnormal to normal 1
(5.6)
0
(0.0)
1
(10.0)
1
(5.6)
0
(0.0)
1
(10.0)
1
(5.9)
0
(0.0)
1
(11.1)
Liver
Normal to abnormal 0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
No change 18
(100.0)
8
(100.0)
10
(100.0)
18
(100.0)
8
(100.0)
10
(100.0)
17
(100.0)
8
(100.0)
9
(100.0)
Abnormal to normal 0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
Spleen
Normal to abnormal 0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
No change 18
(100.0)
8
(100.0)
10
(100.0)
18
(100.0)
8
(100.0)
10
(100.0)
17
(100.0)
8
(100.0)
9
(100.0)
Abnormal to normal 0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
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Current symptoms
Table 7 presents the symptoms expressed as change from the dosing day to 2 days after dosing.
TABLE 7 Reported symptoms: n (%)
Symptom
Dosing period 1 Dosing period 2 Dosing period 3
All Group A Group B All Group A Group B All Group A Group B
Breathlessness
Absent to
present
1
(5.6)
0
(0.0)
1
(10.0)
2
(11.1)
0
(0.0)
2
(20.0)
0
(0.0)
0
(0.0)
0
(0.0)
No change 16
(88.9)
8
(100.0)
8
(80.0)
13
(72.2)
8
(100.0)
5
(50.0)
15
(88.2)
7
(100.0)
8
(80.0)
Present to
absent
1
(5.6)
0
(0.0)
1
(10.0)
3
(16.7)
0
(0.0)
3
(30.0)
2
(11.8)
0
(0.0)
2
(20.0)
Increase cough
Absent to
present
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
4
(23.5)
0
(0.0)
4
(40.0)
No change 17
(94.4)
8
(100.0)
9
(90.0)
12
(66.7)
7
(87.5)
5
(50.0)
9
(52.9)
6
(85.7)
3
(30.0)
Present to
absent
1
(5.6)
0
(0.0)
1
(10.0)
6
(33.3)
1
(12.5)
5
(50.0)
4
(23.5)
1
(14.3)
3
(30.0)
Wheeze
Absent to
present
0
(0.0)
0
(0.0)
0
(0.0)
1
(5.6)
0
(0.0)
1
(10.0)
0
(0.0)
0
(0.0)
0
(0.0)
No change 18
(100.0)
8
(100.0)
10
(100.0)
16
(88.9)
8
(100.0)
8
(80.0)
17
(100.0)
7
(100.0)
10
(100.0)
Present to
absent
0
(0.0)
0
(0.0)
0
(0.0)
1
(5.6)
0
(0.0)
1
(10.0)
0
(0.0)
0
(0.0)
0
(0.0)
Haemoptysis
Absent to
present
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
No change 18
(100.0)
8
(100.0)
10
(100.0)
18
(100.0)
8
(100.0)
10
(100.0)
17
(100.0)
7
(100.0)
10
(100.0)
Present to
absent
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
Chest pain
Absent to
present
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
No change 18
(100.0)
8
(100.0)
10
(100.0)
18
(100.0)
8
(100.0)
10
(100.0)
17
(100.0)
7
(100.0)
10
(100.0)
Present to
absent
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
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TABLE 7 Reported symptoms: n (%) (continued )
Symptom
Dosing period 1 Dosing period 2 Dosing period 3
All Group A Group B All Group A Group B All Group A Group B
Cardiovascular
Absent to
present
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
1
(5.9)
0
(0.0)
1
(10.0)
No change 18
(100.0)
8
(100.0)
10
(100.0)
17
(94.4)
7
(87.5)
10
(100.0)
15
(88.2)
7
(100.0)
8
(80.0)
Present to
absent
0
(0.0)
0
(0.0)
0
(0.0)
1
(5.6)
1
(12.5)
0
(0.0)
1
(5.9)
0
(0.0)
1
(10.0)
Gastrointestinal
Absent to
present
1
(5.6)
1
(12.5)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
2
(11.8)
0
(0.0)
2
(20.0)
No change 16
(88.9)
7
(87.5)
9
(90.0)
17
(94.4)
8
(100.0)
9
(90.0)
12
(70.6)
6
(85.7)
6
(60.0)
Present to
absent
1
(5.6)
0
(0.0)
1
(10.0)
1
(5.6)
0
(0.0)
1
(10.0)
3
(17.7)
1
(14.3)
2
(20.0)
Throat
Absent to
present
2
(11.1)
0
(0.0)
2
(20.0)
1
(5.6)
0
(0.0)
1
(10.0)
1
(5.9)
0
(0.0)
1
(10.0)
No change 13
(72.2)
7
(87.5)
6
(60.0)
17
(94.4)
8
(100.0)
9
(90.0)
14
(82.4)
6
(85.7)
8
(80.0)
Present to
absent
3
(16.7)
1
(12.5)
2
(20.0)
0
(0.0)
0
(0.0)
0
(0.0)
2
(11.8)
1
(14.3)
1
(10.0)
Eye
Absent to
present
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
No change 18
(100.0)
8
(100.0)
10
(100.0)
18
(100.0)
8
(100.0)
10
(100.0)
17
(100.0)
7
(100.0)
10
(100.0)
Present to
absent
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
Ears
Absent to
present
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
No change 18
(100.0)
8
(100.0)
10
(100.0)
18
(100.0)
8
(100.0)
10
(100.0)
17
(100.0)
7
(100.0)
10
(100.0)
Present to
absent
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
Nose
Absent to
present
2
(11.1)
0
(0.0)
2
(20.0)
1
(5.6)
0
(0.0)
1
(10.0)
0
(0.0)
0
(0.0)
0
(0.0)
No change 15
(83.3)
8
(100.0)
7
(70.0)
16
(88.9)
7
(87.5)
9
(90.0)
17
(100.0)
7
(100.0)
10
(100.0)
Present to
absent
1
(5.6)
0
(0.0)
1
(10.0)
1
(5.6)
1
(12.5)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
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Vital signs
Table 8 presents the change from screening day to dosing day. A negative change indicates a decrease in
vital sign parameters.
Biochemistry parameters
Table 9 presents the change from screening day to dosing day. A negative change indicates a decrease in
the biochemistry parameters.
Haematology parameters
Table 10 presents the change from screening day to dosing day. A negative change indicates a decrease in
the haematology parameters.
Gas transfer
Table 11 presents the change from the screening day to 2 days after dosing. A negative change indicates a
decrease in the gas transfer.
In summary, the DMEC did not consider there was a safety signal on reviewing these results and wrote
approving continuation of full recruitment into the trial at the 5-ml dose.
TABLE 7 Reported symptoms: n (%) (continued )
Symptom
Dosing period 1 Dosing period 2 Dosing period 3
All Group A Group B All Group A Group B All Group A Group B
Neurological examination
Absent to
present
1
(5.6)
0
(0.0)
1
(10.0)
1
(5.6)
1
(12.5)
0
(0.0)
3
(17.7)
1
(14.3)
2
(20.0)
No change 14
(77.8)
7
(87.5)
7
(70.0)
13
(72.2)
5
(62.5)
8
(80.0)
13
(76.5)
6
(85.7)
7
(70.0)
Present to
absent
3
(16.7)
1
(12.5)
2
(20.0)
4
(22.2)
2
(25.0)
2
(20.0)
1
(5.9)
0
(0.0)
1
(10.0)
Skin
Absent to
present
2
(11.1)
0
(0.0)
2
(20.0)
1
(5.6)
0
(0.0)
1
(10.0)
1
(5.9)
0
(0.0)
1
(10.0)
No change 16
(88.9)
8
(100.0)
8
(80.0)
17
(94.4)
8
(100.0)
9
(90.0)
15
(88.2)
6
(85.7)
9
(90.0)
Present to
absent
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
1
(5.9)
1
(14.3)
0
(0.0)
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Adverse events and serious adverse events
General adverse events
All recorded AEs were categorised as in Table 12, and the frequency of their occurrence expressed
proportional to the number of patients in each group. All patients in both groups reported AEs, as would
be expected in a population of CF patients monitored for 12 months. However, the majority of AEs were
of a nature expected in this clinical context and frequencies were similar between groups; there were no
statistically significant differences in number overall or once they were broken down into the categories
as tabulated.
One patient in the placebo group (fatigue and increased respiratory symptoms) and one in the
active-treatment group (flu-like symptoms) discontinued study treatment because of AEs.
Serious adverse events
There were no deaths during the study. Six SAEs were documented, all in the active-treatment group
(Table 13). Neither the DMEC nor the TSC considered any SAE was related to the trial medication, but that
one (case 2) was probably related to a trial procedure (bronchoscopy).
TABLE 12 Adverse event frequency in the ITT and PP populations expressed separately for active-treatment and
placebo groups. Numbers represent the total number of AEs in each category proportional to the numbers of
patients in the group. There were no differences seen
Category
ITT population PP population
Placebo
(n= 60)
Active treatment
(n= 76)
Placebo
(n= 54)
Active treatment
(n= 62)
Lower airway respiratory symptoms 7.6 8.0 7.9 9.0
Gastrointestinal symptoms 2.0 1.7 2.1 1.8
Fever or flu-like symptoms 1.1 1.4 1.1 1.4
Headache 1.2 1.1 1.2 1.1
Upper airway symptoms 2.2 3.1 2.3 3.4
Elevated liver function tests 0.3 0.4 0.3 0.4
Haematuria 0.2 0.2 0.2 0.2
Isolated raised inflammatory markers 0.8 0.6 0.8 0.7
Other 3.0 3.0 3.2 3.3
All 18.2 19.6 19.1 21.2
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Other safety assays
There were no clinically relevant changes in haematology (Figure 33), biochemistry (Figures 34 and 35),
urinary markers (Table 14), histology (Figure 36), or lipid staining in sputum (Table 15) or biopsy cells
(Table 16) during the trial. There was no immunological evidence to suggest the development of anti-DNA
antibodies (Table 17) or anti-CFTR T cells (Table 18). There were no treatment-related differences in
change in weight or BMI (Figure 37). Figures 33–37 present longitudinal values as mean (standard error of
the mean; SEM), although in many cases error bars are small and not visible outside the mean point.
TABLE 13 Description of SAEs
Case Description
1 Admission to hospital with acute pancreatitis: 47-year-old pancreatic-sufficient male, with multiple
previous episodes of acute, non-alcohol-related pancreatitis. Managed conservatively. 4 weeks after last
dose
2 Admission to hospital with severe headache, fever, pulmonary exacerbation and new isolate of MRSA:
28-year-old male with flu-like illness within 24 hours of trial bronchoscopy. Hospital admission for
intravenous antibiotics. 5 weeks after last dose
3 Pneumothorax after removal of indwelling intravenous access device: 23-year-old female with
semi-elective admission for removal and replacement of malfunctioning portacath. Small pneumothorax
induced during surgery requiring no intervention. 4 days after last dose
4 Post-surgical infection: 46-year-old female undergoing laparoscopic Nissen’s fundoplication for severe
reflux. 10 days post surgery, admitted with pain and fever secondary to surgical site abscess, treated
20 days after last dose
5 Admission to hospital with headache, vomiting and viral upper respiratory tract infection symptoms:
25-year-old male/female. Overnight admission with conservative management. 11 days after previous dose
6 Admission to hospital with minor vomiting illness: 14-year-old male with diabetes. Admitted for
assistance with diabetic control. 16 days after previous dose
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FIGURE 35 Liver and pancreatic function. (continued )
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TABLE 14 Urinalysis assessed by dipstick for protein, blood and glucose
Urinalysisa
Placebo (n= 54) Active (n= 62)
Pretreatment Post-treatment Pretreatment Post-treatment
Urine proteinb
Negative 52 47 62 56
Trace 2 6 0 5
+ Positive 0 0 0 0
++ Positive 0 1 0 0
+++ Positive 0 0 0 0
++++ Positive 0 0 0 0
No result 0/54 0/54 0/62 1/62
Negative then positive 2 5 0 4
Positive then negative 0 4 0 2
Urine bloodc
Negative 48 47 57 49
Trace 3 1 1 3
+ Positive 0 2 1 1
++ Positive 0 1 3 4
+++ Positive 3 3 0 4
++++ Positive 0 0 0 0
No result 0/54 0/54 0/62 1/62
Negative then positive 2 3 2 4
Positive then negative 4 6 4 5
Urine glucosed
Negative 50 51 55 54
Trace 0 0 1 0
+ Positive 0 1 1 1
++ Positive 1 0 0 0
+++ Positive 1 2 1 2
++++ Positive 2 0 4 4
No result 0/54 0/54 0/62 1/62
Negative then positive 1 1 3 2
Positive then negative 0 1 3 1
a The number of + symbols indicates the level/intensity of positivity based on colour change.
b Analysis is based on two pretreatment and two post-treatment urine samples (collected on different days). In a small number
of patients, analysis of the duplicate samples led to different results. For example, two placebo patients were negative for the
first pretreatment sample, but positive for the second pretreatment sample. Five placebo patients were negative for the first
post-treatment sample, but positive for the second pretreatment sample. These results reflect slight variability in the assays.
c Analysis is based on two pretreatment and two post-treatment urine samples (collected on different days). In a small number
of patients analysis of the duplicate samples led to different results. For example, two placebo patients were negative for the
first pretreatment sample, but positive for the second pretreatment sample. Four placebo patients were positive for the first
pretreatment sample, but negative for the second pretreatment sample. These results reflect slight variability in the assays.
d Analysis is based on two pretreatment and two post-treatment urine samples (collected on different days). In a small number
of patients analysis of the duplicate samples led to different results. For example, one-placebo patients were negative for the
first pretreatment sample, but positive for the second pretreatment sample. One-placebo patients were negative for the first
post-treatment sample, but positive for the second post-treatment sample. These results reflect slight variability in the assays.
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FIGURE 36 Histological assessment of bronchial biopsies. Bronchial biopsies were collected before the first dose
(pre) and 28± 5 days after the last dose (post). Sections were stained with H&E. Out of the 50 possible biopsies,
39 (78%) were analysed. The remaining 11 biopsies were not analysable because of poor sample quality (n= 10) or
because the patient withdrew from the trial (n=1). Sections were scored semiquantitatively using a scale from 0 to 6,
except for seromucinous gland hyperplasia, which was scored as absent (0)/present (1). All data are expressed as
the difference between pre and post treatment, with a positive score indicating an increase in that parameter
following treatment. Dots represent scores for individual biopsies. The horizontal bar indicates the median.
(a) Goblet cell hyperplasia; (b) basement membrane thickening; (c) numbers of lymphocytes; (d) numbers of
neutrophils; (e) numbers of eosinophils; and (f) seromucinous gland hyperplasia.
TABLE 15 Differential counts of lipid-staining cells present in sputum samples from placebo and
active-treatment subjects
Lipid-staining
sputum cells
Placebo, meana
(95% CI), n
Active treatment, meana
(95% CI), n TE, meana (95% CI) p-value
Macrophages –3.27 (–6.60 to –0.05), 24 –2.13 (–5.45 to 1.20), 24 1.14 (–3.63 to 5.92) 0.631
Neutrophils –0.23 (–1.62 to 1.16), 19 0.45 (–0.87 to 1.77), 21 0.69 (–1.27 to 2.64) 0.480
Squamous cells –18.24 (–44.26 to 7.78), 5 –3.49 (–21.23 to 14.25), 9 14.75 (–20.87 to 50.37) 0.360
a ANCOVA-adjusted.
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TABLE 16 Quantification of lipid-laden macrophages in bronchial biopsiesa
Lipid-stained macrophages
Placebo Active treatment
Pretreatment Post-treatment Pretreatment Post-treatment
0 3 3 9 6
1–6 2 2 1 6
7–14 2
≥ 15 1 1
a Bronchial biopsies were collected before the first dose (pretreatment) and 28± 5 days after the last dose (post-treatment).
Lipid-laden macrophages were quantified in 38 out of the 50 possible biopsies (76%). The remaining 12 biopsies were
not analysable because of poor sample quality (n= 7) or because the patients withdrew from the trial (n= 5). Tissue
sections were scored semiquantitatively as containing 0, 1–6, 7–14 or ≥ 15 lipid-laden macrophages per section.
TABLE 17 Quantification of anti-dsDNA antibodies
Result
Placebo Active
Pretreatment Post-treatment Pretreatment Post-treatment
Nuclei anti-nuclear antibodya
Negative 45 43 51 45
+ Diffuse 1
++ Diffuse 1 1
+++ Diffuse
+ Speckled 5 7 5 7
++ Speckled 1 1 4 3
+++ Speckled
No result 3 2 2 5
Nucleoli anti-nuclear antibodyb
Negative 50 50 60 56
+ Nucleolar 1 2 1
++ Nucleolar
+++ Nucleolar
+ Centromere
++ Centromere
+++ Centromere
No result 3 2 2 5
Anti-double-stranded (ds) DNA antibodies were quantified in serum before the first dose (pretreatment) and 4 weeks after
the last dose (post-treatment). Samples were classified as positive or negative.
a Quantification of anti-dsDNA antibodies in nuclei.
b Quantification of anti-dsDNA antibodies in nucleoli.
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TABLE 18 Quantification of CFTR-specific T cells in the PP populationa
CFTR-specific T cells
PP population
Placebo (n= 54) Active (n= 62)
Pre dose Follow-up Pre dose Follow-up
Negative 33 36 37 49
Positive 4 8 1 2
Not determined 17 10 24 11
T-cell conversion 1b 1c
a PBMCs were extracted before the first dose (pre-dose) and 2 or 4 weeks after the last dose (follow-up) and a human
interferon-γ enzyme-linked immunospot assay was carried out. Samples were classified as positive or negative for the
presence of CFTR-specific T cells. Where recovery of viable PBMCs was too low to perform analysis, samples were
classified as ‘Not determined’.
b Indicates a placebo subject negative for CFTR-specific T cells before dosing and T cell converted to positive after the
last dose.
c indicates an active-treatment subject positive for CFTR-specific T cells before dosing and T-cell converted to negative
after the last dose.
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FIGURE 37 Change from baseline: (a) weight; and (b) BMI.
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Chapter 6 Discussion and conclusions
In this, the first trial of non-viral-based gene therapy for CF powered to detect clinically relevant changes,the primary outcome was met. Following 12 monthly nebulised doses of pGM169/G67A, there was a
significant but modest (3.7%, 95% CI 0.1% to 7.3%; p< 0.05) TE in FEV1 favouring active treatment over
placebo. Changes in this outcome were supported by trends in all the secondary outcomes, reaching
statistical significance for FVC and gas trapping on CT scan. Underscoring the mechanism of action, there
was a significant difference in lower airway CFTR-mediated chloride secretion assessed by PD. No clinically
important AEs attributable to the active treatment were seen.
Although these findings are encouraging, it is important to place them in perspective. The active-treatment
group demonstrated stabilisation of FEV1 rather than an improvement, while the placebo group declined.
The reduction in FEV1 in the placebo group was within the range seen in other trials, but greater than
has been reported from registry data.21 We consider that there are two factors which likely explain this.
First, there was a requirement for patients to (a) be clinically stable and (b) have a FEV1 > 50% predicted at
screening. The enthusiasm of patients to pass screening may have led to their being in optimal health at
that time and, thereafter, regressing to the mean. Second, registry data are most commonly obtained from
annual assessment visits, when patients are well; in our clinic, as in most of the UK, annual assessments
are deferred if patients are unwell or experiencing an exacerbation. In this trial, we captured data from all
patients irrespective of whether they were stable or exacerbating; this could lead to an apparent steeper
rate of decline in the placebo group than has been published from registry data sets.
We acknowledge the relatively modest TE in the primary outcome, but would caution against the bar
being set too high for novel drugs in CF, based on comparison with the large response in FEV1 to ivacaftor
in patients with class 3 mutations. Correction of misfolded CFTR is recognised to be a much more difficult
task, as suggested by the recent ivacaftor/lumacaftor trials, with FEV1 outcomes similar to those reported
here. Disease stabilisation would be a worthy addition to the CF armoury, particularly if this could be
extended to disease prevention if treatment was started early on.
The response observed was heterogeneous, with obvious responders and non-responders. Encouragingly,
the data suggest that an approximate doubling of TE (6.4%) could be achieved in the more severe half of
patients stratified by FEV1 and reproduced across a wide range of clinically relevant assays. We consider
the simplest hypothesis to relate to deposition: in patients with lower baseline FEV1 the relatively more
obstructed smaller airways will lead to a larger proportion of the administered dose being deposited
proximally, in the larger airways. In preparation for this trial we assessed deposition in CF patients of
varying FEV1 severity using technetium-99m-labelled human serum albumin delivered via a different
nebuliser system, which has a similar droplet size (3–4 µm) to the pGM169/GL67A formulation. Of the
delivered dose deposited in airway generations 2–8, 2.9% (SEM 0.2%) was in those with 70–90%
predicted FEV1 (n= 33), whereas approximately twice as much (6.0%, SEM 1.0%) was delivered to this
region in patients with 50–70% predicted FEV1 (n= 23). These data are in keeping with the approximately
twofold increase in efficacy we noted in the respective severity groups.
There may also be an influence of the increased mitotic rate of cells in more severely inflamed tissues,97
thereby decreasing the proportion of time that the nuclear membrane is intact, the latter acting as a
barrier to pDNA entry to the nucleus. It will be important to verify or refute these data in a larger trial with
a stratified trial entry design, powered to assess subgroups and that addresses the mechanisms of
response heterogeneity.
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The change in lower airway PD supports our clinical outcomes and suggests that the changes observed
relate to CFTR expression. However, we have also considered the possibility that such clinical changes
could be the result of a non-specific response to the active-treatment formulation. This is difficult to rule
out for two reasons. First, the placebo was 0.9% saline rather than the ideal comparator of a scrambled
CFTR plasmid/liposome complex. Saline was chosen in part based on ethical considerations (not wishing to
expose well-controlled CF patients to first-in-man repeated pulmonary dosing of an untested product as a
placebo), in part on pragmatic financial consideration, and finally a wish to compare therapy against the
natural history of the disease. We know of no evidence suggesting that monthly nebulisation of 0.9%
saline is deleterious to lung function, liposome alone has shown no evidence for producing physiological
improvements in either non-CF (Chadwick et al.62) or CF subjects (Alton et al.58), and pDNA is generally
associated with deleterious rather than non-specific beneficial effects. Furthermore, it was neither noted
evidence for pathophysiological changes in the airways, such as inflammation, remodelling or lipid
accumulation, nor changes in bacterial species, that might explain the changes. Nevertheless, it cannot
be excluded that DNA–liposome complexes induce a previously undocumented augmentation of host
defences, stimulate mucus clearance by non-specific mechanisms or produce bacterial killing not detected
on semiquantitative routine culture. Second, it would have been reassuring additional evidence to
demonstrate more robust evidence for molecular CFTR surrogates. We have repeatedly noted the limited
sensitivity of assays assessing vector-specific mRNA from human samples in vivo.55,58 The ratio of area
sampled to area dosed, is extremely small, and in ovine studies we have shown that a 20-ml nebulised
dose, fourfold greater than that used in the current study, represents the lower threshold for reproducible
detection with this assay in airway tissue samples.98 We have consistently noted that electrophysiological
changes are more readily detectable than mRNA, supported by findings in this study. Although we saw
significant chloride secretory changes in the bronchial but not in the nasal epithelium, we caution against
placing undue weight on either observation. The mechanistic subgroups were opportunistically recruited
to, and were not powered to, detect significant changes at the level of correction observed. Rather we
would conclude that modest, inconsistent changes can be demonstrated in assays that remain suboptimal
to detect low levels of CFTR function when assessed in vivo in man; improvements in these, or other
assays, are needed.
Although we are encouraged by the first demonstration of a significant change in lung function associated
with gene therapy in CF patients, the improvement was modest and at the lower end of the spectrum
seen in clinical trials resulting in changes in patient-related care. Although we did not formally assess
infective exacerbations given the relatively small numbers in our study, using antibiotic courses as a
surrogate, we saw no obvious changes. It is unlikely, therefore, that, without further improvement in
efficacy and response consistency, the current formulation will be suitable for immediate clinical care given
the already high treatment cost in CF. Rather, we believe that a follow-on study should examine dose
escalation, frequency of dosing, and the potentially attractive combination of gene therapy with a CFTR
potentiator. Furthermore, our current study should encourage the introduction of more potent viral
vectors into early-phase trials. We suggest the data reported here provide proof of concept that repeated
administration of CFTR gene therapy can alter clinically relevant parameters, providing another step along
the path of translational CF gene therapy.
Implications for practice
Although encouraging proof of principle that CFTR gene therapy can lead to changes in a clinically relevant
outcome, the modest effect of these to date means that further work is necessary before this becomes a
clinical therapy.
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Recommendations for areas requiring future research
l Seeking further understanding of responders/non-responders.
l Seeking to maximise benefit by:
¢ increasing dose
¢ increasing dosing frequency
¢ co-administration of a potentiator drug
l The development of safe and efficacious viral vectors.
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Appendix 1 Patient information sheets
Adult patient information sheet
ADULT PATIENT INFORMATION SHEET 
 
Study title: A randomised, double-blind, placebo-controlled Phase 2B clinical trial of 
repeated application of gene therapy in patients with cystic fibrosis 
 
Short title: Repeated application of gene therapy in CF patients  
 
Invitation paragraph 
 
You are being invited to take part in a research study.  Before you decide you need to 
understand why the research is being done and what it would involve for you.  Please take 
time to read the following information carefully. Talk to others about the study if you wish.  
 
Please ask us if there is anything that is not clear or if you would like more information.  
Please take as much time as you need to decide whether or not you wish to take part. 
 
Introduction 
There is currently no treatment for Cystic Fibrosis (CF) that completely halts the progression 
of lung damage; all the available therapies help to slow the rate of decline in lung function at 
best.  Because of this, we have formed the UK CF Gene Therapy Consortium, (scientists, 
doctors & nurses based at Imperial College/ Royal Brompton Hospital, Oxford & Edinburgh 
Universities & Hospitals, www.cfgenetherapy.org.uk/) to develop further gene therapy for 
CF.  Gene therapy uses healthy copies of the CFTR gene to replace the damaged versions 
within the nose and lungs of patients with CF.  Each of these three centres has previously 
been involved in clinical gene therapy trials which were designed simply to prove that we 
could deliver healthy genes in this way.  Together, we have designed a programme of 
research to lead to a large, multi-dose clinical trial.  This will be the first trial to give multiple, 
repeated doses and look for clinical benefit.  The gene therapy will consist of the healthy 
CFTR gene, which will be carried into the cells of the airways by a liposome (a fatty 
substance), called GL67A.  This is the same liposome which we used in clinical trials in the 
1990s and we, therefore, have results on its safety and efficacy.  The gene, however, has been 
substantially improved and has recently been used in a pilot clinical trial to ensure its safety 
and to see how long each dose lasts.  The gene therapy can cause a brief change in lung 
function and mild feverish symptoms.  We have therefore decided to use a dose of 5mls (a 
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teaspoonful, delivered by inhalation of a nebulised aerosol) which was found to be the best 
tolerated in the pilot trial.  
 
What is the purpose of the study? 
The purpose of this study is to assess for the first time whether repeated doses of gene therapy 
administered to the lungs of CF patients can lead to clinical improvement. 
 
Why have I been invited? 
You have been invited because you are an adult with CF and you attend the Royal Brompton 
Hospital, one of the hospitals within the Scottish Adult Cystic Fibrosis Service, or one of our 
collaborating patient identification centers.  You are also relatively well, with mild or 
moderate lung involvement, however not so well that we will struggle to measure any 
improvement. This will mean that the nebulised gene therapy has a good chance of reaching 
the cells lining your airways without being blocked by excessive mucus, and that we will 
sample from your airways more easily. If you are a patient from one of our collaborating 
participant identification centres you will attend the Royal Brompton Hospital, Western 
General Hospital Edinburgh or Royal Hospital for Sick Children Edinburgh  for all trial 
related visits but continue your clinical care at your own centre. Trial visits are not a 
substitute for your usual clinic visits and we will not make decisions related to your general 
care, although we will communicate closely with your local team. 
 
If you have been involved in the Run-In study you will be invited for a single screening visit 
to determine whether you will fit the criteria to participate in the multi-dose trial.  If you have 
been newly recruited, i.e. not participated in the Run-In trial, you will be invited for an 
introductory visit to talk to you further about the research and assess your eligibility as well as 
a screening visit. 
 
We think that you may fulfill all of the Inclusion & Exclusion criteria although we will need 
to go through these lists in detail with you; in particular we will be looking for lung function 
within the range of 50-90% and for you to be in a stable condition with no recent changes to 
your CF treatments.  If your recent lung function is close to the cut-offs for being included 
you may wish to perform spirometry to see if you are eligible before discussing all the details 
of the trial with us, as this is quite time consuming. In this case, we will ask you simply to 
sign a form consenting to lung function, which in no way commits you to taking part in the 
trial. If you are unwell at the time you are seen, we may be able to reschedule your visit for 
once you have recovered and are once again stable. 
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Do I have to take part? 
It is completely up to you to decide whether or not to take part.  If you do decide to take part 
you will be given this information sheet to keep and be asked to sign a consent form.  If you 
decide to take part you are still free to withdraw at any time and without giving a reason.  
This will not affect the standard of care you receive. 
 
What will happen to me if I take part? 
After the screening visit, all patients volunteering for the main part of this study will receive 
nebulised doses of either the gene therapy (active) product or placebo (sometimes called the 
‘dummy drug’) at 4 week intervals over a 48 week period.  Once you have agreed to take part 
in the study, you will be assigned by chance (like the flip of a coin, but done by a computer) 
to receive either gene therapy or placebo.  A placebo contains no active ingredient. The 
probability that you will receive gene therapy is 1 in 2 i.e. there is a 50% chance that you will 
receive the gene therapy throughout the trial and a 50% chance that you will receive the 
placebo throughout the trial.  Neither you nor your study doctor will know whether you are 
receiving gene therapy or placebo.  This is termed a ‘double-blind’ study and is extremely 
important for generating results that are meaningful and which will be believed by the wider 
scientific community.  However, in the event of an emergency, the identity of the nebuliser 
solution can be determined rapidly.   
 
The first 20 patients (10 active treatment; 10 placebo) will receive a nebulised dose (5ml) on 
3 occasions at 4-weekly intervals before any further patients are dosed.  This is a safety 
measure to allow the Data Monitoring and Ethics Committee (DMEC, a panel of medical 
experts) to review the clinical and laboratory findings to ensure that everything is satisfactory 
after repeated doses of the active treatment/placebo.  If this proves to be the case these 
patients will continue with subsequent visits and the remaining patients will begin their 
dosing schedule.  Because of the large number of patients (130) involved in the study and the 
restriction on the facilities (special gene therapy cubicles) used we will have to stagger the 
dosing visits so it is likely to take at least 5-6 months before all patients have started their 
dosing schedule. 
 
Were the DMEC to have any concerns with the clinical and laboratory findings, they could 
recommend that we reduce the dose of the gene therapy product.  In this event, and if you 
belonged to the initial 20 patient group, you would unfortunately have to withdraw from the 
trial.  A further group of 20 patients would then be recruited to receive the reduced dose 
(2.5ml) of active treatment/placebo on 3 occasions at 4-weekly intervals.  The DMEC would 
again meet to review the clinical and laboratory findings to ensure that everything is 
107
DOI: 10.3310/eme03050 EFFICACY AND MECHANISM EVALUATION 2016 VOL. 3 NO. 5
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Alton et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
satisfactory.  If this proves to be the case these patients will continue with subsequent visits 
and the remaining patients will begin their dosing schedule.  If the DMEC were to have any 
concerns with the 2.5ml dose the trial would be halted as we do not consider it feasible to 
administer a smaller dose successfully to the lower airways via nebuliser.  
 
A subgroup (at least 24 patients at the London site) will be asked to undergo nasal dosing.  
This will involve some additional tests and up to 5 additional short study visits (although we 
will limit these as much as possible).  This will be explained in detail on another sheet if you 
wish to consider this (see Appendix 1). 
 
A subgroup (at least 24 patients at the London site) will be asked to undergo a flexible 
bronchoscopy (a test to look inside the lungs using a flexible telescope) under general 
anaesthetic on two occasions (prior to the first dose of gene therapy/placebo and between 29 
and 35 days after the 12th dose of gene therapy/placebo). This will involve two additional 
study visits. This will be explained in detail on another sheet if you wish to consider this (see 
Appendix 2). 
 
You will be monitored before and after each nebulised dose (dosing visit) during 12 
scheduled dosing visits. The schedule of visits is 4 weeks +/- 5 days for 48 weeks with further 
details given below. You will be given a flow chart summarising the sequence of study visits: 
1. Introductory visit –new patients only (i.e. those not previously involved in Run-In 
study) (3-4 hours). This is to help us get to know you and for you to familiarise 
yourself with the tests before the trial starts. However, it is not essential and, 
particularly if you have a long distance to travel or other time commitments, we can 
discuss omitting this visit with you.  
2. Eligibility and Consent visit (selected subgroup patients only- see below)* (2-3 
hours) 
3. Screening visit – all patients (3-4 hours)  
4. Pre-dosing nasal PD visits up to 3 (nasal subgroup only) 
5. Pre-dosing bronchoscopy (bronchoscopy subgroup only) 
6. Dosing visits x 12 (4-6 hours) 
7. Post-dosing day 2 visits (1st 3 doses in 1st 20 patients only) (2 hours) 
8. Follow up visits on Days 14 and 28 (+/-2days) post-dosing (3-4 hours)  
9. Post-dosing bronchoscopy Days 27-36 after dose 12 (bronchoscopy subgroup only) 
*As the screening visit must occur within 28 days before the first dosing visit, we will offer 
people taking part in the nasal or bronchoscopy subgroups the opportunity to plan the 
additional investigation visits earlier if convenient. This will require an initial, short visit, at 
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
108
which we assess eligibility, perform a physical examination and limited tests and you will be 
asked to sign consent for the trial.   
 
Should there be any safety concerns, we have the flexibility to see patients for additional 
visits at any time during the study; such visits will of course be kept to an absolute minimum.  
 
The procedures performed at each of these visits are summarised below.  If for any reason we 
are unable to perform a test at a certain visit (eg. if you miss a visit or equipment fails), the 
protocol allows us to consider performing that test at a future visit. A full description of each 
test follows this summary of visits. 
 
PRE-DOSING VISITS 
Introductory visit – if considered necessary for new patients only (i.e. those not 
previously involved in Run-In study). This visit will take around 3-4 hours and will involve: 
• explanation of study  
• full medical history  
• confirmation that you are medically suitable for the trial  
• sign informed consent  
• a simple (bedside) examination of your chest, blood pressure, temperature, pulse, and 
oxygen levels (with a finger probe) 
• blood sampling 
• urine sampling  
• Sputum sample (induction with 7% hypertonic saline if required) 
• spirometry (lung function tests, as usually done in clinic) 
• lung clearance index (LCI) 
• 24 hour sputum weight 
• nasal potential difference measurements may be conducted (nasal PD subgroup only) 
• we will give you a diary card to take home and instructions on how to complete it 
• we will give you a hand-held PiKo-6 device for you to carry out blowing tests (lung 
function) at home 
•  
Screening visit (all patients) 
This visit will take around 3-4 hours and will involve: 
• explanation of the study 
• confirmation that you are medically suitable for the trial  
• sign informed consent (if not already signed at introductory visit)  
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• quality of life questionnaire 
• full medical history and physical examination  
•  a simple (bedside) examination of your chest, blood pressure, temperature, pulse, and 
oxygen levels (with a finger probe) 
• blood sampling 
• urine sampling  
• spirometry (lung function tests, as usually done in clinic) 
• lung clearance index (LCI) 
• exercise bike test 
• body worn activity monitor (which we will show you how to use) 
• chest CT scan 
• gas transfer test  
• Sputum sample (induction with 7% hypertonic saline if required) 
• 24 hour sputum weight 
• nasal potential difference measurements may be conducted (nasal PD subgroup only) 
• we will give you a diary card to take home and instructions on how to complete it 
• we will give you a hand-held PiKo-6 device for you to carry out blowing tests (lung 
function) at home 
 
DOSING VISITS 
Each of the 12 dosing visits will take around 4-6 hours. If you normally take Pulmozyme, you 
will be asked to withhold treatment for 24 hours prior to each visit and for 24 hours after 
dosing.  
Predosing, the following will be performed at every visit: 
• history (we will ask you how well you have been since the last visit and if any of your 
medicines have been changed) 
• a simple (bedside) examination of your chest, blood pressure, temperature, pulse, and 
oxygen levels (with a finger probe) 
• blood sampling 
• spirometry (lung function tests, as usually done in clinic) 
At specified visits, the following will also be performed 
• lung clearance index (LCI) 
• urine sampling 
• quality of life questionnaire 
• exercise bike test 
• body worn activity monitor 
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• chest CT scan 
• gas transfer 
•  24 hour sputum weight and collection of fresh sample 
• nasal PD (subgroup only) 
• bronchial blood flow measurement 
 
Dosing 
Approximately 20 minutes before the nebulised dose is administered, you will receive 200-
400 μg (2-4 puffs) of inhaled salbutamol to prevent airway narrowing and wheeze, which 
may be associated with the gene therapy agent / placebo.  The nebulised dose will then be 
given via a mouthpiece from a clinical nebuliser.  You will be asked to wear a nose clip for 
the duration of the   nebulisation (3 minutes on, 2 minutes off for 8 cycles) which usually 
takes around 40 minutes..  The nebuliser will be administered whilst you are sitting in a 
cubicle to prevent contamination of the immediate environment. You will have contact 
throughout and will be able to communicate with your research nurse through a glass 
window. You will be asked to report any new symptoms.  Although this environment is not 
spacious, we will do our best to make you as comfortable as possible.  We can provide music 
or a DVD player should you wish.  You will be able to leave the cubicle as required for a 
toilet break, although we will ask that you wear a mask over your mouth and nose during this 
time and for 30 minutes after dosing is complete. 
 
If you agree to take part in the nasal dosing subgroup (London site only), we will ask you to 
administer a nasal spray during the ‘off’ nebuliser period, with one spray being delivered to 
each nostril at the beginning and end of the first 6 two minute’off’ periods which will deliver 
a dose of approximately 2 ml. 
 
You will be observed for a minimum of 30 minutes after dosing before leaving the hospital. 
We will listen to your chest and perform pulse oximetry after the dosing and prior to you 
leaving the hospital.  . If either you or we have concerns about your level of well-being after 
treatment, we may suggest that you stay in hospital overnight, although we are not expecting 
this to be the case.  We will ask you to take a standard 1g dose of paracetamol immediately 
after dosing and you will be given another 1g dose of paracetamol to take at home 
approximately 6 hours after dosing.  This is to prevent any mild feverish symptoms that could 
possibly occur after dosing.  
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Day 2 post-dosing visits (first 20 patients after each of the first three doses only) 
The following will be performed: 
• history (we will ask you how you have been since your last visit and if any of your 
medicines have been changed) 
•  a simple (bedside) examination of your chest, blood pressure, temperature, pulse, and 
oxygen levels (with a finger probe) 
• spirometry ((lung function tests, as usually done in clinic) 
• gas transfer 
• blood sampling 
• bring in sputum coughed up over last 24 hours and collect fresh sample 
 
Follow up visits 
There will be two follow up (F/U) visits that will occur at 14 (+/-2) days and 28 (+/-2) days 
after your last dosing visit.   
 
At F/U day 14 we will do the following: 
• history (we will ask you how well you have been since the last visit and if any of your 
medicines have been changed) 
• a simple (bedside) examination of your chest, blood pressure, temperature, pulse, and 
oxygen levels (with a finger probe) 
• quality of life questionnaire 
• spirometry 
• blood sampling 
• lung clearance index (LCI) 
• nasal PD (subgroup only) 
• urine sampling 
• bring in sputum coughed up over last 24 hours and collect fresh sample 
• diary card  check 
• download hand-held PiKo-6 device on which you carried out blowing tests 
 
At F/U day 28 we will do the following: 
• history (we will ask you how well you have been since the last visit and if any of your 
medicines have been changed) 
• all the tests performed at the screening visit 
• collection of diary card and hand-held PiKo-6 device 
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Long term follow up: you will be followed up by your clinical team at scheduled CF clinic 
appointments approximately every 3 months for 2 years. 
 
Description of Tests 
• Full medical history: we will ask about your medical condition(s) including history of 
medications (specifically any additional antibiotics required for your chest), 
operations and allergies plus anything else relevant to the safety of the trial. 
• Clinical examination: we will listen to your lungs using a stethoscope and measure 
your height, weight, temperature, pulse, blood pressure and respiratory rate  
• Pulse oximetry (finger probe): a measurement of the oxygen level in your blood 
using a finger probe 
• Blood test: (at each visit where blood is required, up to 25 mls, (5 teaspoons), will be 
taken for a variety of tests including routine clinical tests e.g. liver and kidney 
function, full blood count, electrolyte (salt) levels and C-reactive protein (a marker of 
inflammation). Samples will be stored for future measurement of inflammatory 
markers and possibly for end-products of gene therapy breakdown. If you wish, we 
will arrange for you to have local anaesthetic, either cream or spray. If you have a 
portacath or similar device and your clinical team is happy for this to be used for 
blood sampling, this may be possible as an alternative.  At one single visit at any time 
during the trial, we will take a sample of blood for DNA (genetic) research. The only 
tests we will perform on this sample will be: 
o Testing for your CF gene(s) if these are not known; we will be happy to let 
you know the results of this test.  This sample will not be used to test for any 
other genetic diseases  
o Testing for common, naturally-occurring changes in genes which don’t cause 
disease but might be involved in how individuals respond to gene therapy, eg, 
inflammatory response genes. This will be most useful in the event that we 
see that some people respond to gene therapy and others do not, to help us 
understand this better. 
• Urine sample: routine testing with a dipstick for protein, sugar etc; we will also 
perform a pregnancy test if you are female.Samples will be stored for future 
measurement of inflammatory proteins and possibly for end-products of gene therapy 
breakdown 
• Spirometry (blowing tests, as usually done in clinic).  
• Lung clearance index (LCI): this test demonstrates how evenly gas is distributed in 
the lungs and is a sensitive marker of airway disease. You will be asked to breathe a 
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tracer gas (SF6) which has no smell or taste and is completely harmless, over a period 
of several minutes. Once levels in your lungs are stable, you will switch to breathing 
air and the time taken for the SF6 to leave the lungs is used to calculate the LCI.  We 
will perform the test 3 times, each one taking about 10 minutes.  
• Exercise bike test: this test will be performed on an exercise bike and is incremental 
(gets more difficult to pedal as it goes on).  Exercise is an event that involves a large 
number of physiological processes from the heart and lungs, to the blood circulation 
and the muscle itself.  This test will enable us to calculate your exercise capacity. 
During the test we will record a breathlessness score and a probe will be attached to 
your finger or ear lobe to measure the oxygen levels in your blood. You will be 
wearing a nose clip and breathing through a mouthpiece. You will be asked to pedal 
at a comfortable speed and maintain this speed throughout the test.  The resistance to 
pedalling will automatically increase each minute and you will be encouraged to 
continue until you either cannot keep up with the speed or feel you have exercised as 
much as you are able; we will ask you to stop if your oxygen level falls.  Once the 
test is complete you will have a 2 minute cool down period, and we will continue to 
monitor your oxygen levels until they return to baseline.  
• Sweat test:  Although the diagnosis of CF is not in doubt, some patients, particularly 
those who were diagnosed many years ago, do not have documented confirmation of 
a diagnostic test in their notes. If you have neither a confirmed genetic diagnosis (2 
mutations) nor a sweat test result, we would like to perform a sweat test as part of the 
trial. An area of the skin on your forearm will be cleaned and 2 electrodes will be 
attached with straps. One of these contains a gel which stimulates sweat and the 
medication is  applied to the skin by a weak current; you will feel a little tingling but 
this is not painful. Following this a collection device will be attached to the skin 
surface and the sweat collected over a 30 minute period. This will then be analysed  
by the laboratory for the high levels of salt seen in CF. 
• Activity monitor: a small band worn on your upper arm that collects step and 
movement data.  You will be asked to wear this for 7 full days after specific study 
visits. 
• Chest computed tomographic (CT) scan: Computed tomography uses x-rays to create 
detailed images of the lungs.  It is a good measure of how CF affects the shape and 
structure of the airways.  For each scan you will be asked to lie still on a table which 
will move slowly through the centre of a large x-ray machine but at no time will you 
be in an enclosed space. You will be able to communicate with the CT staff if you 
need to. You will be given breathing instructions at the time of the scan.  No 
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injections are involved and the procedure is completely painless.  As x-rays are 
involved, you will be exposed to a small amount of radiation.  However, we will be 
using as low a dose as is possible for your scans.  The estimated maximum dose of all 
three scans over the entire study period amounts to 4.5 mSV, which is similar to the 
radiation you would be exposed to as part of natural background radiation over a 2 
year period.  Because even low levels of radiation can be dangerous to an unborn 
child, it is a requirement that all females undergo a urine pregnancy test on the day of 
the procedure.  
• Transfer factor (TLCO): this is a lung function test which measures the rate at which 
gas travels across the lung tissue (alveolus) into the blood stream. Gas transfer is 
usually normal in patients with CF. We are using this test as a safety measure and in 
order to assess whether the gene transfer has an effect on this, we need to make a 
baseline measurement. You will be asked to wear a nose-clip and to breathe out as far 
as you can through a mouth-piece. You will then breathe in as far as possible, a 
mixture of air and low concentration of a tracer gas (less than 0.3% carbon 
monoxide) and hold your breath for 10 seconds before breathing out as far as 
possible. This will be repeated up to 5 times with rest periods in between tests.  This 
concentration of CO is completely harmless and this is a well-established test used 
routinely in clinical practice.  
• Sputum sampling: we will ask you to try and cough up around a teaspoon of sputum; 
if this is not possible for you, we will obtain secretions for microbiology by asking 
you to cough onto a sterile swab or brush .  At either your introductory or screening 
visit and at either of your follow up day 14 or day 28 visits if you are unable to cough 
up a sputum sample, we will use a well-established nebulisation technique to induce 
sputum.  To prevent wheeze (a common side effect), you will be given 200 mcg of 
salbutamol (Ventolin) or an equivalent drug to open up the airways. After 15 minutes 
you will receive a 7% saline nebuliser for 5 minutes, and this will be repeated up to 3 
times. We will monitor your lung function (FEV1
 
) throughout, and should we see a 
significant drop, the test will be stopped. If sputum induction fails, we will obtain 
secretions for microbiology by asking you to cough onto a sterile swab or brush 
Samples will be tested for infection and stored for future measurement of 
inflammatory proteins and possibly for end-products of gene therapy breakdown. 
• CF specific quality of life questionnaire: this will take a total of 10 minutes to 
complete.  
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• Diary card: You will be given a diary card which you will be asked to complete for 
the duration of the study. This will record new symptoms, changes in routine 
treatments etc. 
• Home lung function: You will be taught how to use a small lung function device 
(PiKo-6) and asked to make regular recordings on it at home for the duration of the 
study period. The machine stores all the readings which will be downloaded onto a 
computer at each visit. 
• Bronchial blood flow measurement: (London site only) This test is designed to look 
at the blood flow to the airways which is often increased in patients with airway 
disease, probably reflecting inflammation.  The test takes about 45 minutes to do and 
consists of 10 breath-holding manoeuvres of either 8 or 16 seconds.  For each 
manoeuvre you will be seated, wearing a noseclip and breathing in and out through a 
mouthpiece.  After several normal breaths you will need to breathe in a small amount 
of test gas, which is safe and enriched with oxygen, and hold this breath for 8 or 16 
seconds before breathing out again slowly.  Your heart rate and oxygen saturation 
will also be monitored during the test.  There is a gap (3-4 min) between each of the 
manoeuvres to save the data and calibrate the equipment.  As the blood flow to the 
airways may be affected by alcohol and caffeine, it is requested that you do not 
consume alcohol the night before the test and do not have any caffeine on the day of 
the test.  This test will be undertaken after all other assays / tests if time allows.  If 
you are too tired to do the procedure it will not be done or if during the procedure you 
feel too tired to continue we will stop the test at any time. 
• Nasal PD and nasal brushings: see Appendix 1 (London site only) 
• Bronchoscopy: see Appendix 2 (London site only) 
 
What else will I have to do? 
In addition to the study visits and home monitoring outlined above, we will ask that if you are 
sexually active, you agree to take contraceptive precautions from enrolment into the study 
until 3 months after completion. This is a requirement of the Medicines and Healthcare 
products Regulations Agency (MHRA) and the Gene Therapy Advisory Committee (GTAC) 
for all clinical trials involving gene therapy. Approved (reliable) methods of contraception 
include:  
- ‘the pill’  
- long-acting injections or implants  
- placement of an intrauterine device (IUD; sometimes called a ‘coil’) or system (IUS)  
- condom or occlusive cap with spermicide  
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Exceptions to this can be made in the case of:  
- male trial participants with CF-related infertility, which has been confirmed on semen 
testing 
- male trial participants who have undergone a vasectomy followed by confirmation of 
success  
- female trial participants whose only male sexual partner has undergone a vasectomy 
followed by confirmation of success  
If you do not already fall into one of these groups, we will ask you to attend your General 
Practitioner of local Family Planning Clinic to discuss options. You may also find it useful to 
discuss these issues with your CF Consultant and / or Nurse Specialist who will provide you 
with information relevant to patients with CF. 
There will be no other changes made to your routine clinical care.  
We ask that you consent to our informing your General Practitioner about your involvement 
in the study, including these requirements for contraception. 
 
What is the drug or procedure that is being tested? 
We are testing a formulation consisting of a healthy copy of the CFTR gene mixed with a 
fatty substance which helps the gene enter the cells of the airway. The CFTR gene has been 
changed since our original trial in ways that we believed would make it likely to cause less 
inflammation and last for longer.  We did see some flu-like responses and drops in lung 
function in some people in the Pilot study but by giving a smaller dose (5ml) we were able to 
reduce these side effects. The research team will be happy to provide you with more specific 
scientific details should you wish. 
 
What are the alternatives for diagnosis or treatment? 
As you will know, conventional treatments for CF have improved greatly over the last few 
decades. However, they do not correct the basic defect in your cells, which is what we are 
aiming to do with gene therapy. In general therefore, conventional treatments slow the natural 
progression of lung disease, rather than stop it altogether. Should you wish not to take part, 
your standard clinical care will continue as usual. 
 
What are the possible disadvantages and risks of taking part? 
We are asking for a large time commitment from you over a period of a year.  The study 
requires you to make a minimum of 15 visits and perform multiple tests. As described above, 
most of these are straightforward and many of them will be familiar to you from clinics (and, 
for many of you, your participation in the Run-in).  
The risks that we consider likely are as follows: 
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1. Either the gene therapy or the placebo could cause wheeze or increased cough. To 
limit this, we will administer salbutamol, to relax the airways, prior to nebulisation.  
In our previous study, some of the single dose patients had a fall in their lung 
function several hours after dosing but this was well-tolerated and, for most patients 
receiving 5 ml, was not associated with any increased symptoms. Lung function had 
resolved in all dosing groups within 2 days of the dosing visit. 
2. In the single dose study, some patients developed a temperature and a mild flu-like 
illness within a few hours of dosing.  These side effects were minimal with the 5 ml 
dose that we have chosen for this trial and appear to be responsive to paracetamol, 
which we will ask you to take on two occasions (2hrs and 8 hrs) post-dose whether 
you have side effects or not.  All side effects should have disappeared within 2 days 
of the dosing visit.  
3. The CT scans involve exposure to a small amount of radiation, which in common 
with all radiation does carry a small risk of causing cancer.  We plan to do a type of 
CT scan using lower radiation doses than a standard CT.  The estimated maximum 
dose of all three scans over the entire study period amounts to around 4.5 mSv.  To 
put this in context, the maximum amount of radiation from all three scans over the 
entire study period is equivalent to the amount of natural radiation to which everyone 
is exposed from environmental sources over a period of 2 years.  Female patients of a 
child-bearing age will be required to have a negative pregnancy test on the day of 
each scan. 
4. Please see Appendices 1 and 2 for disadvantages associated with nasal PD and 
bronchoscopy. (These tests are only being performed at the London site.) 
 
What are the possible benefits of taking part? 
Because we are the first research group in the world to administer multiple doses of this gene 
therapy product, and CF is such a chronic disease, we cannot be sure that there will be any 
immediate or long-term benefits of participating in the study. You will be helping to advance 
the field of gene therapy by agreeing to take part.  Should this study be successful, we will 
undertake further trials with a view to developing gene therapy as a treatment.  
 
What happens when the research study stops? 
When you have completed your study visits, you will continue to receive your routine clinical 
care. If you wish, we will keep you informed of any developments that arise from the results 
of this study. 
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What if there is a problem? 
Throughout the study, we will be happy to talk to you or see you at any point should you have 
concerns.  Should you develop any health problems, we will investigate and treat these after 
discussion with your usual medical team. 
An independent Data Monitoring and Ethics Committee (DMEC) will oversee the safety of 
the trial as it progresses. Any significant adverse events will be reported to the DMEC.  
 
Complaints : If you have a concern about any aspect of the study, you should ask to speak to a 
member of your clinical research team (see contact numbers at the end of this Information 
Sheet) who will do their best to answer your questions.  If you remain unhappy and wish to 
complain about any aspect of the way you have been approached or treated during the course 
of this study, the normal National Health Service complaints mechanisms are available to 
you. Details can be obtained from the hospital. 
 
Harm: In the event that something does go wrong and you are harmed during the research due 
to someone’s negligence, then you may have grounds for legal action or compensation, but 
you may have to pay your legal costs. The normal National Health Service complaints 
mechanisms will still be available to you (if appropriate).  
 
Imperial College London holds Public Liability ("negligent harm") and Clinical Trial ("non-
negligent harm") insurance policies which apply to this trial.  Liability for the gene therapy 
product design will be accepted by Oxford University and Imperial College 
London.  Liability for the protocol design will be accepted collectively by Oxford University, 
Edinburgh University and Imperial College London.  Clinical negligence insurance 
/ indemnity is provided by the NHS. 
 
Will my taking part in the study be kept confidential? 
Yes.  
All information collected during the course of the study will be coded and kept strictly 
confidential.  Clinical results and analysis will be collated by the Imperial College Trials Unit.  
All samples will be stored indefinitely in a coded fashion to preserve confidentiality. Codes 
will be held by a single investigator at each site.  If you consent to take part in the research, 
any of your medical records may be inspected for purposes of analysing the results.  They 
may also be looked at by people from regulatory authorities to check that the study is being 
carried out correctly.  Your name, however, will not be disclosed outside the hospital. 
If you agree to take part, your GP will be informed and your hospital notes will be flagged to 
ensure that other members of the clinical team are also informed. 
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What if relevant new information becomes available? 
Sometimes during the course of a research project, new information becomes available about 
the test/treatment that is being studied.  If this happens, your research doctor will tell you 
about it and discuss with you whether you want to continue in the study.  If you decide to 
withdraw, your research doctor will make arrangements for your normal clinical care to 
continue.  If you decide to continue in the study you will be asked to sign an updated consent 
form. 
Also, on receiving new information your research doctor might consider it to be in your best 
interest to withdraw you from the study.  He/she will explain the reasons and arrange for your 
normal clinical care to continue.   
 
What will happen if I don’t want to carry on with the study? 
You will be free to discontinue the study at any time, without giving a reason, and this will 
not affect your clinical care in any way. For patients who have commenced dosing we would 
be grateful if you could attend at least a 14 and 28 day follow up appointment as part of the 
trial. Samples already obtained will be used for this and other ethically approved studies 
unless you specifically request samples to be destroyed. In addition we would like to discuss 
your progress with your clinical team after your  routine clinic visits to gather as much 
information as possible for the trial and ensure continuing patient safety.  
 
What will happen to any samples I give?  
Samples will be stored in a coded fashion so that, with the exception of one or two key 
people, the researchers will not be able to identify individual patients.  Many of the samples 
will be frozen and stored indefinitely.  We are working closely with the other members of the 
UK Gene Therapy Consortium in Oxford, Edinburgh and Southampton Universities and will 
be sending coded samples to them for analysis and storage.  We will also be sending coded 
blood samples to colleagues at the University of Pennsylvania, USA.  We would wish that 
any spare samples left over could be used in other ethically-approved research protocols and 
would ask you to agree to this by gifting your samples to us as part of consenting to this 
study.  All of our storage conditions comply with the regulations of the Human Tissue Act 
and/ or the Human Tissue Act (Scotland) 2006. 
 
 
 
What will happen to the results of the research study? 
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At the end of the study, all results will be analysed, and will be reported at conferences and 
published in the Medical press.  Results of the study will also be made available to study 
participants on request.  You will not be identified in any report/publication. 
 
Will my expenses for taking part in the study be reimbursed? 
Yes. We understand the inconvenience involved in taking part in such a study and will be 
happy to reimburse travel expenses for the visits you will be asked to make. 
 
Who is organising and funding the research? 
The study is being funded by the National Institute for Health Research & Medical Research 
Council. There is no financial gain to either the Hospital or the staff for including and looking 
after patients in this study. 
 
Who has reviewed this study? 
This study has been submitted for review by the Gene Therapy Advisory Committee, the 
national body charged with assessing the ethical aspects of any clinical trial involving gene 
therapy. 
 
Thank you for considering taking part in this study 
We very much hope that after reading this information and talking to the research team, you 
feel able to take part, but please be assured that should you not wish to, this will in no way 
affect your clinical care. 
 
For further information please contact:  
Royal Brompton Hospital, London  
Clare Saunders (Clinical Trial Co-ordinator) – Tel:                    
cfgenetherapy@rbht.nhs.uk 
Prof Jane Davies - Tel:  
Prof Eric Alton - Tel:  
 
Western General Hospital, Edinburgh  
Dr J A Innes – Tel:  
Dr Hala Elgmati - Tel:  
Maria Dewar (Research Manager) – Tel:  
Lothian.cfgtscotland@nhs.net 
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Appendix 1 
 
Nasal dosing Subgroup (London site only)  
A group of at least 24 patients in the trial will be asked to undergo nasal dosing and have 
nasal potential difference (nPD) measured and nasal brushings taken.  Because the nostrils are 
relatively easy to access, and these measurements can therefore be made repeatedly, this 
offers us a valuable opportunity to study how well the gene is expressing at different time 
points during the study. This is optional and you do not have to take part in this additional 
testing if you do not wish to.  If you do agree and are considered suitable, there will be a 2 in 
3 chance that you will be randomized to receive the active gene therapy rather than placebo. 
 
The section below explains what you will be asked to do in addition to the visits already 
described in the main Information Sheet 
 
Additional pre-1st dose visits: 
 
Eligibility and Consent (E&C) visit  
In certain cases to ease scheduling, we will schedule the nPD tests several months ahead of 
your planned dosing dates. In this case, the E&C visit will take place, which will include: 
• We will confirm that you are eligible to take part and ask you to sign the Consent Form 
• We will take a full medical history and perform a standard (bedside) examination 
including heart rate, breathing rate, blood pressure, pulse oximetry, temperature, and 
listen to your chest 
• blood sampling 
• urine sampling 
• Spirometry  
• Nasal potential difference measurement may be performed at this visit or on separate 
occasion  
 
Nasal PD visits 
You will be asked to have 3 nPD measurements before receiving your first dose of gene 
therapy. A maximum of 2 measurements can be performed at a visit. These may be performed 
at E&C, Introductory or Screening visits, or may be scheduled separately to suit you. On a 
single occasion, either with or after your 3rd nPD, you will undergo a nasal brushing test. 
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Nasal Dosing: You will be taught how to use the nasal spray and will be asked to administer 
a nasal spray during the ‘off’ nebuliser period, with one spray being delivered to each nostril 
at the beginning and end of the first 6 two minute ‘off’ periods which will deliver a dose of 
approximately 2 ml. 
 
Nasal potential difference (nPD): We will perform nasal PD on three occasions before the 
first dose (this is because we know the measurements are quite variable and want to be as 
certain as possible that any changes we see are due to the gene therapy and not just this 
variability), and after the sixth dose and at two time points after the twelfth doseWe may do 
additional nasal PDs post dose 3, 6 and 9 if opportunity arises and you are agreeable. This test 
is a sensitive way of measuring salts moving in and out of the cells lining the nose. The 
readings are different in patients with CF from those without and this test has been used 
clinically for many years in difficult diagnoses.  As gene therapy is directed at correcting 
these cells, this test can help tell us how well the gene therapy is working.  A small abrasion 
is made with a sterile device on the skin of the forearm; this is not painful.  An electrode wire 
is attached to the abraded skin and a small volume of cream is applied and kept in place with 
a piece of tape.  A soft catheter is inserted about 5-7 cm into one nostril until a stable reading 
is obtained.  This will then be taped in place.  A series of solutions is perfused into the nostril; 
you will be asked to lean forward so that drops fall into a bowl rather than go down the back 
of your throat. The response to these solutions is measured on a portable computer. The 
whole test takes approximately 20 minutes. We may wish to perform this on both nostrils 
(one after the other) depending on the results.  
 
The more common side effects include: 
• A slight salty taste from the solutions in your nose 
• Sneezing or mild discomfort during insertion of the catheter 
• Mild discomfort on your arm for a short while following skin abrasion 
 
 
Nasal brushing: We will obtain cells lining the nose by inserting a small, sterile brush into 
the nostrils, one at a time. The procedure is not particularly pleasant and makes the eye on 
that side water slightly.  It is however very quick, each nostril taking only approximately 5 
seconds.  We will perform nasal brushing on one occasion at or after your third nasal PD visit 
and again at the end of the trial. 
 
123
DOI: 10.3310/eme03050 EFFICACY AND MECHANISM EVALUATION 2016 VOL. 3 NO. 5
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Alton et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
Rarely, patients are unhappy to have tests performed on their nose as they find this 
unpleasant; if you feel this way and are also in the bronchoscopy subgroup, we can include 
you in the nasal dosing group and perform only a single nPD and brushing pre and post-
dosing whilst you are under anaesthetic.  
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Appendix 2 
 
Bronchoscopy Subgroup (London site only) 
 
A group of at least 24 patients in this trial will be asked to undergo two bronchoscopies, one 
before the first dose of gene therapy / placebo and the second between day 29 and 35. After 
the 12th dose of  gene therapy / placebo. The purpose of this is to make measurements of the 
levels and function of the CFTR gene in the hope that we can learn how much gene we need 
to replace in order to achieve health benefits.  As with the nasal group, this is optional and 
you do not need to take part in this subgroup if you do not want to. If you do agree and are 
considered suitable, there will be a 2 in 3 chance that you will be randomised to receive the 
active gene therapy rather than placebo. 
 
The section below explains what you will be asked to do in addition to the visits already 
described in the main Information Sheet 
 
Additional visits: 
 
Eligibility and Consent (E&C) visit  
In certain cases to ease scheduling, we will schedule the bronchoscopy several months ahead 
of your planned dosing dates. In this case, the E&C visit will take place, which will include: 
• We will confirm that you are eligible to take part and ask you to sign the Consent Form 
• We will take a full medical history and perform a standard (bedside) examination 
including heart rate, breathing rate, blood pressure, pulse oximetry, temperature, and 
listen to your chest 
• blood sampling 
• urine sampling 
• Spirometry  
 
Flexible bronchoscopy under general anaesthetic (GA):  
This will be performed once before you start dosing and again at the end, between 29 and 35 
days after your 12th dosing visit. 
The bronchoscope allows us a view down into your airways; once you have been 
anaesthetized and are fully asleep, we will make a general inspection of lung inflammation, 
plugging etc and will then take 2 biopsies and 10 airway wall brushings from one lung.  These 
are safe procedures, although a small amount of airway wall bleeding is common and you 
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may notice some blood in your sputum for a few days afterwards.  We will also make PD 
measurements down the bronchoscope onto the airway surface in a fashion similar to that 
described for the nPD (see Appendix 1). We will, as is usual clinical practice, record the 
entire procedure onto a DVD, which you may view afterwards with us should you wish. 
The samples that we obtain will be tested using: 
i. Molecular tests to tell us whether the gene has reached these parts of 
the lung and successfully entered the airway lining cells 
ii. Stains to demonstrate whether the CFTR protein has been produced  
iii. Routine histology (examination under a microscope) 
We estimate that the whole procedure will take approximately 45-60 minutes. At the end of 
the procedure, we will give you a single dose of the antibiotic(s) most suited to the bacteria 
found most recently in your lungs (sputum or cough swab) to limit the chance of a fever after 
the procedure. 
You will have the opportunity to meet and talk to both the Consultant Anaesthetist and 
Consultant Respiratory Physician performing the procedure beforehand and ask any 
additional questions you may have. All staff are fully trained and experienced in these 
procedures, which are performed regularly at this hospital as part of routine clinical 
management. 
You will be monitored and observed for at least 4 hours after the bronchoscopy.  We 
anticipate that most patients will recover fully within this time period and feel able to be 
discharged. Should this not be the case, we will ask that you remain in hospital overnight for 
further observation. You will not be able to drive and so should it be more convenient for 
your travel arrangements, we will arrange for you to stay overnight either at the hospital or at 
a local hotel.  
 
In summary, bronchoscopy is generally a safe procedure and performed regularly in hospitals.   
 
The more common side effects are; 
• Drowsiness after the anaesthetic – this should wear off after a few hours 
• A mild, sore throat for a day or so 
• Fever (this will be made less likely with the use of an IV antibiotic and the end of the 
procedure) 
• A small amount of blood (specks) may come up when you cough for a day or so due 
to the biopsies 
Rarely, an anaesthetic can lead to an increase in symptoms such as cough and sputum 
production. Major blood loss or a chest infection after bronchoscopy are very rare.   
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Many thanks for considering these additional tests; please feel free to ask any questions you 
may have. 
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Parent information sheet
PARENT INFORMATION SHEET 
 
Study title: A randomised, double-blind, placebo-controlled Phase 2B clinical trial of 
repeated application of gene therapy in patients with cystic fibrosis 
 
Short title: Repeated application of gene therapy in CF patients  
 
Invitation paragraph 
 
Your child/ ward (hereafter referred to as ‘child’) is being invited to take part in a research 
study and has been given an Information sheet similar to this one. This is specifically for 
parents/ carers, to help you decide whether you wish your child to participate. Before you 
decide you need to understand why the research is being done and what it would involve for 
you both.  Please take time to read the following information carefully. Talk to others about 
the study if you wish.   
 
Please ask us if there is anything that is not clear or if you would like more information.  
Please take as much time as you need to decide with your child whether or not you and they 
wish to take part. 
 
Introduction 
There is currently no treatment for Cystic Fibrosis (CF) that completely halts the progression 
of lung damage; all the available therapies help to slow the rate of decline in lung function at 
best.  Because of this, we have formed the UK CF Gene Therapy Consortium, (scientists, 
doctors & nurses based at Imperial College/ Royal Brompton Hospital, Oxford & Edinburgh 
Universities & Hospitals, www.cfgenetherapy.org.uk/) to develop further gene therapy for 
CF.  Gene therapy uses healthy copies of the CFTR gene to replace the damaged versions 
within the nose and lungs of patients with CF.  Each of these three centres has previously 
been involved in clinical gene therapy trials which were designed simply to prove that we 
could deliver healthy genes in this way.  Together, we have designed a programme of 
research to lead to a large, multi-dose clinical trial.  This will be the first trial to give multiple, 
repeated doses and look for clinical benefit.  The gene therapy will consist of the healthy 
CFTR gene, which will be carried into the cells of the airways by a liposome (a fatty 
substance), called GL67A.  This is the same liposome which we used in clinical trials in the 
1990s and we, therefore, have results on its safety and efficacy.  The gene, however, has been  
substantially improved and has recently been used in a pilot clinical trial to ensure its safety 
and to see how long each dose lasts.  The gene therapy can cause a brief change in lung 
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function and mild feverish symptoms.  We have therefore decided to use a dose of 5mls (a 
teaspoonful, delivered by inhalation of a nebulised aerosol) which was found to be the best 
tolerated in the pilot trial.  
 
What is the purpose of the study? 
The purpose of this study is to assess for the first time whether repeated doses of gene therapy 
administered to the lungs of CF patients can lead to clinical improvement. 
 
Why has my child been invited? 
He/she has been invited because they are have CF and attend the Royal Brompton Hospital, 
one of the hospitals within the Scottish Paediatric Cystic Fibrosis Service,  or one of our 
collaborating patient identification centres.  They are also relatively well, with mild or 
moderate lung involvement, however not so well that we will struggle to measure any 
improvement. This will mean that the nebulised gene therapy has a good chance of reaching 
the cells lining your child’s airways without being blocked by excessive mucus, and that we 
will sample from their airways more easily.  If your child is a patient from one of our 
collaborating participant identification centres they will attend the Royal Brompton Hospital 
or Western General Hospital / Royal Hospital for Sick Children Edinburgh for all trial related 
visits but continue their clinical care at their own centre. Trial visits are not a substitute for 
usual clinic visits and we will not make changes to your child’s usual treatment. We will 
communicate closely with your local team and let them know of anything that might 
influence treatment decisions.  
 
If your child has been involved in the Run-In study they will be invited for a single screening 
visit to determine whether they will fit the criteria to participate in the multi-dose trial.  If 
your child has been newly recruited, i.e. not participated in the Run-In trial, they will be 
invited for an introductory visit to talk to you and your child further about the research and 
assess their eligibility, as well as attending a subsequent screening visit. 
 
We think that your child may fulfill all of the Inclusion & Exclusion criteria although we will 
need to go through these lists in detail with you; in particular we will be looking for lung 
function within the range of 50-90% and for your child to be in a stable condition with no 
recent changes to their CF treatments.  If your childs recent lung function is close to the cut-
offs for being included we may wish to perform spirometry to see if they are eligible before 
discussing all the details of the trial with us, as this is quite time consuming. In this case, we 
will ask you both simply to sign a form consenting to lung function, which in no way 
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commits you to taking part in the trial. If your child is unwell at the time they are seen, we 
may be able to reschedule their visit for when they have recovered and are once again stable. 
 
Does my child have to take part? 
It is completely up to you to decide with your child whether or not they wish take part.  If 
he/she does decide to take part you will be given this information sheet to keep and be asked 
to sign a consent form.  Your child will also be asked to sign a separate form agreeing to take 
part. If you and your child decide to take part you are still free to withdraw at any time and 
without giving a reason.  This will not affect the standard of care your child receives. 
 
What will happen  if we take part? 
After the screening visit, all patients volunteering for the main part of this study will receive 
nebulised doses of either the gene therapy (active) product or placebo (sometimes called the 
‘dummy drug’) at 4 week intervals over a 48 week period.  Once you have agreed for your 
child to take part in the study, they will be assigned by chance (like the flip of a coin, but 
done by a computer) to receive either gene therapy or placebo.  A placebo contains no active 
ingredient. The probability that you will receive gene therapy is therefore 1 in 2 i.e. there is a 
50% chance that your child will receive the gene therapy throughout the trial and a 50% 
chance that your child will receive the placebo throughout the trial.  Neither you nor your 
child’s study doctor will know whether your child are receiving gene therapy or placebo.  
This is termed a ‘double-blind’ study and is extremely important for generating results that 
are meaningful and which will be believed by the wider scientific community.  However, in 
the event of an emergency, the identity of the nebuliser solution can be determined rapidly.   
 
When would our child take part?The first 20 patients (10 active treatment; 10 placebo) will 
receive a nebulised dose (5ml) on 3 occasions at 4-weekly intervals before any further 
patients are dosed.  This is a safety measure to allow the Data Monitoring and Ethics 
Committee (DMEC, a panel of medical experts) to review the clinical and laboratory findings 
to ensure that everything is satisfactory after repeated doses of the active treatment/placebo.  
If this proves to be the case these patients will continue with subsequent visits and the 
remaining patients will begin their dosing schedule.  Because of the large number of patients 
(130) involved in the study and the restriction on the facilities (special gene therapy cubicles) 
used we will have to stagger the dosing visits so it is likely to take at least 5-6 months before 
all patients have started their dosing schedule. 
 
Were the DMEC to have any concerns with the clinical and laboratory findings, they could 
recommend that we reduce the dose of the gene therapy product.  In this event, and if your 
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child belonged to the initial 20 patient group, they would unfortunately have to withdraw 
from the trial.  A further group of 20 patients would then be recruited to receive the reduced 
dose (2.5ml) of active treatment/placebo on 3 occasions at 4-weekly intervals.  The DMEC 
would again meet to review the clinical and laboratory findings to ensure that everything is 
satisfactory.  If this proves to be the case these patients will continue with subsequent visits 
and the remaining patients will begin their dosing schedule.  If the DMEC were to have any 
concerns with the 2.5ml dose the trial would be halted as we do not consider it feasible to 
administer a smaller dose successfully to the lower airways via nebuliser.  
 
A subgroup (at least 24 patients at the London site) will be asked to undergo nasal dosing.  
This will involve some additional tests and up to 3 additional short study visits (although we 
will limit these as much as possible) .  This will be explained in detail on another sheet if you 
wish to consider this (see Appendix 1). 
 
A subgroup (at least 24 patients at the London site) will also be asked to undergo a flexible 
bronchoscopy (a test to look inside the lungs using a flexible telescope) under general 
anaesthetic on two occasions (prior to the first dose of gene therapy/placebo and between 29 
and 35 days after the 12th dose of gene therapy/placebo). This will involve two additional 
study visits. This will be explained in detail on another sheet if you wish to consider this (see 
Appendix 2). 
 
How often will we need to visit the hospital for this study? 
There will be a minimum of 15 visits over one year.  Your child will be monitored before and 
after each nebulised dose (dosing visit) during 12 scheduled dosing visits. The schedule of 
visits is 4 weeks +/- 5 days for 48 weeks with further details given below. You will be given a 
flow chart summarising the sequence of study visits: 
1. Introductory visit – new patients only (i.e. those not previously involved in Run-In 
study) (3-4 hours) This is to help us get to know you and your child and for you both 
to familiarise yourself with the tests before the trial starts. However, it is not essential 
and, particularly if you have a long distance to travel or other time commitments, we 
can discuss omitting this visit with you. 
2. Eligibility and Consent visit (selected subgroup patients only- see below)* (2-3 
hours) 
3. Screening visit – all patients (3-4 hours)  
4. Pre-dosing nasal PD visits up to 3 (nasal subgroup only) 
5. Pre-dosing bronchoscopy (bronchoscopy subgroup only) 
6. Dosing visits x 12 (3-4 hours) 
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7. Post-dosing day 2 visits (1st 3 doses in 1st 20 patients only) (2 hours) 
8. Follow up visits on Days 14 and 28 (+/-2days) post-dosing (3-4 hours)  
9. Post-dosing bronchoscopy Days 27-36 after dose 12 (bronchoscopy subgroup only) 
*As the screening visit must occur within 28 days before the first dosing visit, we will offer 
people taking part in the nasal or bronchoscopy subgroups the opportunity to plan the 
additional investigation visits earlier if convenient. This will require an initial, short visit, at 
which we assess eligibility, perform a physical examination and limited tests and you will be 
asked to sign consent for the trial.   
 
Should there be any safety concerns, we have the flexibility to see patients for additional 
visits at any time during the study; such visits will of course be kept to an absolute minimum.  
 
The procedures performed at each of these visits are summarised below.  If for any reason we 
are unable to perform a test at a certain visit (eg. if you miss a visit or equipment fails), the 
protocol allows us to consider performing that test at a future visit. A full description of each 
test follows this summary of visits. 
 
PRE-DOSING VISITS 
Introductory visit – if considered necessary for new patients only (i.e. those not 
previously involved in Run-In study).  This visit will take around 3-4 hours and will involve: 
• explanation of study  
• full medical history  
• confirmation that your child is medically suitable for the trial  
• sign informed consent  
• a simple (bedside) examination of your child’s chest, blood pressure, temperature, pulse, 
and oxygen levels (with a finger probe) 
• blood sampling 
• urine sampling  
• Sputum sample (induction with 7% hypertonic saline if required) 
• spirometry (lung function tests, as usually done in clinic) 
• lung clearance index (LCI) 
• 24 hour sputum weight 
• nasal potential difference measurements may be conducted (nasal PD subgroup only) 
• we will give your child a diary card to take home and instructions on how to complete it 
• we will give your child a hand-held PiKo-6 device for you to carry out blowing tests 
(lung function) at home 
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Screening visit (all patients) 
This visit will take around 3-4 hours and will involve: 
· explanation of the study 
· confirmation that your child is medically suitable for the trial  
· sign informed consent (if not already signed at introductory visit)  
· quality of life questionnaire 
· full medical history and physical examination  
·  a simple (bedside) examination of your child’s chest, blood pressure, temperature, pulse, 
and oxygen levels (with a finger probe) 
· blood sampling 
· urine sampling  
· spirometry (lung function tests, as usually done in clinic) 
· lung clearance index (LCI) 
· exercise bike test 
· body worn activity monitor (which we will show you and your child how to use) 
· chest CT scan 
· gas transfer test  
· Sputum sample (induction with 7% hypertonic saline if required) 
· 24 hour sputum weight 
· nasal potential difference measurements may be conducted (nasal PD subgroup only) 
· we will give your child a diary card to take home and instructions on how to complete it 
· we will give your child a hand-held PiKo-6 device for you to carry out blowing tests 
(lung function) at home 
 
DOSING VISITS 
Each of the 12 dosing visits will take around 3-4 hours. If your child normally takes 
Pulmozyme (DNase), they will be asked to withhold treatment for 24 hours prior to each visit 
and for 24 hours after dosing.  
Predosing, the following will be performed at every visit: 
· history (we will ask your child how well they have been since the last visit and if any of 
their medicines have been changed) 
· a simple (bedside) examination of your child’s chest, blood pressure, temperature, pulse, 
and oxygen levels (with a finger probe) 
· blood sampling 
· spirometry (lung function tests, as usually done in clinic) 
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At specified visits, the following will also be performed 
• lung clearance index (LCI) 
• urine sampling 
• quality of life questionnaire 
• exercise bike test 
• body worn activity monitor 
• chest CT scan 
• gas transfer 
•  24 hour sputum weight and collection of fresh sample 
• nasal PD (London site subgroup only) 
• bronchial blood flow measurement (London site subgroup only) 
Dosing 
Approximately 20 minutes before the nebulised dose is administered, your child will receive 
200-400 µg (2-4 puffs) of inhaled salbutamol to prevent airway narrowing and wheeze, which 
may be associated with the gene therapy agent / placebo.  The nebulised dose will then be 
given via a mouthpiece from a clinical nebuliser.  Your child will be asked to wear a nose clip 
for the duration of the   nebulisation (3 minutes on, 2 minutes off for 8 cycles) which usually 
takes around 40 minutes..  The nebuliser will be administered whilst your child is sitting in a 
cubicle to prevent contamination of the immediate environment. Your child will have contact 
throughout and will be able to communicate with a research nurse through a glass window.  
You will be able to wait nearby, but will not be able to be in the cubicle while your child is 
receiving his/her nebulised dose. Your child will be asked to report any new symptoms.  
Although this environment is not spacious, we will do our best to make your child as 
comfortable as possible.  We can provide music or a DVD player should they wish.  They 
will be able to leave the cubicle as required for a toilet break, although we will ask that they 
wear a mask over their mouth and nose during this time and for 30 minutes after dosing is 
complete. 
 
If you agree for your child to take part in the nasal dosing subgroup (London site only), we 
will ask your child to administer a nasal spray during the ‘off’ nebuliser period, with one 
spray being delivered to each nostril at the beginning and end of the first 6 two minute’off’ 
periods which will deliver a dose of approximately 2 ml. 
 
Your child will be observed for a minimum of 30 minutes  after dosing before leaving the 
hospital. We will listen to your child’s chest and perform pulse oximetry before they leave the 
hospital.   If there are any concerns about your child’s level of well-being after treatment, we 
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may suggest that they stay in hospital overnight, although we are not expecting this to be the 
case.  We will ask your child to take a standard dose of paracetamol immediately post-dosing 
and you will be given another dose of paracetamol for your child to take at home 
approximately 6 hours after dosing.  This is to prevent any mild feverish symptoms that could 
possibly occur after dosing.  
 
Day 2 post-dosing visits (first 20 patients after each of the first three doses only) 
The following will be performed: 
• history (we will ask your child how they have been since their last visit and if any of 
their medicines have been changed) 
•  a simple (bedside) examination of your child’s chest, blood pressure, temperature, 
pulse, and oxygen levels (with a finger probe) 
• spirometry ((lung function tests, as usually done in clinic) 
• gas transfer 
• blood sampling 
• bring in sputum coughed up over last 24 hours and collect fresh sample 
 
Follow up visits 
There will be two follow up (F/U)visits that will occur at 14 (+/-2) days and 28 (+/-2) days 
after your child’s last dosing visit.   
 
At F/U day 14 we will do the following: 
• history (we will ask your child how well you have been since the last visit and if any of 
their medicines have been changed) 
• a simple (bedside) examination of your child’s chest, blood pressure, temperature, pulse, 
and oxygen levels (with a finger probe) 
• quality of life questionnaire 
• spirometry 
• blood sampling 
• lung clearance index (LCI) 
• nasal PD (subgroup only) 
• urine sampling 
• bring in sputum coughed up over last 24 hours and collect fresh sample 
• diary card  check 
• download hand-held PiKo-6 device on which your child carried out blowing tests 
At F/U day 28 we will do the following: 
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• history (we will ask your child how well they have been since the last visit and if any of 
their medicines have been changed) 
• all the tests performed at the screening visit 
• collection of diary card and hand-held PiKo-6 device 
 
Long term follow up: your child will be followed up by their clinical team at scheduled CF 
clinic appointments approximately every 3 months for 2 years. 
 
Description of Tests 
• Full medical history: we will ask about your child’s medical condition(s) including 
history of medications (specifically any additional antibiotics required for their 
chest), operations and allergies plus anything else relevant to the safety of the trial. 
• Clinical examination: we will listen to your child’s lungs using a stethoscope and 
measure their height, weight, temperature, pulse, blood pressure and respiratory rate  
• Pulse oximetry (finger probe): a measurement of the oxygen level in your child’s 
blood using a finger probe 
• Blood test: (at each visit where blood is required, up to 25 mls, (5 teaspoons), will be 
taken for a variety of tests including routine clinical tests e.g. liver and kidney 
function, full blood count, electrolyte (salt) levels and C-reactive protein (a marker of 
inflammation). Samples will be stored for future measurement of inflammatory 
proteins and possibly for end-products of gene therapy breakdown. If you or your 
child wish, we will arrange for your child to have local anaesthetic, either cream or 
spray.  If your child has a portacath, we may be able to use this to take blood samples 
if they would prefer. At a single visit at any time during the trial, we will take a 
sample of blood for DNA (genetic) research. The only tests we will perform on this 
sample will be: 
o Testing for your child’s CF gene(s) if these are not known; we will be happy 
to let you know the results of this test.  This sample will not be used to test 
for any other genetic diseases  
o Testing for common, naturally-occurring changes in genes which might be 
involved in how people respond to gene therapy, eg, inflammatory response 
genes. We will do this testing in the event that we see that some people 
respond to gene therapy and others do not, to help us understand this better. 
• Urine sample: routine testing with a dipstick for protein, sugar etc; we will also 
perform a pregnancy test if your child is female   Samples will be stored for future 
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measurement of inflammatory proteins and possibly for end-products of gene therapy 
breakdown.   
• Spirometry (blowing tests, as usually done in clinic).  
• Lung clearance index (LCI): this test demonstrates how evenly gas is distributed in 
the lungs and is a sensitive marker of airway disease. Your child will be asked to 
breathe a tracer gas (SF6) which has no smell or taste and is completely harmless, 
over a period of several minutes. Once levels in your child’s lungs are stable, they 
will switch to breathing air and the time taken for the SF6 to leave the lungs is used to 
calculate the LCI.  We will perform the test 3 times, each one taking about 10 
minutes.  
• Exercise bike test: this test will be performed on an exercise bike and is incremental 
(gets more difficult to pedal as it goes on).  Exercise is an event that involves a large 
number of physiological processes from the heart and lungs, to the blood circulation 
and the muscle itself.  This test will enable us to calculate your child’s exercise 
capacity. During the test we will record a breathlessness score and a probe will be 
attached to your child’s finger or ear lobe to measure the oxygen levels in their blood. 
Your child will be wearing a nose clip and breathing through a mouthpiece. They will 
be asked to pedal at a comfortable speed and maintain this speed throughout the test.  
The resistance to pedalling will automatically increase each minute and your child 
will be encouraged to continue until they either cannot keep up with the speed or feel 
they have exercised as much as they are able; we will ask your child to stop if their 
oxygen level falls.  Once the test is complete your child will have a 2 minute cool 
down period, and we will continue to monitor their oxygen levels until they return to 
baseline.  
• Sweat test:  Although the diagnosis of CF is not in doubt, some patients, particularly 
those who were diagnosed many years ago, do not have documented confirmation of 
a diagnostic test in their notes. If your child has neither a confirmed genetic diagnosis 
(2 mutations) nor a sweat test result, we would like to perform a sweat test as part of 
the trial. An area of the skin on your childs forearm will be cleaned and 2 electrodes 
will be attached with straps. One of these contains a gel which stimulates sweat and 
the medication is applied to the skin by a weak current;  there will be a little tingling 
but this is not painful. Following this a collection device will be attached to the skin 
surface and the sweat collected over a 30 minute period. This will then be analysed  
by the laboratory for the high levels of salt seen in CFActivity monitor: a small band 
worn on your child’s upper arm that collects step and movement data.  Your child 
will be asked to wear this for 7 full days after specific study visits. 
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• Chest computed tomographic (CT) scan: Computed tomography uses x-rays to create 
detailed images of the lungs.  It is a good measure of how CF affects the shape and 
structure of the airways.  For each scan your child will be asked to lie still on a table 
which will move slowly through the centre of a large x-ray machine but at no time 
will they be in an enclosed space. Your child will be able to communicate with the 
CT staff if they need to. They will be given breathing instructions at the time of the 
scan.  No injections are involved and the procedure is completely painless.  As x-rays 
are involved, your child will be exposed to a small amount of radiation.  However, we 
will be using as low a dose as is possible for  your child’s scans.  The estimated 
maximum dose of all three scans over the entire study period amounts to 4.5 mSV, 
which is similar to the radiation your child would be exposed to as part of natural 
background radiation over a 2 year period.  Because even low levels of radiation can 
be dangerous to an unborn child, it is a requirement that all females undergo a urine 
pregnancy test on the day of the procedure.  
• Transfer factor (TLCO): this is a lung function test which measures the rate at which 
gas travels across the lung tissue (alveolus) into the blood stream. Gas transfer is 
usually normal in patients with CF. We are using this test as a safety measure and in 
order to assess whether the gene transfer has an effect on this, we need to make a 
baseline measurement. Your child will be asked to wear a nose-clip and to breathe 
out as far as they can through a mouth-piece. They will then breathe in as far as 
possible, a mixture of air and low concentration of a tracer gas (less than 0.3% carbon 
monoxide) and hold their breath for 10 seconds before breathing out as far as 
possible. This will be repeated up to 5 times with rest periods in between tests.  This 
concentration of CO is completely harmless and this is a well-established test used 
routinely in clinical practice.  
• Sputum sampling: we will ask your child to try and cough up around a teaspoon of 
sputum; if this is not possible , we will obtain secretions for microbiology by asking 
your child to cough onto a sterile swab or brush .   At either your child’s introductory 
or screening visit and at either of their follow up day 14 or day 28 visits if your child 
is unable to cough up a sputum sample, we will use a well-established nebulisation 
technique to induce sputum.  To prevent wheeze (a common side effect), your child 
will be given 200-400 µg (2-4 puffs)of salbutamol (Ventolin) or an equivalent drug to 
open up the airways. After 15 minutes your child will receive a 7% saline nebuliser 
for 5 minutes, and this will be repeated up to 3 times. We will monitor your child’s 
lung function (FEV1
 
) throughout, and should we see a significant drop, the test will 
be stopped. If sputum induction fails, we will obtain secretions for microbiology by 
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
138
asking your child to cough onto a sterile swab or brush.  Samples will be tested for 
infection and stored for future measurement of inflammatory proteins and possibly 
for end-products of gene therapy breakdown. CF specific quality of life 
questionnaire: this will take a total of 10 minutes to complete.  
• Diary card: Your child will be given a diary card which they will be asked to 
complete for the duration of the study. This will record new symptoms, changes in 
routine treatments etc. 
• Home lung function: You and your child will be taught how to use a small lung 
function device (PiKo-6) and asked to make regular recordings on it at home for the 
duration of the study period. The machine stores all the readings which will be 
downloaded onto a computer at each visit. 
• Bronchial blood flow measurement: (London site only) This test is designed to look at 
the blood flow to the airways which is often increased in patients with airway disease, 
probably reflecting inflammation.  The test takes about 45 minutes to do and consists 
of 10 breath-holding manoeuvres of either 8 or 16 seconds.  For each manoeuvre your 
child will be seated, wearing a noseclip and breathing in and out through a 
mouthpiece.  After several normal breaths they will need to breathe in a small amount 
of test gas, which is safe and enriched with oxygen, and hold this breath for 8 or 16 
seconds before breathing out again slowly.  Their heart rate and oxygen saturation 
will also be monitored during the test.  There is a gap (3-4 min) between each of the 
manoeuvres to save the data and calibrate the equipment.  As the blood flow to the 
airways may be affected by caffeine, it is requested that your child does not consume 
any caffeine on the day of the test.  This test will be undertaken after all other assays / 
tests if time allows.  If your child is too tired to do the procedure it will not be done or 
if during the procedure they feel too tired to continue we will stop the test at any time. 
• Nasal PD and nasal brushings: see Appendix 1 (London site only) 
• Bronchoscopy: see Appendix 2 (London site only) 
 
What else will we have to do? 
In addition to the study visits and home monitoring outlined above, we will ask that if your 
child is sexually active, they agree to take contraceptive precautions from enrolment into the 
study until 3 months after completion. This is a requirement of the Medicines and Healthcare 
products Regulations Agency (MHRA) and the Gene Therapy Advisory Committee (GTAC) 
for all clinical trials involving gene therapy. We will talk to them and you about approved 
(reliable) methods of contraception. 
There will be no other changes made to your child’s routine clinical care.  
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We ask that you consent to our informing your child’s General Practitioner about their 
involvement in the study, including these requirements for contraception. 
 
What is the drug or procedure that is being tested? 
We are testing a formulation consisting of a healthy copy of the CFTR gene mixed with a 
fatty substance which helps the gene enter the cells of the airway. The CFTR gene has been 
changed since our original trial in ways that we believed would make it likely to cause less 
inflammation and last for longer.  We did see some flu-like responses and drops in lung 
function in some people in the Pilot study but by giving a smaller dose (5ml) we were able to 
reduce these side effects. The research team will be happy to provide you and your child with 
more specific scientific details should you wish. 
 
What are the alternatives for diagnosis or treatment? 
As you and your child will know, conventional treatments for CF have improved greatly over 
the last few decades. However, they do not correct the basic defect in your child’s cells, 
which is what we are aiming to do with gene therapy. In general therefore, conventional 
treatments slow the natural progression of lung disease, rather than stop it altogether. Should 
you or child wish not to take part, your child’s standard clinical care will continue as usual. 
 
What are the possible disadvantages and risks of taking part? 
We are asking for a large time commitment from you and your child over a period of a year.  
The study requires you and your child to make a minimum of 15 visits and perform multiple 
tests. As described above, most of these are straightforward and many of them will be 
familiar to you and your child from clinics (and also if your child participated in the Run-in).  
The risks that we consider likely are as follows: 
1. Either the gene therapy or the placebo could cause wheeze or increased cough. To 
limit this, we will administer salbutamol, to relax the airways, prior to nebulisation.  
In our previous study, some of the single dose patients had a fall in their lung 
function several hours after dosing but this was well-tolerated and, for most patients 
receiving 5 ml, was not associated with any increased symptoms. Lung function had 
resolved in all dosing groups within 2 days of the dosing visit. 
2. In the single dose study, some patients developed a temperature and a mild flu-like 
illness within a few hours of dosing.  These side effects were minimal with the 5 ml 
dose that we have chosen for this trial and appear to be responsive to paracetamol, 
which we will ask your child to take on two occasions (2hrs and 8 hrs) post-dose 
whether they have side effects or not.  All side effects should have disappeared within 
2 days of the dosing visit.  
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
140
3. The CT scans involve exposure to a small amount of radiation, which in common 
with all radiation does carry a small risk of causing cancer.  We plan to do a type of 
CT scan using lower radiation doses than a standard CT.  The estimated maximum 
dose of all three scans over the entire study period amounts to around 4.5 mSv.  To 
put this in context, the maximum amount of radiation from all three scans over the 
entire study period is equivalent to the amount of natural radiation to which everyone 
is exposed from environmental sources over a period of 2 years.  Female patients of a 
child-bearing age will be required to have a negative pregnancy test on the day of 
each scan. 
4. Please see Appendices 1 and 2 for disadvantages associated with nasal PD and 
bronchoscopy. (These tests are only being performed at the London site.) 
 
What are the possible benefits of taking part? 
Because we are the first research group in the world to administer multiple doses of this gene 
therapy product, and CF is such a chronic disease, we cannot be sure that there will be any 
immediate or long-term benefits of participating in the study. Your child will be helping to 
advance the field of gene therapy by agreeing to take part.  Should this study be successful, 
we will undertake further trials with a view to developing gene therapy as a treatment.  
 
What happens when the research study stops? 
When your child has completed their study visits, they will continue to receive their routine 
clinical care. If you wish, we will keep you and your child informed of any developments that 
arise from the results of this study. 
 
What if there is a problem? 
Throughout the study, we will be happy to talk to you and your child, or see you both at any 
point should you have concerns.  Should your child develop any health problems, we will 
investigate and treat these after discussion with your usual medical team. 
An independent Data Monitoring and Ethics Committee (DMEC) will oversee the safety of 
the trial as it progresses. Any significant adverse events will be reported to the DMEC.  
 
Complaints : If you have a concern about any aspect of the study, you should ask to speak to a 
member of your child’s clinical research team (see contact numbers at the end of this 
Information Sheet) who will do their best to answer your questions.  If you remain unhappy 
and wish to complain about any aspect of the way you or your child have been approached or 
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treated during the course of this study, the normal National Health Service complaints 
mechanisms are available to you. Details can be obtained from the hospital. 
 
Harm: In the event that something does go wrong and your child is harmed during the 
research due to someone’s negligence, then you may have grounds for legal action or 
compensation, but you may have to pay your legal costs. The normal National Health Service 
complaints mechanisms will still be available to you (if appropriate).  
 
Imperial College London holds Public Liability ("negligent harm") and Clinical Trial ("non-
negligent harm") insurance policies which apply to this trial.  Liability for the gene therapy 
product design will be accepted by Oxford University and Imperial College 
London.  Liability for the protocol design will be accepted collectively by Oxford University, 
Edinburgh University and Imperial College London.  Clinical negligence insurance 
/ indemnity is provided by the NHS. 
 
Will my child’s participation in the study be kept confidential? 
Yes.  
All information collected during the course of the study will be coded and kept strictly 
confidential.  Clinical results and analysis will be collated by the Imperial College Trials Unit.  
All samples will be stored indefinitely in a coded fashion to preserve confidentiality. Codes 
will be held by a single investigator at each site.  If you consent to your child taking part in 
the research, any of their medical records may be inspected for purposes of analysing the 
results.  They may also be looked at by people from regulatory authorities to check that the 
study is being carried out correctly.  Your child’s name, however, will not be disclosed 
outside the hospital. 
If you agree to your child taking part, their GP will be informed and your hospital notes will 
be flagged to ensure that other members of your child’s clinical team are also informed. 
  
What if relevant new information becomes available? 
Sometimes during the course of a research project, new information becomes available about 
the test/treatment that is being studied.  If this happens, your child’s research doctor will tell 
you about it and discuss with you and your child whether you want your child to continue in 
the study.  If you decide to withdraw your child, your child’s research doctor will make 
arrangements for their normal clinical care to continue.  If you decide that your child can 
continue in the study you will be asked to sign an updated consent form. 
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Also, on receiving new information your child’s research doctor might consider it to be in 
your child’s best interest to withdraw them from the study.  He/she will explain the reasons 
and arrange for your child’s normal clinical care to continue.   
 
What will happen if I don’t want my child to carry on with the study? 
Your child will be free to discontinue the study at any time, without giving a reason, and this 
will not affect their clinical care in any way.  For patients who have commenced dosing we 
would be grateful if  they could attend at least a 14 and 28 day follow up appointment as part 
of the trial. Samples already obtained will be used for this and other ethically approved 
studies unless you specifically request samples to be destroyed. In addition we would like to 
discuss your child’s progress with their clinical team after their routine clinic visits to gather 
as much information as possible for the trial and ensure continuing patient safety. 
 
What will happen to any samples  my child gives?  
Samples will be stored in a coded fashion so that, with the exception of one or two key 
people, the researchers will not be able to identify individual patients.  Many of the samples 
will be frozen and stored indefinitely.  We are working closely with the other members of the 
UK Gene Therapy Consortium in Oxford, Edinburgh and Southampton Universities and will 
be sending coded samples to them for analysis and storage.  We will also be sending coded 
blood samples to colleagues at the University of Pennsylvania, USA.  We would wish that 
any spare samples left over could be used in other ethically-approved research protocols and 
would ask you to agree to this by gifting your samples to us as part of consenting to this 
study.  All of our storage conditions comply with the regulations of the Human Tissue Act 
and/ or the Human Tissue Act (Scotland) 2006. 
What will happen to the results of the research study? 
At the end of the study, all results will be analysed, and will be reported at conferences and 
published in the Medical press.  Results of the study will also be made available to study 
participants on request.  Your child will not be identified in any report/publication. 
 
Will my expenses for my child’s taking part in the study be reimbursed? 
Yes. We understand the inconvenience involved in taking part in such a study and will be 
happy to reimburse travel expenses for the visits you will be asked to make with your child. 
 
Who is organising and funding the research? 
The study is being funded by the National Institute for Health Research & Medical Research 
Council. There is no financial gain to either the Hospital or the staff for including and looking 
after patients in this study. 
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Who has reviewed this study? 
This study has been submitted for review by the Gene Therapy Advisory Committee, the 
national body charged with assessing the ethical aspects of any clinical trial involving gene 
therapy. 
 
Thank you for considering taking part in this study 
We very much hope that after reading this information and talking to the research team, you 
and your child feel able to take part, but please be assured that should you or your child not 
wish to, this will in no way affect your child’s clinical care. 
 
For further information please contact:  
Royal Brompton Hospital, London  
Clare Saunders (Clinical Trial Co-ordinator) – Tel: 0207 352 8121 ext. 3516 
cfgenetherapy@rbht.nhs.uk 
Prof  Jane Davies - Tel:  
Prof Eric Alton - Tel:  
 
 
Royal Hospital for Sick Children, Edinburgh  
Dr Steve Cunningham – Tel:  
Dr David Armstrong – Tel:  
Kay Riding (Senior Research Nurse)- Tel:  
Maria Dewar (Research Manager) – Tel:  
Lothian.cfgtscotland@nhs.net 
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Appendix 1 
 
Nasal dosing Subgroup (London site only) 
 
A group of at least 24 patients in the trial will be asked to undergo nasal dosing and have 
nasal potential difference (nPD) measured and nasal brushings taken.  Because the nostrils are 
relatively easy to access, and these measurements can therefore be made repeatedly, this 
offers us a valuable opportunity to study how well the gene is expressing at different time 
points during the study. This is optional and you do not have to take part in this additional 
testing if you do not wish to.  If you do agree and are considered suitable, there will be a 2 in 
3 chance that you will be randomised to receive the active gene therapy rather than placebo. 
 
The section below explains what you will be asked to do in addition to the visits already 
described in the main Information Sheet 
 
Additional pre-1st dose visits: 
 
Eligibility and Consent (E&C) visit  
In certain cases to ease scheduling, we will schedule the nPD tests several months ahead of 
your planned dosing dates. In this case, the E&C visit will take place, which will include: 
• We will confirm that you are eligible to take part and ask you to sign the Consent Form 
• We will take a full medical history and perform a standard (bedside) examination 
including heart rate, breathing rate, blood pressure, pulse oximetry, temperature, and 
listen to your chest 
• blood sampling 
• urine sampling 
• Spirometry  
• Nasal potential difference measurement may be performed at this visit or on separate 
occasion  
 
Nasal PD visits 
You will be asked to have 3 nPD measurements before receiving your first dose of gene 
therapy. A maximum of 2 measurements can be performed at a visit. These may be performed 
at E&C, Introductory or Screening visits, or may be scheduled separately to suit you. On a 
single occasion, either with or after your 3rd nPD, you will undergo a nasal brushing test. 
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Nasal Dosing: You will be taught how to use the nasal spray and will be asked to administer 
a nasal spray during the ‘off’ nebuliser period, with one spray being delivered to each nostril 
at the beginning and end of the first 6 two minute ‘off’ periods which will deliver a dose of 
approximately 2 ml. 
 
Nasal potential difference (nPD): We will perform nasal PD on three occasions before the 
first dose (this is because we know the measurements are quite variable and want to be as 
certain as possible that any changes we see are due to the gene therapy and not just this 
variability), and after the sixth dose and at two time points after the twelfth dose. We may do 
additional nasal PDs post dose 3, 6 and 9 if opportunity arises and you are agreeable  This test 
is a sensitive way of measuring salts moving in and out of the cells lining the nose. The 
readings are different in patients with CF from those without and this test has been used 
clinically for many years in difficult diagnoses.  As gene therapy is directed at correcting 
these cells, this test can help tell us how well the gene therapy is working.  A small abrasion 
is made with a sterile device on the skin of the forearm; this is not painful.  An electrode wire 
is attached to the abraded skin and a small volume of cream is applied and kept in place with 
a piece of tape.  A soft catheter is inserted about 5-7 cm into one nostril until a stable reading 
is obtained.  This will then be taped in place.  A series of solutions is perfused into the nostril; 
you will be asked to lean forward so that drops fall into a bowl rather than go down the back 
of your throat. The response to these solutions is measured on a portable computer. The 
whole test takes approximately 20 minutes. We may wish to perform this on both nostrils 
(one after the other) depending on the results.  
 
The more common side effects include: 
· A slight salty taste from the solutions in your nose 
· Sneezing or mild discomfort during insertion of the catheter 
· Mild discomfort on your arm for a short while following skin abrasion 
 
Nasal brushing: We will obtain cells lining the nose by inserting a small, sterile brush into 
the nostrils, one at a time. The procedure is not particularly pleasant and makes the eye on 
that side water slightly.  It is however very quick, each nostril taking only approximately 5 
seconds.  We will perform nasal brushing on one occasion at or after your third nasal PD visit 
and again at the end of the trial. 
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Rarely, patients are unhappy to have tests performed on their nose as they find this 
unpleasant; if your child feels this way they and are also in the bronchoscopy subgroup, we 
can include them in the nasal dosing group and perform only a single nPD and brushing pre 
and post-dosing whilst they are under anaesthetic.  
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Appendix 2 
 
Bronchoscopy Subgroup (London site only) 
 
A group of at least 24 patients in this trial will be asked to undergo two bronchoscopies, one 
before the first dose of gene therapy / placebo and the second between day 29 and 35. after 
the 12th dose of  gene therapy / placebo. The purpose of this is to make measurements of the 
levels and function of the CFTR gene in the hope that we can learn how much gene we need 
to replace in order to achieve health benefits.  As with the nasal group, this is optional and 
you do not need to take part in this subgroup if you do not want to. If you do agree and are 
considered suitable, there will be a 2 in 3 chance that you will be randomised to receive the 
active gene therapy rather than placebo. 
  
 
The section below explains what you will be asked to do in addition to the visits already 
described in the main Information Sheet 
 
Additional visits: 
 
Eligibility and Consent (E&C) visit  
In certain cases to ease scheduling, we will schedule the bronchoscopy several months ahead 
of your planned dosing dates. In this case, the E&C visit will take place, which will include: 
• We will confirm that you are eligible to take part and ask you to sign the Consent Form 
• We will take a full medical history and perform a standard (bedside) examination 
including heart rate, breathing rate, blood pressure, pulse oximetry, temperature, and 
listen to your chest 
• blood sampling 
• urine sampling 
• Spirometry  
 
Flexible bronchoscopy under general anaesthetic (GA):  
This will be performed once before you start dosing and again at the end, between 29 and 35 
days after your 12th dosing visit. 
The bronchoscope allows us a view down into your airways; once you have been 
anaesthetized and are fully asleep, we will make a general inspection of lung inflammation, 
plugging etc and will then take 2 biopsies and 10 airway wall brushings from one lung.  These 
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are safe procedures, although a small amount of airway wall bleeding is common and you 
may notice some blood in your sputum for a few days afterwards.  We will also make PD 
measurements down the bronchoscope onto the airway surface in a fashion similar to that 
described for the nPD (see Appendix 1). We will, as is usual clinical practice, record the 
entire procedure onto a DVD, which you may view afterwards with us should you wish. 
The samples that we obtain will be tested using: 
i.Molecular tests to tell us whether the gene has reached these parts of the lung 
and successfully entered the airway lining cells 
ii.Stains to demonstrate whether the CFTR protein has been produced  
iii.Routine histology (examination under a microscope) 
We estimate that the whole procedure will take approximately 45-60 minutes. At the end of 
the procedure, we will give you a single dose of the antibiotic(s) most suited to the bacteria 
found most recently in your lungs (sputum or cough swab) to limit the chance of a fever after 
the procedure. 
You will have the opportunity to meet and talk to both the Consultant Anaesthetist and 
Consultant Respiratory Physician performing the procedure beforehand and ask any 
additional questions you may have. All staff are fully trained and experienced in these 
procedures, which are performed regularly at this hospital as part of routine clinical 
management. 
You will be monitored and observed for at least 4 hours after the bronchoscopy.  We 
anticipate that most patients will recover fully within this time period and feel able to be 
discharged. Should this not be the case, we will ask that you remain in hospital overnight for 
further observation. You will not be able to drive and so should it be more convenient for 
your travel arrangements, we will arrange for you to stay overnight either at the hospital or at 
a local hotel.  
 
In summary, bronchoscopy is generally a safe procedure and performed regularly in hospitals.   
 
The more common side effects are; 
• Drowsiness after the anaesthetic – this should wear off after a few hours 
• A mild, sore throat for a day or so 
• Fever (this will be made less likely with the use of an IV antibiotic and the end of the 
procedure) 
• A small amount of blood (specks) may come up when you cough for a day or so due 
to the biopsies 
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Rarely, an anaesthetic can lead to an increase in symptoms such as cough and sputum 
production. Major blood loss or a chest infection after bronchoscopy are very rare.   
Many thanks for considering these additional tests; please feel free to ask any questions you 
may have. 
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
150
Paediatric information sheet
PAEDIATRIC INFORMATION SHEET 
 
Study title: A randomised, double-blind, placebo-controlled Phase 2B clinical trial of 
repeated application of gene therapy in patients with cystic fibrosis 
 
Short title: Repeated application of gene therapy in CF patients  
 
Invitation paragraph 
We would like to tell you about a research study we are doing. A research study 
is a way to learn more about something. 
 
Before you decide if you want to join in, it is important to understand why the research 
is being done and what it would involve for you. So please read this sheet carefully. Talk 
about it with your family, friends, doctor or nurse if you want to. 
 
Why are we doing this research and what is the medicine being tested? 
We are a group of scientists and doctors working together trying to develop a new type 
of treatment for patients with cystic fibrosis, called gene therapy. We are called the 
UK CF Gene Therapy Consortium. Cystic fibrosis is caused by a faulty gene. A gene is 
part of your cells that tells your body how to grow. Gene therapy replaces faulty CF 
genes with healthy copies within the nose and lungs. We have done research to find the 
best type of gene therapy, the best dose and the best nebuliser and we know that we 
can get the gene into the right place within the cells of the airways. This trial is to see 
whether the medicine can make people with CF better (higher lung function, feeling 
better, fewer infections etc). We don‛t know yet if the medicine works. 
 
Why have I been invited to take part? 
You have been invited to join this study because you have cystic fibrosis and we think 
you are likely to be in a group of patients with good (but not perfect) lung function.  You 
may have been kindly helping with our Run-in study, in which case you will probably know 
quite a lot about gene therapy and the sorts of tests we‛re doing. If you‛re new to this 
research, you will have the opportunity to hear more about it and we will answer any 
questions you may have. In this study, around 130 people, which includes children (12 
years and above), will help test this medicine in our clinical sites based in London and 
Edinburgh.  If you are a patient from one of our collaborating participant identification 
centres you will attend the Royal Brompton Hospital or the Western General Hospital / 
Royal Hospital for Sick Children Edinburgh for all trial related visits but continue your 
clinical care at your own centre. Trial visits are not a substitute for your usual clinic 
visits and we will not make decisions about your treatment. We will be in close touch 
with your usual centre and will let them know the results of tests if we think they need 
to know. 
 
We think you are likely to be in a group of patients with good (but not perfect) lung 
function. Because the trial itself is relatively long to talk through, we may ask you to 
perform lung function first to make sure that you will be in the right group to take part. 
If you fall below this range at the time of your visit we may be able to arrange for you 
to come again to test you again. 
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Do I have to be in this study? 
No. It is up to you to decide (with your parents). If you do decide to take part, your 
research doctor will ask you to sign a form giving your agreement to take part. You will 
be given a copy of this information sheet and your signed form to keep.  
 
You can decide to take part now but change your mind later and stop being in the study 
without needing to give a reason. If you decide to stop, this will not affect the care you 
will receive at your normal CF centre. 
 
Talk with your Mum or Dad or guardian before you decide. We will also ask your Mum or 
Dad or guardian if it is okay for you to be in this study. Even if they say “yes”, you have 
the final say and it is okay for you to say “no”. 
 
 
 
What will happen to me if I take part? 
This is quite a complicated study so we have attached a flow chart to the end of this 
sheet, which might help explain what‛s going to happen  
 
Firstly, we will see you at the hospital for one or two visits (2-3 hours each) to check 
you over, make sure you are fine to take part and do some tests; we call these ‘baseline‛ 
tests and we will be looking at whether they change once you have had the treatment. If 
you are suitable and you agree to take part, the next stage is that a computer decides 
whether you get the gene therapy, or a ‘dummy‛ medicine (half the people will be in each 
group). Neither you nor the study team will know which group the computer has placed 
you in. We know this is the best way to be certain whether a new medicine is actually 
working.  
 
You will then have a visit every month for 12 months. At each visit you will receive a dose 
of the study medicine (gene therapy or dummy) and we will do some tests too.  If you 
normally take DNase, we will ask you to miss this on the day of dosing and the next day 
(we will have checked this is okay with your clinic doctors). The tests are explained in 
detail further down this sheet. First we will give you a few puffs of a blue inhaler 
(salbutamol/ventolin) to open up your airways and reduce the chance that the medicine 
will make you wheezy. The gene therapy medicine (or dummy drug) will be in a nebuliser, 
which you will breathe in for around 40 minutes, with regular breaks.  We will ask you to 
wear a noseclip while using the nebuliser, to make sure that all the medicine is getting 
into your lungs, but you will be able to take this off during the breaks. The nebuliser pot 
will be covered in tape so that none of us can see inside., We do all this inside a special 
cubicle to make sure that the nebulised medicine does not get everywhere; there is a 
window so you can see chat to the study nurse, and your parent or guardian will just be in 
the next room. You can come out if you need to, but we will ask you to wear a mask for 
the first half hour.  After you have finished your dosing we will examine you and give you 
a dose of paracetamol (which should make side effects unlikely). You can then go home 
and we would like you to take another dose of paracetamol about 6 hours later. At the 
end of the 12 monthly visits, we will ask you to come back to the hospital for further 
tests 2 and 4 weeks later. That is the end of the study, but we will keep in touch with 
your regular clinic team to see how you are doing.  
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There are some patients in London who will be asked if they want to do also be part of a 
smaller study.  Twenty four people will be asked to be in a ‘nasal subgroup‛ – these 
patients will also be asked to spray some medicine up their nose during their nebuliser 
breaks. We will show them how to do them. There is more information about this test in 
Appendix 1 at the bottom of this test. 
 
Another small study will also be the ‘bronchoscopy subgroup‛, where 24 patients will also 
have a camera look into their lungs.  There is more information about this test in 
Appendix 2 at the bottom of this sheet. 
 
If you are asked to be in either of these groups, you can say no and still carry on with 
the rest of the study. 
 
 
What are the tests I will have at the study visits? 
You can see which tests are done at each visit on the sheet your parent/guardian has 
been given. 
• Full medical history: we will ask about your general health, whether you‛ve had 
operations and which medicines you take normally; this will be very like your 
clinic doctors do in out-patients. 
• Clinical examination: we will listen to your lungs using a stethoscope and measure 
your height, weight, temperature, pulse, blood pressure and respiratory rate 
(you will have had all of this done in clinic too). 
• Pulse oximetry (finger probe): we will measure the oxygen level in your blood 
using a finger clip. 
• Blood test: There are quite a few blood tests needed in this trial, so we can be 
certain the medicine is safe. We will only let a very experienced person take 
your blood. If you like you may have anaesthetic cream or spray.  If you have a 
portacath, and you would prefer that we used this to take blood samples, we may 
be able to use it instead. 
• Urine sample: we will ask you to pee into a pot and give us a sample for testing. 
If you are a girl and you have started your periods, we will also do a pregnancy 
test, because we are not allowed to test this medicine on pregnant women. 
• Spirometry (blowing tests, as usually done in clinic).  
• Lung clearance index (LCI): this test shows how evenly gas is distributed in the 
lungs and is a good marker of how healthy your lungs are. You will be asked to 
breathe a special gas mixture for a few minutes. You can‛t smell or taste this gas 
and it has no side effects.  Once levels in your lungs are stable, we will switch 
you to breathing normal air and the time taken for the gas to leave the lungs is 
used to calculate the LCI.  We will do the test 3 times, each one taking about 10 
minutes.  
• Exercise bike test: This test allows us to see how much exercise you can do and 
involves pedalling a bike which is fixed to the ground, whilst we monitor your 
heart rate and oxygen levels (finger clip). We will ask you to breathe through a 
mouth piece and wear a nose clip. You will be asked to pedal at a comfortable 
speed and to keep it up.  The pedalling will get harder and harder and we will ask 
you to carry on until you either cannot keep up or you feel exhausted. We will 
ask you to stop if your oxygen level falls.  Once the test is complete you will have 
a 2 minute cool down period, and we will continue to monitor your oxygen levels 
until they return to back to normal.  
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• Sweat Test: Although we are not in doubt about your diagnosis, if we can not 
find a document showing your blood test results, or your sweat test result we 
would like to perform one as part of the trial. An area of the skin on your arm 
will be cleaned and 2 electrodes will be attached with straps. One of these 
contains a gel which stimulates sweat and the medication is applied to the skin by 
a weak current; you will feel a little tingling but this is not painful. Following this 
a collection device will be attached to the skin surface and the sweat collected 
over a 30 minute period. This will then be analysed  by the laboratory for the 
high levels of salt seen in CF. 
• Activity monitor: this is a small band worn on your upper arm that collects step 
and movement data.  You will be asked to wear this for 7 full days after 3 of the 
study visits. 
• Chest computed tomographic (CT) scan: CT uses x-rays to create detailed images 
of the lungs.  It is a good measure of how CF affects the shape of the airways.  
For each scan you will be asked to lie still on a table which will move slowly 
through the centre of a large x-ray machine, but at no time will you be in an 
enclosed space. You will be able to talk to the CT staff if you need to. You will be 
given breathing instructions at the time of the scan.  No injections are involved 
and the test is completely painless.   
• Transfer factor (TLCO): this is a lung function test which measures how well gas 
travels across the lungs into the blood. You will probably have had this test 
before, as part of your annual assessment. You will be asked to wear a nose-clip 
and to breathe out as far as you can through a mouth-piece. You will then 
breathe in, as far as possible, a mixture of air and a low concentration of a 
‘tracer‛ gas and hold your breath for 10 seconds, before breathing out as far as 
possible. This will be repeated up to 3 times with rest periods in between tests.   
• Sputum sampling: we will ask you to try and cough up around a teaspoon of 
sputum. At one of your first visits and one of your follow-up if you can‛t cough up 
sputum we will ask you to breathe in a salty solution which makes this easier. We 
will give you some ventolin beforehand to stop you becoming wheezy but if you 
feel tight, tell us. We will check your lung function through the test and stop if 
it falls. If we don‛t manage to get any sputum at the end of this, we will ask you 
to do a cough swab. For some visits, we will ask you to collect all your sputum for 
the 24 hours before you come and bring this with you.  
• CF specific quality of life questionnaire: we will ask you to complete some 
questions about how you are feeling, which takes around 10 minutes.  
• Diary card: we will ask you to write down at home when you are feeling unwell or 
when your treatments change. You may want to do this with a parent. 
• Home lung function: we will show you how to use a small lung function machine at 
home which stores the results inside. We can then put the results onto a 
computer the next time you come to the hospital. 
• Bronchial blood flow measurement: This test will just be for the people in London 
only. It is designed to look at blood flow to the airways, which is often increased 
in people with lung disease. It involves you breathing a small amount of a special 
gas combination (once again, you cannot smell this and it is harmless). You will be 
sitting down, wearing a nose clip and breathing in and out through a mouthpiece. 
After several normal breaths you will be asked to hold your breath for a fixed 
period (either 8 or 16 seconds) before breathing out again slowly. This will be 
repeated 10 times with a gap (3-4min) between each to allow us to save the data 
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and reset the equipment. Your heart rate and oxygen levels will be monitored 
during the test. The whole test takes about 45 minutes to complete  
• Nasal potential difference (Nasal PD) and nasal brushings: London subgroup only 
- see Appendix 1 
• Bronchoscopy: London subgroup only - see Appendix 2 
 
 
What other medicines can I have instead? 
You probably know a lot about your CF and the types of medicines you normally take. You 
will continue on these whether or not you decide not to take part in this trial. Any other 
decisions about changing your medicines will be made by your usual CF team. 
 
What are the side effects of the medicines and might I get some if I take part in 
the research? 
We have chosen a dose that we hope has the least chance of side effects, but at higher 
doses this medicine did make some people feel a little fluey- they had a temperature for 
a few hours and felt a bit shivery. This is why we ask all patients to take some 
paracetamol after receiving the medicine. Most people also have a slight drop in their 
lung function, but they felt fine in themselves at this dose. If you do get any side 
effects, please tell your Mum or Dad, who will report them to the study team. Do not 
worry about telling us about any side effects, it will not mean that we will automatically 
take you off the trial.  
 
What are the possible benefits of taking part? 
We don‛t know if being in this study will help you, but what we find out will help other 
people with cystic fibrosis. If we show that gene therapy can make people with CF 
better, we will work hard towards future trials which could lead to it becoming available 
as a treatment. 
 
What happens if the research project stops? 
When the study stops you will be looked after as usual by your hospital CF team and 
continue to take your usual treatments.  
 
What happens if new information about the research medicine comes along? 
Sometimes during research, new things are found out about the research medicine. Your 
doctor will tell you all about it if this happens. What is best for you might be: 
• To carry on as before 
• To stop taking part and go back to your usual treatment 
 
What if there is a problem or something goes wrong? 
If you have any concern about any aspect of this study you should speak to your study 
doctor who will do their best to answer your questions. 
 
Will anyone else know I am doing this? 
We will keep all your information confidential. This means that we will only tell those 
people who have a right or need to know. Wherever possible, we will only send out 
information that has your name and address removed. We will let your family doctor (GP) 
know that you are taking part in the study. 
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What will happen to any samples I give? 
Samples such as blood, sputum, urine will be labelled with a special code, used for testing 
and stored for future tests. Some of the time we will be sending the samples out to 
other groups working with us; they will only have the code numbers and would not be able 
to tell that the sample was from you.  
 
Who is organizing the research? 
This study is being organized by the UK CF Gene Therapy Consortium. 
 
Who has reviewed the study? 
Before any research goes ahead it has to be checked by a Research Ethics Committee. 
They make sure the research is fair. This project has been checked by the Gene 
Therapy Advisory Committee, which specialises in trials such as this. 
 
Can I ask questions? 
You can ask questions about the study now. You can ask questions about the study 
whenever you want to. If you forget to ask a question and think of it later, you can call 
the doctor or ask your Mum, Dad or guardian to call the phone numbers below.  You can 
ask the next time you see your doctor if you want to. 
 
 
For further information please contact:  
 
Royal Brompton Hospital, London  
Clare Saunders (Clinical Trial Co-ordinator) – Tel: 
cfgenetherapy@rbht.nhs.uk 
Prof Jane Davies - Tel:  
Prof Eric Alton - Tel:  
 
Royal Hospital for Sick Children, Edinburgh  
Dr Steve Cunningham – Tel:   
Dr David Armstrong – Tel:  
Kay Riding (Senior Research Nurse)- Tel:   
Maria Dewar (Research Manager) – Tel:  
Lothian.cfgtscotland@nhs.net 
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Appendix 1 
Nasal dosing Subgroup 
 
A group of at least 24 patients in the trial will be asked to have doses sprayed into their 
nose as well as the nebulisers.  Because the nose is easy to measure from, we can get 
extra valuable information from this. This is optional and you do not have to take part in 
this substudy if you do not wish to.   
 
Nasal Dosing: You will be taught how to use the nasal spray and will be asked to squirt 
one spray into each nostril every 5 minutes; the entire 2 mls will take around 1 hour to 
administer and will be given at the same time as your nebulised dose, during the 2 minute 
breaks.  
 
Nasal potential difference (nPD): These are measurements made in the nostril and 
help us to know how well the gene therapy is working. The test does not hurt; some 
children have this done if we are finding it difficult to decide whether they have CF and 
they don‛t usually mind. We will do this three times before your first dose (this is 
because we know the measurements can change quite a bit and we want to be as certain 
as possible that any changes we see are due to the gene therapy and not just these 
normal changes), and after the sixth and twelfth doses.  We would also like to do tests 
after the third, sixth and ninth doses if you have time and don‛t mind. We rub a small 
area on your arm and then attach a wire with some cream and tape it on.  A soft tube is 
then put into your nostril and taped in place. Whilst you lean forward over a bowl, some 
salty solutions pass through the tube and out of your nose; we watch the response of 
your nose to this on a portable computer. The whole test takes approximately 20 
minutes. We may wish to perform this on both nostrils (one after the other) depending 
on the results. There are no serious side effects but you might get a slight salty taste 
from the solutions in your nose or feel like sneezing. 
 
Nasal brushing: On two visits only, we will take some cells from the lining of your nose 
with a small brush. This is not particularly nice but only takes about 5 seconds. We can 
get a million cells by doing this, which really helps us to find out how well the gene 
therapy is working. 
 
If you don‛t want to have the nasal test but would not mind taking part in the 
bronchoscopy subgroup we can still include you in the nasal dosing group and perform 
only a single nasal test and brushing, once before and once after dosing whilst you are 
under anaesthetic. 
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Appendix 2 
Bronchoscopy Subgroup 
 
A bronchoscope is a flexible telescope which allows the doctor to look down into your 
lungs, take samples and make measurements. It is done whilst you are asleep under a 
general anaesthetic. In this trial a group of at least 24 patients will be asked to have 
two of these tests, one before the first dose of gene therapy / placebo and the second 
at the end of the trial. The tests will allow us to learn how much gene we need to replace 
in order to achieve health benefits.  As with the nasal group, this is optional and you do 
not need to take part in this subgroup if you do not want to.   
 
We will take 2 small biopsies (pieces of the lining of the breathing tubes, about the size 
of a pinhead) and 10 airway wall brushings from one lung; we will also make measurements 
with a salty solution that will tell us how well the gene therapy is working.  You will not 
feel any of this as you will be asleep and they are very safe procedures. You might 
notice you cough up tiny flecks of blood in your sputum afterwards for a day or two. This 
is nothing to worry about. 
 
You will be asleep for around 45-60 minutes. Afterwards we will give you a dose of 
antibiotics through a cannula that you will have had put in whilst you‛re asleep. When 
you‛re fully awake, this can come out.  
 
We will keep an eye on you for 4 hours afterwards. Most likely you will then feel fine 
and be able to go home. The side effects you might have are 
• Drowsiness after the anaesthetic – this should wear off after a few hours 
• A mild, sore throat for a day or so 
• A temperature (this will be made less likely with the use of an IV antibiotic at 
the end of the procedure) 
• A small amount of blood (specks) may come up when you cough for a day or so 
due to the biopsies 
Many thanks for considering these additional tests; please feel free to ask any questions 
you may have. 
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Appendix 2 Dose preparation sheet
Investigator’s Brochure Appendix                                              EudraCT: 2011-004761-33 
 
Investigator’s Brochure Appendix VII 
 
Investigational product dose preparation sheets can be found below: 
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Investigational Product pGM169/GL67A  
EudraCT: 2011-004761-33          Dose Preparation Overview v01 
Dose Preparation Overview  
pGM169/GL67A or 0.9% (w/v) NaCl placebo will be administered to the nose and/or 
the lungs of trial subjects. Randomisation of trial subjects to pGM169/GL67A or 0.9% 
(w/v) NaCl placebo is co-ordinated by the Imperial College Trials Unit. 
 
For nasal administration, the nominal dose administered will be 2mL pGM169/GL67A 
or placebo. For lung administration, the nominal dose administered will be 5mL of 
pGM169/GL67A or placebo.  
 
Sterile 0.9% (w/v) NaCl saline solution for intravenous infusion is supplied by 
pharmacy and used to prepare nasal and lung placebo doses as appropriate. 
 
pGM169/GL67A is supplied by the sponsor in single-use packages sufficient to 
prepare a 10mL aliquot of pGM169/GL67A. 
 
One 10mL aliquot of pGM169/GL67A is used to fill a nasal spray device sufficient to 
deliver the 2mL necessary for nasal administration. 
 
One 10mL aliquot of pGM169/GL67A is used to prepare up to two (2) 5mL lung 
doses. Thus up to two lung doses may be prepared from one single-use package. 
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Investigational Product    pGM169/GL67A            Patient ID: __________ 
EudraCT: 2011-004761-335 Preparation of 10mL pGM169/GL67A Worksheet v01 Date: ________ 
Preparation of 10mL pGM169/GL67A Worksheet 
Final Material For Clinical trial use only 
 
Date: Patient ID: 
Pharmacy Batch Number: 10ml Aliquot Number: 
 
Data entry by: Data checked by: 
 
Time box removed from freezer: __________________________hrs 
Time recorded by: Time checked by: 
 
Raw Material Manufacturer Form Batch 
number 
Retest 
or 
expiry 
date 
Quantity Assembled 
by 
Check  
by 
pGM169/GL67A NHSBT/CBC  Pouch      
pGM169/GL67A NHSBT/CBC  Box      
pGM169 
(Blue crimp) 
VGX vial      
GL67A 
(Red crimp) 
Octoplus vial      
Water For 
Injection 
 Ampoule      
Container Manufacturer Form Batch 
number 
Expiry 
date 
Quantity Assembled 
by 
Check  
by 
5ml Syringe BD Syringe      
1ml Syringe BD Syringe      
Barrel      
Plunger      
Interim container 
Double lumen 
syringe 
 
Mixer      
Final  
container 
 
 
Universal 
tube 
(Sterilin) 
 
 
 
 
 
 
 
 
 
 
 
Cleaning log checked by: Temperature log checked by: 
Approval to proceed:  Pharmacist/Senior Technician 
 
 
Isolator is clean and free of items not required for this procedure.  
Signed:________________________________
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Investigational Product    pGM169/GL67A            Patient ID: __________ 
EudraCT: 2011-004761-335 Preparation of 10mL pGM169/GL67A Worksheet v01 Date: ________ 
Method  Step 1- Prepare Pneumatic mixer 
 
1) Follow SOP CFGT/SOP/601/SD LMD2 Pneumatic mixer: Open cylinder valve with gas spanner to 
pressurise regulator. Ensure adequate cylinder pressure (>70 psi) before commencing studies. 
 
Pressure adequate         Yes __________check 
      No __________check 
Method  Step 2- Hydration of GL67A 
 
2a) Allow vials to warm to room temperature for 10-15 minutes. 
Time vials at room temperature:  Time removed from freezer (from page 1):   __________ hrs
     Time ready to start: __________ hrs 
Timings recorded by: Timings checked by: 
If time ready to start <10minutes then wait until 10 minutes has elapsed. 
 
2b) Add 5.25 ml of sterile water for injection to the GL67A vial through the septum using a sterile 
green 21G butterfly needle and a 5 ml and 1 ml syringe. 
Volume measured by _______________________  Volume checked by_______________________ 
 
2c) As per SOP CFGT/SOP/603/SD GL67A Hydration, place the GL67A vial firmly in rack of the 
vortexer. Set the speed to 2500 and the time to 40 minutes and then switch on the vortexer. 
 
2d) Vortex the vial of GL67A on a setting of 2500 for forty (40) minutes. 
 
2e) During hydration of GL67A (red crimp vial) in the vortexer, occasionally gently shake the vial of 
pGM169 (blue crimp vial) to encourage thawing.   
 
2f) Remove vial of GL67A (red crimp vial) from vortexer and visually inspect to confirm that the 
material is completely dissolved (no white residues on the bottom of the vial, no visible lumps of 
material in suspension).   
Note that in some cases it may take longer than 40 min for the lipid to dissolve completely. If lipid is 
not completely dissolved, use the vortexer as described for additional 10 minute cycles until the 
material is completely dissolved. If total vortexing material exceeds 100 minutes, discard GL67A 
 
Additional Vortex start time:  __________ am  / pm 
Final Vortex stop time:  __________ am  / pm 
Total vortexing time:  __________ minutes 
 
Timings recorded by: Timings checked by: 
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Investigational Product    pGM169/GL67A            Patient ID: __________ 
EudraCT: 2011-004761-335 Preparation of 10mL pGM169/GL67A Worksheet v01 Date: ________ 
Method  Step 3- Formation of pGM169/GL67A  
3a) Visually inspect appearance of solution in pGM169 (blue crimp) vial to confirm that the material is 
completely thawed (no visible lumps of material in suspension). 
Note that in some cases the pGM169 may not be completely thawed. If pGM169 is not completely 
thawed, gently shake vial to encourage thawing until there are no visible lumps of material in 
suspension. 
GL67A and pGM169 solution homogeneous by visual inspection:    
Assessed by: Checked by: 
 
 
3b) Check calibration of the pneumatic mixer is within acceptable limits (SOP CFGT/SOP/601/SD 
LMD2 Pneumatic mixer). 
 
Adjustment required:       ______ Yes 
        ______ No 
Assessed by: Checked by: 
 
3c) Fill double lumen syringe as described in SOP CFGT/SOP/602/SD Preparation of pGM169/GL67A 
complexes with five (5) ml of solution from GL67A (red crimp) vial through the septum using a sterile 
16 gauge needle and sterile 5 ml syringe and transfer to lumen two (2) of double lumen syringe.  
Volume measured by:______________________ Volume checked by:_________________________ 
 
3d) Fill double lumen syringe as described in SOP CFGT/SOP/602/SD with five (5) ml of solution from 
pGM169 (blue crimp) vial through the septum using a sterile 16 gauge needle and sterile 5 ml syringe 
and transfer to lumen one (1) of double lumen syringe. 
Volume measured by:______________________ Volume checked by:_________________________ 
 
3e) Insert double lumen syringe into pneumatic mixer as described in SOP CFGT/SOP/602/SD, place 
20 ml steralin immediately below the protruding static mixer element to collect mixed formulation and 
operate as described in SOP CFGT/SOP/602/SD.  
 
Activate static mixer:        ______ Check 
 
3e) Record time preparation was completed:    __________ hrs 
Time recorded by: Time checked by:: 
 
Method Step 4- Labelling of pGM169/GL67A investigational product 
4a) Calculate and record dosage expiry time.  
Dosage expiry time = time preparation was completed (recorded at 3e) plus 4 hours. 
Record dosage expiry time:      __________ hrs 
Time calculated by: Time checked by: 
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Investigational Product    pGM169/GL67A            Patient ID: __________ 
EudraCT: 2011-004761-335 Preparation of 10mL pGM169/GL67A Worksheet v01 Date: ________ 
 
4b) Label Sterilin Universal tube containing final dosage form with label adhering to following format: 
Master Label: Sample Label: 
pGM169/GL67A 
Batch:  
10mL  
Patient ID: 
Expiry time: 
Date:  
10ml Aliquot number: 
Room temperature storage 
Clinical trial use only 
 
 
4c) Confirm final dosage form labelling and release: 
Labelling 
Number of labels issued Number of units expected 
Labels  issued by  Units prepared by  
Labels  checked by   Units checked by  
Number of labels used  Number of units prepared  
Number of samples used  Number of units issued  
Discrepancy  Discrepancy  
Explanation for discrepancy  Explanation for discrepancy  
Label reconciliation 
Completed by 
 Product reconciliation  
Completed by 
 
 
 
Product Release 
Number of units for inspection  
Number of units rejected  
Discrepancy  
Comment 
 
 
 
 
Pharmacists inspection completed: Name                                 Date 
 
Releasing Pharmacists sign off: Name                                 Date 
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Investigational Product pGM169/GL67A  
EudraCT: 2011-004761-33 CFGT/SOP/601/MD UKCFGT LMD-2 Pneumatic Mixer v01 
SOP: CFGT/SOP/601/MD 
 
LMD-2 Pneumatic mixer 
 
Introduction 
The LMD-2 pneumatic mixer device is a specialised piece of equipment designed 
specifically for use within the UK Cystic Fibrosis Gene Therapy Consortium to enable 
rapid and reproducible mixing of lipid and DNA components for clinical applications. 
The device consists of a fully adjustable pneumatic piston that can be used in conjunction 
with a dual lumen syringe and static mixer to achieve controlled and reproducible mixing 
of plasmid DNA and GL67A components of gene transfer formulations. 
 
                              
 
Procedure 
1. LMD-2 Setup  
 
1.1    Required apparatus 
LMD-2 pneumatic mixing device (Intertronics Ltd) 
Compressed air/nitrogen cylinder capable of 50 psi output pressure 
Suitable gas regulator with G3/8 male output connector 
G3/8 to G1/4 steel sleeve connector (RS Components Cat 367-5590) 
G1/4 to 6 mm push-fit straight connector (RS Components Cat 726-718) 
6 mm nylon pressure tubing (RS Components Cat 726-718) 
Gas joint sealing tape (RS Components Cat 231-964) 
 
 Setup 
 Attach gas regulator to suitable compressed air/nitrogen cylinder and open cylinder 
valve with gas spanner to pressurise regulator. Ensure adequate cylinder pressure (>200 
psi) on the right hand dial before commencing studies. If pressure is too low then replace 
cylinder. 
Switch 
Tubing 
connector 
Syringe  
chamber 
(open) 
Rate 
adjuster 
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Investigational Product pGM169/GL67A  
EudraCT: 2011-004761-33 CFGT/SOP/601/MD UKCFGT LMD-2 Pneumatic Mixer v01 
 Connect 6mm pressure tubing to regulator via G1/4 to 6 mm push-fit connector and 
G3/8 to G1/4 steel sleeve connector. 
 
 
       
 
 Wrap one layer of gas joint sealing tape around G3/8 male thread on regulator outlet 
connector (A) 
 Thread G3/8 to G1/4 steel sleeve connector (B) onto regulator outlet (A) and tighten 
into place with 24 mm spanner 
 Thread G1/4 to 6 mm push-fit connector (C) into G3/8 to G1/4 steel sleeve connector 
(B) and tighten into place with 16 mm spanner 
 Insert length of 6mm pressure tubing (D) into G1/4 to 6 mm push-fit connector (C). 
Push firmly into place and check that it is secure by gently trying to pull the tubing free 
 If the tubing needs to be removed, press firmly down on the blue securing ring at the 
connector outlet whilst pulling the tube free. This does not require a great deal of force 
and if there is considerable resistance ensure that the securing ring is depressed 
sufficiently. Do not try to force the tubing out as this will result in damage to the 
connector. 
 Insert the other end of the 6mm pressure tubing into the 6 mm push fit connector 
located at the base of the rear of the LMD-2 (see below). Ensure secure connection as 
above. 
 
 
 
 Close syringe chamber door on front of LMD-2 by pushing it flat against the body of 
the device and ensure pneumatic switch is in the OFF (switch upwards) position (see 
below). 
 
B 
A B C D 
D 
C A 
Rear tubing connector 
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Investigational Product pGM169/GL67A  
EudraCT: 2011-004761-33 CFGT/SOP/601/MD UKCFGT LMD-2 Pneumatic Mixer v01 
 
 
 pressurise LMD-2 by opening gas regulator tap (turn clockwise) and turning until 
output pressure on regulator reads 50 ± 5 psi (left hand dial). 
 Check for any leaks evident as “hissing” or obvious escape of gas from connections 
and tubing. If leaks are present, turn off the regulator (turn handle anti-clockwise), allow 
any gas within the system to escape and then tighten affected connector or apply sealing 
tape where necessary. Re-pressurise system. 
 LMD-2 is now charged and ready to use 
 
2. Operation and calibration of LMD-2 
 
2.1 The LMD-2 device utilises gas pressure from the compressed air cylinder to 
drive a plunger that in turn depresses the plunger on the dual syringe mixing 
device. 
2.2 With the switch in the OFF position the pneumatic plunger remains in its 
“REST” position at the top of the syringe chamber (see below). 
 
        
ON 
OFF 
Pneumatic switch 
OFF 
 
“REST” 
ON 
Plunger 
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Investigational Product pGM169/GL67A  
EudraCT: 2011-004761-33 CFGT/SOP/601/MD UKCFGT LMD-2 Pneumatic Mixer v01 
2.3 To activate the device, ensure that the syringe door is closed and depress the 
switch to the ON position (down). The plunger will descend through the syringe 
chamber until it reaches the bottom. 
2.4 IMPORTANT – the plunger will not automatically return to the top of the 
chamber. Once the plunger reaches the bottom of the chamber you MUST 
immediately deactivate the device by lifting the switch to the OFF position (up) 
to prevent damage to the device. This will also return the plunger to the “REST’’ 
position. 
2.5 A flow regulator valve positioned on the left hand side of the mixer unit 
determines plunger speed. Regulator valve is labelled “Rate adjustment >” (see 
below) and is adjusted using a flat screwdriver. 
 
 
 
2.6 To adjust the plunger speed insert screwdriver into slot on regulator valve and 
turn clockwise for SLOWER and anti-clockwise for FASTER plunger 
movement. 
2.7 To determine the plunger velocity use a stopwatch accurate to 1/100th second to 
time a full depression from the top of the chamber to the bottom with no mixer 
syringe inserted into device. 
2.8 With plunger in the “REST” position and switch turned OFF. Activate device 
and start stopwatch. When plunger reaches the bottom of the chamber stop 
stopwatch and record time. Turn switch OFF to return plunger to “REST” 
position. 
2.9 Adjust regulator valve until desired plunger velocity is achieved. A turn to 
clockwise will slow the velocity. 
2.10 All mixer studies should be carried out with plunger taking 4 ± 0.5 s to travel 
from the top of the chamber to the bottom. This range is equivalent to mixing 
speeds of 2.1 to 2.7 ml/s/syringe. 
2.11 Plunger velocity should be confirmed and adjusted, if necessary, prior to each 
use.  
 
 
3. Disassembly of the LMD-2 
 
3.1 The LMD-2 can be left pressurised between mixing runs. However, it is 
recommended that it should be depressurised if it is to be left unused for periods 
greater than 2 hr. 
Rate adjustment valve 
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Investigational Product pGM169/GL67A  
EudraCT: 2011-004761-33 CFGT/SOP/601/MD UKCFGT LMD-2 Pneumatic Mixer v01 
3.2 To depressurise the LMD-2 turn off the gas regulator on the cylinder by turning 
the handle anti-clockwise. 
3.3 NOTE – output pressure on regulator will still read approximately 50 psi as the 
tubing between the regulator and the mixing device REMAINS PRESSURISED. 
3.4 To release pressure in tubing repeatedly activate/deactivate the LMD-2 several 
times. 
3.5 Upon each activation the measured pressure on the regulator output dial will fall 
as gas within the system is purged. 
3.6 Repeat until regulator output dial reads 0 psi. 
3.7 It is now safe to disconnect tubing if required or simply re-pressurise system for 
next mixing experiments. 
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Investigational Product pGM169/GL67A  
EudraCT: 2011-004761-33 CFGT/SOP/602/MD Preparation of pGM169/GL67A Complexes v01 
SOP: CFGT/SOP/602/MD 
 
Preparation of pGM169/GL67A complexes with the LMD-2 
 
Required apparatus 
LMD-2 pneumatic mixing device setup and calibrated as described above 
Dual lumen syringe barrels (Plas-Pak Industries Cat 14B35(S505A) 
Dual lumen syringe plungers (Plas-Pak Industries Cat 14C35(S446) 
Eight element static mixers (Plas-Pak Industries Cat 003M08B005-3(S732) 
16G disposable needles with Luer fitting hub (Sigma Cat Z118036) 
5 ml sterile disposable syringes with Luer fitting hub  
Thawed vial of pGM169 plasmid  
Thawed and re-suspended vial of GL67A 
 
 
 
Method 
1 For preparation of 10 ml aliquot of pGM169/GL67A complexes. 
2 Fully insert a single dual lumen syringe plunger (E) into a single dual lumen syringe 
barrel (F). 
3 Withdraw plunger until end of plunger approaches the end of the syringe barrels. At 
this point there will be resistance to any further withdrawal of the plungers and the 
syringe barrels will be filled with air (see below). 
 
 
 
4 Hold dual lumen syringe assembly with the syringe barrels uppermost and the plunger 
pointing downwards. Support in this inverted position. 
E 
F 
G 
Plunger 
Static mixer 
Barrel 
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Investigational Product pGM169/GL67A  
EudraCT: 2011-004761-33 CFGT/SOP/602/MD Preparation of pGM169/GL67A Complexes v01 
5 Attach a 16G needle to a disposable 10ml syringe and take up 5ml of room air into the 
syringe barrel. 
6 Holding a vial of pGM169 upright, insert the needle through the top of the rubber 
stopper on the vial and inject the 5 ml of air into the vial. Hold the needle firmly in 
place to resist the increased pressure in the vial trying to push it out. 
7 With the syringe now emptied, carefully invert the vial with the needle and syringe 
still in situ. Keeping the tip of the needle below the surface of the DNA solution, 
withdraw 5 ml of pGM169 into the syringe. 
8 Remove the needle and syringe from the DNA vial and insert into one barrel of the 
dual lumen syringe assembly via the small hole at the tip of the barrel (see below). 
 
 
 
9 Carefully inject 5 ml of pGM169 into the syringe barrel.  
10 Remove and discard 5 ml syringe and 16G needle.  
11 Repeat the procedure using a fresh 16G needle and 5 ml syringe to transfer 5 ml of re-
suspended GL67A from the vial to the other barrel on the dual lumen syringe. 
12 Whilst keeping the dual lumen syringe inverted, attach the 8 element static mixer (G) 
to the end of the dual lumen syringe by pushing into place and then rotating the mixer 
90˚ clockwise to lock into position beneath plastic retainers. 
13 It is now safe to hold the dual lumen syringe assembly containing 5ml of pGM169 
and 5ml of GL67A vertically with the static mixer pointing downwards. Some air (1-
2ml) will remain within the syringe barrels. This is normal and important to allow 
complete emptying of the syringes upon activation of the mixer. 
14 Check calibration of LMD-2 is within acceptable limits (see setup and calibration 
section of SOP: CFGT/SOP/601/MD). 
15 Open the syringe chamber door of the pressurised and calibrated (see SOP: 
CFGT/SOP/601/MD) LMD-2 by pulling the top of the anterior clear perspex panel 
gently forwards – you will hear a small escape of gas as you open the door. This is 
normal and prevents activation of the device whilst the door is open. 
16G syringe needle 
Syringe exit hole 
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Investigational Product pGM169/GL67A  
EudraCT: 2011-004761-33 CFGT/SOP/602/MD Preparation of pGM169/GL67A Complexes v01 
16 Insert the dual syringe assembly into the syringe chamber such that the tip of the static 
mixer protrudes through the hole at the bottom of the chamber (see below). 
 
 
 
17 Close the syringe door by pushing it gently backwards until it clicks into place. The 
device is now primed and ready for operation. 
18 Place a sterile 20ml Sterilin tube immediately below the protruding static mixer 
element to collect mixed formulation (see below). 
 
 
 
19 Activate pneumatic mixer by turning the switch on the right hand side of the device to 
the ON position (down). The pneumatic plunger will descend and push the dual 
plunger of the dual lumen syringe assembly. Mixed pGM169/GL67A complexes will 
be ejected from the static mixer into the 20 ml Sterilin collection tube. 
20 When the dual syringe has been fully depressed, quickly return the switch to the OFF 
position (up) to return the pneumatic plunger to the “REST” position. 
21 Screw cap into place on 20 ml Sterilin tube and store at room temperature for 20 min 
before use. 
22 Open syringe chamber door and remove and discard empty dual lumen syringe. 
Removal is aided by pushing the static mixer vertically upwards from beneath. 
23 Mixer is now ready for next sample. 
Static mixer 
Syringe chamber door 
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Investigational Product pGM169/GL67A  
EudraCT: 2011-004761-33 CFGT/SOP/603/MD Preparation of pGM169/GL67A 
Complexes v01 
SOP: CFGT/SOP/603/MD 
 
GL67A Hydration 
 
Required apparatus 
VWR-DVX2500 vortexer 
Foam rack 
 
 
Method 
1. Place the vial containing GL67A and water (red crimp vial) into the foam rack  
(Figure 1) 
 
  Figure 1 
 
2. Place the foam rack into the VWR-DVX2500 vortexer (Figure 2) 
 
 Figure 2 
 
3. Lower the top plate onto the foam rack and tighten screws on both sides (Figure 3) 
 
   Figure 3 
 
4. Set to maximum speed (2500 rpm) for 40 min and press run button 
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Investigational Product pGM169/GL67A  
EudraCT: 2011-004761-33 CFGT/SOP/603/MD Preparation of pGM169/GL67A 
Complexes v01 
5. After required time unscrew top plate and lift up, remove vial and check that lipid has 
completely resolved (no white residues on the bottom of the vial, no visible lumps of 
material in suspension).   
 
6. If the lipid is not dissolved repeat steps 1-3. Set to maximum speed (2500 rpm) for 10 
min and press run button 
 
7. Repeat step 5 and check that lipid has completely resolved (no white residues on the 
bottom of the vial, no visible lumps of material in suspension).   
 
8. If the lipid is not dissolved repeat steps 1-3. Set to maximum speed (2500 rpm) for 10 
min and press run button.  
 
9. Repeat step 5 and check that lipid has completely resolved (no white residues on the 
bottom of the vial, no visible lumps of material in suspension).   
 
10. If the lipid is not dissolved repeat steps 1-3. Set to maximum speed (2500 rpm) for 10 
min and press run button. 
 
11. Repeat step 5 and check that lipid has completely resolved (no white residues on the 
bottom of the vial, no visible lumps of material in suspension).   
 
12. If the lipid is not dissolved repeat steps 1-3. Set to maximum speed (2500 rpm) for 10 
min and press run button. 
 
13. Repeat step 5 and check that lipid has completely resolved (no white residues on the 
bottom of the vial, no visible lumps of material in suspension).   
 
14. If the lipid is not dissolved repeat steps 1-3. Set to maximum speed (2500 rpm) for 10 
min and press run button. 
 
15. Repeat step 5 and check that lipid has completely resolved (no white residues on the 
bottom of the vial, no visible lumps of material in suspension).   
 
16. If the lipid is not dissolved repeat steps 1-3. Set to maximum speed (2500 rpm) for 10 
min and press run button. 
 
17. Repeat step 5 and check that lipid has completely resolved (no white residues on the 
bottom of the vial, no visible lumps of material in suspension).   
 
18. Discard GL67A, if the total vortexing time exceeds 100 min.  
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Appendix 3 Blinding protocol
CFGT/SOP/638/MDT version 2 
Blinding Procedure – How to tape the nebulisers
SOP Reference:  CFGT/SOP/638/MDT 
Version Number: Final Version 2; 01 Jun 2013 
Effective Date:  01 Jun 2013 
Last Review: 01 Jun 2013 
Author: Katie Bayfield, Paula Carvelli, David Armstrong 
Approved by (Edinburgh):
Signature:
Date:
Approved by (Imperial): 
Signature:
Date:
Approved by (Oxford): 
Signature:
Date:
Amended
Version 
Date
(DD/MON/YY)
Outline of Change Page with 
change
1 17 Apr 2012 Slight change of method of taping 3 
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CFGT/SOP/638/MDT version 2 
CFGT SOP 
OUTLINE OF PROCEDURE 
PRINCIPLE 
The multidose trial (MDT) will be placebo controlled; therefore all aspects 
of the trial where a patient or staff member could be un-blinded to the 
product or placebo must be monitored and controlled, including delivery of 
the pots to and from pharmacy. This protocol also reduces infection risk for 
the patient. 
OBJECTIVE
1) To correctly and appropriately tape the nebuliser pots so that a 
patient or staff member cannot be un-blinded to product or placebo 
inside.
2) To ensure the nebulisers and nasal spray pots are infection free. 
3) To ensure that the nasal pot does not leak. 
SECTION 1 Summary of health and safety
GENERAL The main risks involved in this protocol are: 
N/A
PROTECTIVE EQUIPMENT 
N/A
EQUIPMENT 
 Nebuliser packing (nebuliser pot + nebuliser tubing) 
 White electrical tape 
 Gloves 
 Lab Coat 
 Extractor Hood 
 Scissors 
 Filter paper 
 Falcon pot – Blue max 17 x 120mm style 
 Antibacterial wipes 
SPILLAGE PROCEDURES 
N/A
WASTE DISPOSAL  
General waste 
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CFGT/SOP/638/MDT version 2 
SECTION 2 Protocol 
1. Put on all personal protective equipment. 
2. Switch on the extractor hood. 
3. Ensure all of the equipment required is at hand. 
4. Wipe the surface with an antibacterial wipe and cover with a sterile 
utility drape/clean surface cover. 
5. Open the nebuliser packaging and remove the nebuliser.
6. Dispose of the mouthpiece and retain the packing with nebuliser 
tubing in a box (the Pari Filter/Ventil set will be used to dose the 
patients – not this mouthpiece). 
7. Wipe the nebuliser with antibacterial wipes and leave to dry. 
8. Fold a piece of opaque circular filter paper into 4 ‘pie’ segments and 
cut the end off to reveal a hole in the middle (see figure 2). 
9. Place the filter paper into the end of the nebuliser. 
10. Tape the bottom of the nebuliser with 4 strips of tape ensuring that   
a hole is left in the middle (see figure 3). 
11. Prepare strips of tape or wind the tape around the nebuliser pot 
starting at the bottom and working up the pot until the pot is fully 
covered (see figure 1). Ensure that the tape strips always 
overlap, that the end of the nebuliser pot is neat and that there 
are no gaps.
12. Clean the sterile tube lid (see figure 4) with the antibacterial wipe; 
place the tube lid into the hole of the nebuliser. 
13. Complete the quality control sheet (see appendix 1) with another
person and amend the nebuliser pot if necessary. 
14. Place into a sealable bag and send to pharmacy. 
   Figure 1.          Figure 2. 
              Figure 3.        Figure 4.
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CFGT/SOP/638/MDT version 2 
Appendix 1 
Quality Control of nebuliser pot taping 
Lot
Number
Nebuliser
Box 
number
Person
completing
Date Reviewer Date Satisfactory? Re-
taped?
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
      Y/N Y/N/n/a
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Appendix 4 Cystic Fibrosis Questionnaire –
Revised quality-of-life questionnaire
Adolescents and Adults (Patients 14 Years Old and Older)
 CYSTIC FIBROSIS QUESTIONNAIRE - REVISED
Understanding the impact of your illness and treatments on your everyday life can help your healthcare team 
keep track of your health and adjust your treatments.  For this reason, this questionnaire was specifically 
developed for people who have cystic fibrosis.  Thank you for your willingness to complete this form. 
Instructions: The following questions are about the current state of your health, as you perceive it.  This 
information will allow us to better understand how you feel in your everyday life.    
Please answer all the questions. There are no right or wrong answers! If you are not sure how to 
answer, choose the response that seems closest to your situation. 
A. What is your date of birth? 
Date 
Day Month Year 
B. What is your gender?
 Male  Female 
C.  During the past two weeks, have you been on holiday or 
out of school or work for reasons NOT related to your 
health? 
 Yes  No 
D. What is your current marital status? 
 Single/never married 
 Married 
 Widowed 
 Divorced 
 Separated 
 Remarried  
 With a partner
E. Which of the following best describes your racial 
background? 
 White - UK 
 White - other 
    Indian/ Pakistani 
Chinese/ Asian 
    African 
  Caribbean 
Other [not represented above or people whose predominant 
origin cannot be determined/ mixed race] 
Prefer not to answer this question 
F. What is the highest level of education you have        
completed? 
 Some secondary school or less 
 GCSEs/ O-levels 
 A/AS-levels 
 Other higher education 
 University degree 
  Professional qualification or post-graduate study
G.  Which of the following best describes your current work 
or school status? 
 Attending school outside the home 
 Taking educational courses at home 
 Seeking work
 Working full or part time (either outside the home or 
at a home-based business) 
 Full time homemaker 
 Not attending school or working due to my health  
 Not working for other reasons 
Section I. Demographics Please fill-in the information or tick the box indicating your answer.
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Adolescents and Adults (Patients 14 Years Old and Older)
 CYSTIC FIBROSIS QUESTIONNAIRE - REVISED
Section II. Quality of Life
During the past two weeks, to what extent have you had difficulty:
A lot of 
difficulty 
Some 
difficulty 
A little 
difficulty 
No
 difficulty 
Please tick the box indicating your answer.
  1.  Performing vigorous activities such as running or playing sports.....................  
  2.  Walking as fast as others ...................................................................................  
  3. Carrying or lifting heavy things such as books, shopping, or school bags........
  4.  Climbing one flight of stairs ..............................................................................  
  5.  Climbing stairs as fast as others.........................................................................  
During the past two weeks, indicate how often: Always Often Sometimes Never 
  6.  You felt well .......................................................................................................
  7.  You felt worried ..................................................................................................
  8.  You felt useless ...................................................................................................
  9.  You felt tired .......................................................................................................
10. You felt full of energy.........................................................................................
11. You felt exhausted ..............................................................................................
12. You felt sad .........................................................................................................
Please circle the number indicating your answer. Please choose only one answer for each question. 
Thinking about the state of your health over the last two weeks:   
13. To what extent do you have difficulty walking? 
1. You can walk a long time without getting tired 
2. You can walk a long time but you get tired 
3. You cannot walk a long time because you get tired quickly 
4. You avoid walking whenever possible because it’s too tiring for you 
14. How do you feel about eating? 
1. Just thinking about food makes you feel sick 
2. You never enjoy eating 
3. You are sometimes able to enjoy eating 
4. You are always able to enjoy eating 
15. To what extent do your treatments make your daily life more difficult?  
1. Not at all 
2. A little 
3. Moderately 
4. A lot 
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Adolescents and Adults (Patients 14 Years Old and Older)
 CYSTIC FIBROSIS QUESTIONNAIRE - REVISED
16. How much time do you currently spend each day on your treatments? 
1. A lot 
2. Some 
3. A little 
4. Not very much 
17. How difficult is it for you to do your treatments (including medications) each day? 
1. Not at all 
2. A little 
3. Moderately 
4. Very 
18. How do you think your health is now? 
1. Excellent 
2. Good
3. Fair
4. Poor
Please select a box indicating your answer. 
Thinking about your health during the past two weeks, indicate the 
extent to which each sentence is true or false for you.
Very
true
Somewhat 
true
Somewhat
false
Very
false
19. I have trouble recovering after physical effort......................................................
20.  I have to limit vigorous activities such as running or playing sports....................
21. I have to force myself to eat..................................................................................
22. I have to stay at home more than I want to ............................................................
23. I feel comfortable discussing my illness with others .............................................
24. I think I am too thin ..............................................................................................
25. I think I look different from others my age...........................................................
26. I feel bad about my physical appearance ..............................................................
27. People are afraid that I may be contagious ...........................................................
28. I get together with my friends a lot .......................................................................
29. I think my coughing bothers others ......................................................................
30. I feel comfortable going out at night.....................................................................
31. I often feel lonely..................................................................................................
32. I feel healthy .........................................................................................................
33. It is difficult to make plans for the future (for example, going to college, getting 
married, getting promoted at work, etc.) ..............................................................
34.  I lead a normal life ................................................................................................
.
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Adolescents and Adults (Patients 14 Years Old and Older)
 CYSTIC FIBROSIS QUESTIONNAIRE - REVISED
Section III. School, Work, or Daily Activities
Questions 35 to 38 are about school, work, or other daily tasks. 
35. To what extent did you have trouble keeping up with your schoolwork, professional work, or other daily activities during the past
two weeks?
1. You have had no trouble keeping up 
2. You have managed to keep up but it’s been difficult 
3. You have been behind 
4. You have not been able to do these activities at all 
36. How often were you absent from school, work, or unable to complete daily activities during the last two weeks because of your 
illness or treatments? 
            Always       Often                     Sometimes                   Never
37. How often does CF get in the way of meeting your school, work, or personal goals?
  Always              Often                Sometimes          Never
38. How often does CF interfere with getting out of the house to run errands such as shopping or going to the bank? 
  Always              Often                Sometimes          Never
Section IV. Symptom Difficulties
Please select a box indicating your answer.
Indicate how you have been feeling during the past two weeks. A great deal Somewhat A little Not at all 
39. Have you had trouble gaining weight? ......................................................
40. Have you been congested? ........................................................................
41. Have you been coughing during the day? .................................................
42. Have you had to cough up mucus? ............................................................
Go to 
Question 44 
43. Has your mucus been mostly:    Clear  Clear to yellow   Yellowish-green  Green with traces of blood  Don't know 
How often during the past two weeks: Always Often Sometimes Never
44. Have you been wheezing? ......................................................................... 
45. Have you had trouble breathing? ............................................................... 
46. Have you woken up during the night because you were coughing?.......... 
47.  Have you had problems with wind? .......................................................... 
48.  Have you had diarrhoea? ........................................................................... 
49.  Have you had abdominal pain?.................................................................. 
50.  Have you had eating problems?................................................................. 
Please make sure you have answered all the questions.
THANK YOU FOR YOUR COOPERATION!
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Appendix 5 Statistical Analysis Plan
Gene Therapy CF MDT                                                                                                  
 
Imperial Clinical Trials Unit 
 
MDT GT-CF 
    A randomised, double-blind, placebo-controlled Phase 2B clinical trial of repeated 
application of gene therapy in patients with cystic fibrosis  
 
Short title: Repeated application of gene therapy in CF patients 
 
Chief Investigator: Professor Eric Alton 
e.alton@imperial.ac.uk 
 
 
EudraCT NUMBER:      2011-004761-33 
SPONSOR:       Imperial College London 
SPONSOR PROTOCOL NUMBER:   CRO881 
FUNDER:         MRC-UK Efficacy and Mechanism Evaluation  
         Programme 
PHASE:       II-B 
STUDY COORDINATION CENTRE:  Imperial Clinical Trial Unit 
SAP Version:       V2.1 
DATE:        27th February, 2015  
 
 
Statistical Analysis Plan (SAP) 
Non-confidential 
 
 
SAP Working Group: 
 Professor Gordon Murray 
Senior Statistician 
Gordon.Murray@ed.ac.uk 
 
Dr George Bouliotis 
Trial Statistician 
georgios.bouliotis@imperial.ac.uk 
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1. Approvals  
 
This SAP is approved by: 
Name Role Signature Date 
10.5 Prof. Eric Alton 10.6 Chief 
Investigator 
 
 
 
10.7 Prof. Jane 
Davies 
10.8 Co-investigator  
 
 
10.9 Prof. Gordon 
Murray 
10.10 Senior 
Statistician 
 
 
 
10.11 Dr. George 
Bouliotis 
10.12 Trial 
Statistician 
 
 
 
10.13 Dr 
Stephen Hyde 
10.14 Trial 
Statistician 
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Revision History 
 
Version Reason for Update Date Author 
V0.0 Creation of new 
statistical analysis plan 
13-03-2014 Gordon Murray  
  
V0.1 Revision following 
teleconference on 9th 
April 2014 between E 
Alton, J Davies, U 
Griesenbach and G 
Murray 
09-04-2014 Gordon Murray  
 
V1.0 Revision following 
undertaking statistical 
analysis by George 
Bouliotis 
20-06-2014 Gordon Murray 
&  
George 
Bouliotis 
V 1.1 Revision with 
comments from both 
statisticians GM and 
GB 
10-07-2014 Gordon Murray 
& George 
Bouliotis 
V1.2 Revision with 
comments from 
investigators 
15-07-2014 Gordon Murray 
& George 
Bouliotis 
V2.0 Finalised SAP 23-07-2014 Gordon Murray 
& George 
Bouliotis 
V2.1 Revision following 
unblinding & trial data 
analysis including (i) 
correct protocol 
number; (ii) 
clarification of the ITT 
and randomised 
populations (p.10); 
(iii) clarification of 
STATS software used 
(p.11); (iv) change >4 
doses to ≥4 doses 
(Appendix B, p.16).  
27-02-2015 Gordon Murray 
& Stephen 
Hyde 
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1. Approvals 
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2. Study Objectives / Hypotheses Testing     
2.1. Primary Objectives 
i) To assess the clinical benefit of repeated doses of pGM169/GL67A administered to the 
lungs of patients with CF over a period of 48 weeks 
ii) To assess the safety and tolerability of repeated doses of pGM169/GL67A administered 
to the lungs of patients with CF over the same period 
iii) To assess gene expression of the formulation over the same period 
 
    
2.2. Secondary Objectives   
i) To assess a number of secondary outcomes related to the efficacy, safety and tolerability of 
the active treatment (see appendices A & B)     
ii) To explore relationships between gene expression data (PD and mRNA) with clinical 
outcomes 
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3. Background / Introduction       
3.1. Introduction  
The Cystic Fibrosis gene therapy multidose randomised trial recruits patients in three clinical 
centres: Royal Brompton Hospital (London) and Western General Hospital and Royal Hospital for 
Sick Children (Edinburgh). The aim of this study is to investigate safety/tolerability as well as 
efficacy of repeated doses of pGM169/GL67A administered to the lungs of patients with CF over a 
period of 48 weeks, and also to assess gene expression of the formulation over the same period. The 
purpose of this Statistical Analysis Plan is to give a more detailed and comprehensive description of 
the methods for the analysis of the data, to enhance robustness, and to avoid post hoc decisions that 
may affect the interpretation of the results of the statistical analysis. 
3.2. Study Design  
This is a randomised, double-blind placebo-controlled study. Randomisation will be on a 1:1 basis, 
stratified for centre, age and FEV1, in multiple UK centres. There are two sub-studies integrated into 
the main trial, where patients are randomised 2:1 in favour of active treatment. 
3.3. Study Endpoints (see appendix A for details) 
3.3.1. Primary endpoints: 
3.3.1.1. Secondary endpoints (Efficacy): 
3.3.1.2. Secondary endpoints (Safety): 
3.3.1.3. Gene expression outcomes (Nasal & Bronchoscopy Sub-studies only) 
 
3.4. Treatment Groups 
Administration of 5 ml pGM169/GL67A or placebo (0.9% saline) via nebuliser to the 
lungs every 4 weeks for 12 doses 
Administration of 2 ml pGM169/GL67A or placebo (0.9% saline) via nasal spray to the 
nose every 4 weeks for 12 doses (nasal sub-study only)  
Two sub-studies are proposed: one undergoing nasal dosing and assessment and the 
other undergoing bronchoscopic assessment. Subgroups of patients at the London site 
will be enrolled for gene expression measurement in both nose (Nasal sub-study: n=24) 
and lower airway via bronchoscopy (Bronchoscopy sub-study: n=24).   
3.5. Study Population  
Children (12 years and above) and adults with cystic fibrosis confirmed on standard diagnostic 
criteria, attending or referred into the study sites and fulfilling the inclusion/ exclusion criteria.   
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3.6. Intervention being tested 
pGM169/ GL67A in 5 ml dose via nebuliser every 28 +/-5 days; same as 2 ml nasal spray (subgroup 
only).  
3.7. Sample Size  
This study plans to enrol at least 130 subjects;  
3.8. Schedule of Time and Events 
All subjects will receive 12 doses of nebulised gene therapy at intervals of 4 weeks over a 48 week 
period. After dose 12 there will be 2 formal follow-up visits, at 14 and 28 days post-dose. Evaluation 
for all participants will be made at baseline and subsequently on a monthly basis, at 48 weeks and 
they will be followed long term.    
3.9. Randomisation  
Randomisation will be on a 1:1 basis, stratified for centre, age and FEV1. Randomisation in the nasal 
and bronchoscopy sub-studies will be 2:1 in favour of active treatment, to enrich power for the 
actively-treated patients. The randomisation algorithm has been developed by the Imperial CTU. 
4. Analysis Datasets & Derived Variables 
The primary analysis will be on a per-protocol basis. In a subsidiary intention to treat analysis, 
participants will be analysed in accordance with the treatment to which they are randomised, 
regardless of the treatment that they actually receive. The baseline will be defined as the mean of 
Screening and Pre-dose 1 values, and the end value will be defined as the mean of the measures 
obtained 14 and 28 days after the final dose 
4.1. Derived Variables 
4.1.1. Primary-Outcome Variables   
•    FEV1 percent predicted   
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4.1.2. Secondary-Outcome Variables (see appendix A & B)  
  
 
4.2. Safety Variables (see appendix B) 
Adverse Events  
• Any adverse event listed in the related forms 
 
Serious Adverse Events 
• Serious Adverse Events (death, life threatening, prolongation of existing inpatient 
hospitalisation, persistent or significant disability or incapacity) 
   
5. Statistical Analysis        
5.1. Exploratory and descriptive analyses 
Where possible, the relationship between the outcomes and other variables will be explored 
graphically. Histograms and box-plots will be used to assess the distributional assumptions and to 
check for possible outliers. Appropriate transformations (logarithms) will be applied, where this is 
useful, in order to satisfy distributional assumptions (normality). Categorical variables (binary, 
ordered and multinomial) will be presented in terms of frequencies and percentages, whilst 
continuous variables will be presented using the mean, standard deviation (SD), median, lower and 
upper quartiles, minimum, maximum and number of patients with an observation (n). In general, 
minimum and maximum will be quoted to the number of decimal places as recorded in the CRF or 
other appropriate source data. Means, medians, quartiles and SDs will be quoted to one further 
decimal place. Percentages will be rounded to two decimal places.  
All applicable statistical tests will be 2-sided and will be performed using a 5% significance level, 
leading to 95% (2-sided) confidence intervals (CIs). No formal adjustment will be made to 
significance levels to allow for multiplicity, as there is a single pre-specified primary outcome 
measure. However, a very large number of secondary analyses (of exploratory value) are planned, 
and so p-values for these secondary analyses will need to be interpreted cautiously. A bootstrapped 
CI will be presented in some occasions, where this is useful and appropriate.  
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5.2. Associational analyses/Modelling 
As this is a classic multicentre placebo-controlled trial, the primary analysis will compare the two 
randomised groups in terms of the mean percent change in percent predicted FEV1 from baseline to 
end of treatment. We are aware of various analyses commonly employed for this task. Among them, 
the analysis of covariance (ANCOVA) is well established and reliable. The ANCOVA model will 
include baseline percent predicted FEV1 together with the other variables used in the randomisation 
algorithm as covariates. ‘Baseline’ will be taken as the average of the FEV1 values from the two pre-
treatment assessments. ‘End of treatment’ will be taken as the average of the values taken at 14 and 
28 days after final treatment. The treatment effect will be presented as an adjusted difference in 
mean percent change along with its corresponding 95% confidence interval. Also within-group 
(FEV1) change over time will be investigated. No interim efficacy analyses are planned. 
5.3. Managing Missing Values 
The per-protocol primary analysis of the primary endpoint will be replicated using imputation 
methods to allow for missing data. This will serve as a sensitivity analysis if less than 10% of 
outcome values are missing, or as the primary analysis if more than 10% is missing. The analysis of 
all other secondary outcome measures will be based only on patients with complete data. 
5.4. Analysis Populations 
The intention to treat (ITT) population will comprise all randomised subjects with usable follow-up 
(i.e. post-randomisation) data.   
The per-protocol (PP) population will comprise those members of the ITT population who 
completed the study without a major protocol violation and who complied adequately with the 
randomised treatment i.e. received ≥9 doses. The PP population will be confirmed before database 
lock. The primary and major secondary efficacy analyses will be performed using the PP population. 
The safety population will comprise all recruited patients who received at least one dose of study 
medication. 
 
5.5. Baseline characteristics  
These will be presented in the form of summary tables       
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5.6. Quality Control (QC) of Statistical Analysis 
Isolated data errors detected in the database as a result of the QC checks that are deemed significant 
will be submitted for enquiry to the trial manager or designee. Systematic data errors in the data 
reporting will be investigated further; the data will be corrected if necessary, and the appropriate 
table then re-checked. 
A random selection of unique analysis and summary tables will be checked and validated using 
manual methods (e.g. comparison by a calculator, spreadsheet, database output or any alternative 
summarisation tool) and with differing statistical programming (e.g. Stata approaches “collapsing” 
Vs. “reshaping”). QC of statistical analyses will be performed by peer review of program code, log 
and output. The primary analysis will be replicated independently and the reasons for any 
discrepancies identified and resolved. 
5.7. Software and Programming 
Data management will use Excel; descriptive statistics and standard analyses will be performed 
using STATA, Prism, Minitab and/or IBM Statistics SPSS. More complex models will be fitted using 
R.  
6. Patient Disposition, Demographics, Baseline/Clinical Characteristics  
No formal statistical testing will be performed on patient disposition, or on demographic or 
baseline/clinical, or concomitant medication data. Summaries of patient disposition will be based 
on all patients and summaries of all other data described in this section will be based on the ITT 
population, unless otherwise stated. 
6.1. Patient Disposition and Withdrawals 
The number and percentage of patients randomised, dosed, completed and discontinued will be 
presented by treatment and overall. The number of patients discontinued early from the study will 
be summarised by reason for withdrawal and treatment. 
6.2. Analysis Populations 
A summary table will be produced detailing the number and percentage of patients in each 
population for each treatment and overall. The reasons for exclusion from the PP population will be 
included in the summary. 
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6.3. Demographic Characteristics 
Demographic data will be reported overall and by treatment group, stratified by whether or not 
included in a sub-study. Summary statistics (mean, SD, median, lower and upper quartiles, 
minimum, maximum and n) will be presented for age, height, weight, BMI % predicted FEV1 and 
FVC. Number and percentage of patients will be presented for gender, centre, CFTR mutation 
(classified as on pg 15) pre-specified treatments (pg 15), P. aeruginosa infection status (pg 15),  
pancreatic insufficiency, CF related diabetes and smoking history.  
. 
6.4. Extent of Exposure and Treatment Compliance 
Tabulate by treatment group (stratified by sub-study inclusion) the number of patients receiving a 
total of 0, 1, 2, …, 12 doses.  
7. Analysis Plan Details 
7.1. Primary Outcome Measure 
The primary analysis will compare the two randomised groups in terms of the mean percent change 
in percent predicted FEV1 from baseline to end of treatment. So for example, a patient with a 
baseline mean percent predicted FEV1 of 60% increasing to 66% by the end of the study would be 
analysed as having had a 10% increase from baseline. An analysis of covariance (ANCOVA) model 
will be used to compare the two randomised groups with this percent increase in predicted FEV1 as 
the response variable. Baseline percent predicted FEV1 will be used as a covariate in the model 
together with the variables used in the randomisation algorithm (Age [<18 years versus ≥ 18 years 
on day of randomisation], Centre [Edinburgh versus London], and Stratum [Included in one or both 
of the gene expression sub-studies versus not], but not categorised FEV1 as this is already included 
as a continuous covariate). 
 ‘Baseline’ will be taken as the average of the percent predicted FEV1 values from the two pre-
treatment assessments (Screening and Pre-dose 1). ‘End of treatment’ will be taken as the average of 
the values taken at 14 and 28 days after the final treatment. Should any patients only have a single 
baseline value, or a single end of treatment value, then this value will be used in place of the mean of 
the two relevant values. The treatment effect will be presented as an adjusted difference in mean 
percent change along with its corresponding 95% confidence interval.  
The primary analysis will be performed on the per-protocol (PP) population, so that all included 
patients will have received 9 or more doses of trial treatment. If any patients in the PP population 
have missing outcome data then the above analyses will be repeated after the missing values have 
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been estimated using an imputation technique. The imputation will be based on the matrix of the 15 
percent predicted FEV1 values (Screening; Pre-dose 1; Pre-dose 2; …; Pre-dose 12; 14 days post-dose 
12; 28 days post-dose 12) for the patients in the PP population, and will use single imputation, with 
the EM approach. If more than 10% of the patients in the PP population have missing outcome data 
then the analysis based on imputation will be taken as the primary analysis. 
As a sensitivity analysis the above analyses will be repeated, but with the logarithm (base 10) of the 
end of treatment percent predicted FEV1 taken as the response variable, and the logarithm of the 
baseline percent predicted FEV1 included as a covariate in place of its raw value. The other 
covariates will be as described above. 
As a further sensitivity analysis the primary analysis will be repeated after having excluded the small 
number of patients who were suffering from an acute exacerbation of their condition at the time of 
their end of study assessments. These patients will be identified ahead of database lock. 
An exploratory analysis will compare the two groups in terms of the evolution of FEV1 over the 
duration of the trial. For descriptive purposes, mean, SD and n for percent predicted FEV1, stratified 
by treatment group and sub-study stratum, for Screening; Pre-dose 1; Pre-dose 2; …; Pre-dose 12; 14 
days post-dose 12; 28 days post-dose12 will be tabulated for both the ITT and PP populations. 
Profile plots will be used to display the evolution of percent predicted FEV1 for individual patients 
(using the ITT population). 
A more formal comparison of the groups in terms of the evolution of percent predicted FEV1 over 
the duration of the trial will be based on an ‘area under the curve’ (AUC) approach. Baseline FEV1 
will be defined as previously as the mean of the Screening and Pre-dose 1 values. The ‘area under the 
curve’ value will be taken as the area under the curve, using the trapezoidal rule, based on whichever 
of the following values are available: Pre-dose 2, Pre-dose 3, …, Pre-dose 12; 14 days post-dose 12; 
28 days post-dose 12. Where appropriate, ‘14 days post-dose 12’  and ‘28 days post-dose 12’ will be 
replaced by ‘14 days post-final dose’ and ‘28 days post-final dose’ respectively. The area under the 
curve value will be divided by the total length of time between the first and last values used for the 
AUC calculation, to give a mean on treatment percent predicted FEV1. 
The randomised groups will then be compared formally in terms of percent change from baseline to 
on treatment percent predicted FEV1, using the same ANCOVA approach as was used in the primary 
analysis. This analysis will be performed for both the ITT and PP populations. 
Finally and in addition to this and as a model validation task only for the primary outcome, we are 
intended to repeated the analysis but this time reflecting the repeated-measurement nature of the 
197
DOI: 10.3310/eme03050 EFFICACY AND MECHANISM EVALUATION 2016 VOL. 3 NO. 5
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Alton et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
Gene Therapy CF MDT                                                                                               
 
study by using the well-established random-effects models. Among various considerable benefits, 
repeated-measures regressions can accommodate the repeated visits, will strengthen comparisons 
and will allow robust predictions (e.g. random effects for sites) avoiding possibly unattainable 
assumptions of ANCOVA (homogeneity of slopes, compound symmetry within (measurements) 
correlation etc). Models’ fit will be visually compared and statistically tested. Such modelling 
approach will help us to estimate the treatment effect more precisely after adjusting for a series of 
relevant covariates, both continuous and categorical and finally report estimates with reasonable 
confidence intervals. We anticipate that the study is not powerful enough to support those 
prespecified subgroup analyses and thus, mixed-effects models will provide a reasonable alternative 
to fixed-effects models. In any case, a trade-off between statistical robustness, estimates’ precision, 
and simplicity will guide our model selection process. Finally, both fixed and mixed effects models 
will include interactions for exploring the action-mechanism of the intervention. 
 
7.2. Secondary Outcome Measures 
In general, unless specified otherwise below, the secondary outcome measures will be summarized 
per visit and analysed formally using analysis of covariance to compare mean values at end of 
treatment adjusted for baseline values, together with the variables used in the randomisation 
algorithm (Age [<18 years versus ≥ 18 years on day of randomisation], Centre [Edinburgh versus 
London], percent predicted FEV1 on day of Screening [<70% versus ≥70%] and Stratum [Included 
in one or both of the gene expression sub-studies versus not]). 
Effects on longitudinal data will also be explored; the outcomes for which this would be relevant are 
marked with an asterisk in Appendices A, B & C 
Variables’ transformation and missing-values imputation will be applied where this is required (e.g. 
when severe deviation from gaussianity, and/or considerable missingness is observed) and analyses 
will be re-run and compared as an additional “security” procedure, especially for LCI, CT 
parameters and CFQR.  
 
8. Safety/Adverse Events 
These analyses will be performed on the Safety Population. As well as summarising and analysing 
data as for the secondary outcome measures, where appropriate outlying values of clinical relevance 
will be flagged. Should a safety signal be observed, AEs will be explored in more detail. 
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9. Subgroup Analyses 
As set out in Section 2 above, the study is not adequately powered to explore subgroup effects for the 
primary outcome measure, although we shall look at the stability of treatment effect over subgroups 
defined by the covariates included in the ANCOVA model (Age, Centre, Baseline percent predicted 
FEV1 and sub-group stratum). A formal analysis will be performed by including interaction terms in 
the model. A similar approach will be used with certain secondary outcome measures which are 
closer to the direct mechanism of action of the study intervention, as there is likely to be more 
statistical power with such variables to explore subgroup effects which could support a ‘stratified 
medicine’ approach to the use of gene therapy.  
Predefined subgroup analysis for response: 
 
Subjects randomised to active treatment will be further explored using the following categories for 
differences in response of the primary outcome : 
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A. ENTRY CHARACTERISTICS 
1. Severity of lung physiology at baseline (mean of pre-treatment values as used for primary 
outcome analysis): 
a. Mean pre-dose FEV1%:  
i. upper and lower half cut off at median 
ii. top vs bottom quartiles 
b. Mean pre-dose LCI (groups as above) 
2. Predominantly small vs large airways disease as defined on pre-dosing CT: 
a. Small: air trapping + small plugs > score for bronchiectasis (severity and extent) + 
large plugs 
3. P. aeruginosa positive vs negative at entry (on any of pre-dosing cultures) 
4. CFTR mutations in 6 separate groups: 
a. F508del/F508del 
b. F508del heterozygotes: 
i. Class 1 
ii. Class 2 
iii. Classes 3-6 
c. Class 1 heterozygote (2nd allele anything other than F508del) 
d. Homozygous or compound het for 2 mutations from classes 3-6  
5. Gender 
6. Age: <18 vs 18 yrs + 
7. Con meds at baseline (no adjustment for introduction of drugs during trial): 
a. DNase (also called pulmozyme or dornase alpha) 
b. Corticosteroids, inhaled or oral (any of: flixotide, seretide, fluticasone, fluticasone/ 
salmeterol, clenil, beclomethasone, pulmicort, budesonide, symbicort, budesonide/ 
fornoterol, prednisolone) 
c. Azithromycin (also called Zithromax) 
d. Hypertonic saline (also called nebusal or mucoclear)  
B. TREATMENT ASSOCIATED AEs 
8. Presence or absence of acute post-dosing (on day of dosing or within next 2 days) adverse 
events on ≥4 doses: 
a. Systemic (any of: headache, tiredness, lethargy, flu-like, or fever) 
b. Lung (any of: increased cough, wheeze, shortness of breath, increased sputum)  
 
TOTAL number of subgroups: 24 
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Gene expression and clinical outcomes 
Clinical outcomes for patients in the nasal and/ or bronchoscopic subgroups will be further explored 
on the basis of whether there is evidence of molecular (RNA or DNA positive or negative) or 
electrophysiological evidence of CFTR expression. This will initially focus on FEV1, LCI, CT and 
CFQR, but may be expanded to include all listed outcomes. 
For this analysis, the above outcomes will initially be compared for the actively treated group on the 
basis of: 
a) Molecular: positive versus negative: 
a. RNA  
b. DNA  
b) Electrophysiological response: 
a. Nasal: total Cl- secretion at end of trial (mean of F/U1 and F/U2 nPD values) 
greater (more negative) than at start (mean of all pre-dosing values)- yes/ no 
b. Bronchial: mean ZCI on bronchoscopy 2 greater (more negative) than at 
bronchoscopy- 1 yes/ no 
Subsequent analyses may also be performed by categorising response as detailed in Appendix B, 
Secondary Outcome Full Analysis. 
 
10. Changes to the Planned Analyses 
Any changes to the planned analyses will be fully documented and explained 
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APPENDIX A: Secondary Endpoints – Efficacy 
Relative change in other spirometric measures 
FEV1 Z score 
FVC Z score 
FEV1/FVC ratio 
MEF 25-75 
Lung clearance index 
Mean LCI*(end offset) 
Mean FRC(end offset) 
Chest CT scan 
Extent bronchiectasis 
severity bronchiectasis 
wall thickness 
small mucus plugs 
large mucus plugs 
air trapping 
consolidated lung 
Total CT score 
Quality of Life Questionnaires (%) 
Physical* 
respiratory symptoms * 
Exercise capacity 
VO2 at AT* 
VO2max* 
Activity monitoring 
average mins/ day spent at >3 METs* 
(moderate, vigorous, very vigorous)
Serum inflammatory markers
Serum calprotectin (ug/ml)* Please include an analysis of pre-dosing 
vs D2 for any patients where this is available
Gene Therapy CF MDT
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Sputum culture (to include aspirates from bronchoscopy) 
Pseudomonas aeruginosa (all)* 
Pseudomonas aeruginosa 
non mucoid 
Pseudomonas aeruginosa mucoid 
Staphylococcus aureus * 
Aspergillus fumigatus* 
Non tuberculous mycobacteria* (NTM)  
Sputum weight, cell counts and inflammatory markers 
24 hour weight* 
Total cell count*
Neutrophils* 
lipid laden sputum macrophages* 
lipid laden sputum epithelial cells 
solid content 
Calprotectin* 
IL8* 
Extracellular DNA 
Frequency of antibiotics for increased chest symptoms (days and courses); hospital admissions for 
chest symptoms (days and episodes) 
cumulative tally over on-Rx period
number of courses 
period between dose 1 and 1st treatment course 
AEs including SAEs 
Con meds: 
Increase/ decrease in standard CF Rx over trial period
termed ‘Mycobacterium….’
Gene Therapy CF MDT
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Electrophysiological measures: nasal and lower airway potential 
difference (subgroups only; per protocol population only) 
Nasal: 
basal 
delta amiloride 
delta zero chloride 
delta zero chloride isoprenaline 
total chloride secretion 
(sum of delta ZC + delta ZCI) 
Bronchial:
mean of 4 carinal basal measurements 
mean of distal basals 1-3
delta zero chloride isoprenaline 1 
delta zero chloride isoprenaline 2 
delta zero chloride isoprenaline 3 
maximal ZCI 
mean ZCI 
Gene expression on nasal and bronchial brushings 
(mRNA; subgroups only- see appendix for details) 
DNA TaqMan (nasal) 
Consensus RNA Score (nasal) 
Consensus DNA Score (bronch)
Consensus RNA Score (bronch)
Urine biomarkers 
Protein 
Glucose 
N-acetyl-b-d glucosaminidase (NAG)
Gene Therapy CF MDT
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12. APPENDIX B: Secondary Endpoints – Safety 
Sputum producer: yes, no, variable?     
Clinical examination parameters: temperature, HR, 
RR, BP, chest sounds  
 
Transcutaneous oxygen saturation     
  
Serum inflammatory markers  
(Hb, platelets, CRP*, white blood cell count*, 
neutrophil count, ESR, IL-6*,)    
IL-6: Please include 
an analysis of pre-
dosing vs D2 for any 
patients where this is 
available 
Renal and hepatic function  
(U, Cr, AST,  gGT, bili, amylase)    
 
Gas transfer    
 KCOc    
Immune response markers (anti-nuclear 
double-stranded DNA antibodies, CFTR-
specific T cell responses):    
 
 anti-DNA antibodies – nuclei    
 anti-DNA antibodies-nucleoli    
 anti-double stranded DNA    
 CFTR-specific T cells    
Biopsy: inflammation, remodelling (all-0-4 
scores)    
 
 Goblet cell hyperplasia    
 basement membrane thickening    
 lymphocytes/plasma cells    
 neutrophils    
 eosinophils    
 lipid laden macrophages    
 lipid laden epithelial cells    
 other lipid laden cells    
 lipid (present/absent)    
Other outcomes that need reporting:    
 Protocol deviations (have been grouped into 
categories listed in comments box on relevant page)  
 
 number of doses received    
           early termination numbers and reasons   
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Safety report as presented to DMC for early ‘intensively 
monitored’ cohort- does not require re-analysis 
The only exception to 
this is serum IL-6 
and calprotectin 
which were not 
available at that time 
and should be 
examined now 
 
 
*Any item marked with an asterisk is for future ‘AUC’ type longitudinal analysis
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Statistical Analysis Of Nasal & Bronchial Brushing DNA & RNA Samples 
 
These outcomes look indicate successful delivery and expression of the transgene; DNA 
(DNA TaqMan) and RNA (consensus RNA score) will be recorded only for the two 
subgroups (nasal and bronchoscopy). Treatment and placebo groups will be compared 
with regard to post-treatment results. Pre-treatment results are present as a control 
and should all be negative; any positive values are likely to indicate contamination and 
will need to be reported. 
 
Nasal Brushing 
“Post” nasal brushing data can be found at one of: F/U2, Bronch2 or unscheduled 
“Pre” nasal brushing @ visit Screening, Screening2, Unscheduled 
One  
Data to be analysed is within NB N tab for “Pre” 
Line 5 DNA TaqMan 
Line 9  Consensus RNA Score 
 
Data to be analysed is within NB N tab for “Post” 
Line 5 DNA TaqMan 
Line 9  Consensus RNA Score 
 
Bronchial Brushing 
“Pre” bronchial brushing @ visit Bronch 
“Post” bronchial brushing @ visit Bronch2 
 
Data to be analysed is within BRO BRU 1 tab for “Pre” 
Line 9 Consensus DNA Score & Consensus RNA Score 
 
Data to be analysed is within BRO BRU 2 tab for “Post” 
Line 13 Consensus DNA Score & Consensus RNA Score 
 
 
  
Possible Scores 
Each score has ONE of FIVE possible values, charted on a Y axis in this order: 
%VE  (Absolute % vector/endogenous CFTR DNA or mRNA)) 
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PBNQ  (Positive But Not Quantifiable–typically trace vector & some 
endogenous) 
Zero  (Zero %VE CFTR DNA or mRNA–no vector & some endogenous) 
ND  (Not Determined–no vector & no endogenous) 
NS  (No Sample) 
 
%VE is entered numerically and has an expected range of 1E-4 to 1E6 
PBNQ, ND & NS are entered as radio buttons 
Zero is entered as 0 within the %VE numerical range 
 
Data Coding (Post-eCRF Pre-Stats Analysis)  
Positive %VE values are accepted. The expected range is 1E-4 to 1E6 
Determine minimum value of ALL %VE values. 
If minimum value ≥ 1E-4 then use category values described below 
Else adjust category values described below  
PBNQ values are coded 1E-5 
%VE values of 0 are coded 1E-6 
ND values are coded 1E-7 
NS values are coded 1E-8 
 
Analysis 
Will be categorical in the first instance comparing proportions of positive and negative samples in 
the two groups: 
All samples that have a non-zero %VE value OR a PBNQ value are positive. 
All samples that have a zero %VE value are negative  
Samples that have a ND or NS value have effectively failed the analysis and should be ignored (there 
are very few, possibly none of these, so they won’t greatly skew any analysis) 
 
Subsequently, a Mann-Whitney test will be performed on the following basis: 
1) include all positive %VE and zero %VE data 
2) exclude ND and NS samples 
3) recode PBNQ samples to a %VE value below lowest positive %VE  (e.g. 1e-5 assuming lowest %VE 
is 1e-4) 
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13. APPENDIX C: Secondary outcome full analysis 
 
Category 1: Spirometric values: FEV1 (L), FVC (L), Piko FEV1 and FEV6 
 
Category 2: Quality of Life: Role, Vitality, Emotion, Social, Health perception, 
Body image, eating disturbances, treatment burden, weight, digestive symptoms  
 
Category 3: Exercise capacity: VE max, VO2/Kg at AT, VO2/kg at max 
 
Category 4: Infection: Candida species, Burkholderia cepacia complex (any 
organism that starts Burkholderia), Methicillin resistant Staphylococcus aureus 
(MRSA), Stenotrophomonas maltophilia, Haemophilis influenza, Alcaligenes 
xylosoxidans  
 
Category 5: Sputum markers: viable cell count, macrophages, lymphocytes, 
eosinophils, other lipid laden sputum cells 
 
Category 6: Safety 
a) Post-dosing-pre-dosing delta: RR, SaO2    
b) Serum biochemistry: ALT, Alk phos, alb, Ca 
c) Urine: Blood (is the patient menstruating?- yes and no, collected separately), 
leucocytes, bilirubin  
d) CT scans: dose 4 CT scan worse/ better? 
e) Gas transfer: TLCOc 
 
              Category 7: Electrophysiology 
In the initial analysis patients in the actively treated groups are defined as demonstrating 
evidence of chloride secretion if the mean post-end of trial total Cl- secretion is greater (more 
negative) than the mean pre-dosing values. 
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In this more detailed analysis we may also look at all or any of the following methods of 
categorising subjects: 
a) Any one on-treatment trace demonstrating total Cl- greater (more 
negative) than:  
a. pre-dosing mean: yes/ no  
b. pre-dosing maximal (most negative): yes/ no 
b) Any one on-treatment trace demonstrating total Cl- greater (more 
negative) by at least 5mV than:  
a. pre-dosing mean: yes/ no  
b. pre-dosing maximal (most negative): yes/ no 
c) End of trial mean Cl- secretion of -5mV or more: yes/ no 
d) As above a-c) for ZC and ZCI phases independently 
e) Changes in basal values 
f) Changes in amiloride response 
g) For any of the above, during-trial measurements may be taken into 
account with an area under the curve analysis 
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